DDrare: Database of Drug Development for Rare Diseases

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：1,398，薬物数：1,426（DrugBank：306），標的遺伝子数：216，標的パスウェイ数：210］

Searched query = "Multiple sclerosis", "Neuromyelitis optica", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = (-)-trans-delta-9-tetrahydrocannabinol; (im) avonex®; (r) 3-(5-dimethylcarbamoyl-pent-1-enyl)-n-(2-hydroxy-1- methylethyl) benzamide; 0,5 mg fingolimod; 0.25mg rpc1063; 1 - andrographis paniculata p/st extract; 1% steroid cream; 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1h-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone; 1.0mg rpc1063; 10 milligram (mg) fampridine-sr (4-aminopyridine, 4-ap); 10000iu vitamin d; 11c-acetate; 11c-pib; 13-pcv booster; 13-valent pneumococcal conjugate vaccine (13-pcv); 15 mg fampridine-sr (4-aminopyridine, 4-ap); 18f-dpa-714 and 18f-fdg; 18f-fdg; 19 nor vitamin d; 2 - excipients; 2-cda; 2-cda, 2-chloro-2’-deoxy-beta-d-adenosine; 2-cda, 2-chloro-2’-deoxy-ß-d-adenosine; 2-chloro-2'-deoxyadenosine, 2cda; 2-chloro-2’-deoxyadenosine (2-cda); 20 mg fampridine-sr (4-aminopyridine, 4-ap); 20 mg ga; 200106 or emd 28162; 20mg/0.5ml ga; 20mg/0.5ml glatiramer acetate; 23-ppv; 23-valent pneumococcal polysaccharide vaccine; 23-valent pneumococcal polysaccharide vaccine (23-ppv); 25oh-vitamin d; 2b3-201; 2cda; 3 mg melatonin; 3,4-diaminopyridine; 4-aminopyridine; 4-ap; 4.5 mg naltrexone; 40 mg ga; 40 mg glatiramer acetate; 5 mg melatonin; 5000iu vitamin d; 52069.00.01; 9060x; 95% pure ecgc capsules 200mg; A4i antagonist; Ab1010; Abatacept; Abobotulinumtoxin a; Abr-215062 sodium salt; Abt-555; Abt-874/human monoclonal antibody against il-12; Abx-1431 hcl; Acetaminophen; Acetaminophen tab 650mg; Acetate; Acetazolamide; Acetylcysteine; Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,; Aclasta; Aclasta 5 mg infusionslösung; Aclasta 5mg solution for infusion; Act-128800; Act-128800 dose 1; Act-128800 dose 2; Act-128800 dose 3; Acth; Acthar; Acthar gel; Acthar gel (acth); Active comparator receiving extavia®; Active control; Actos (pioglitazone); Acyclovir; Adderall xr; Adderall xr 10 mg; Adderall xr 5mg; Adenosine; Adrenocorticotropic hormone; Adrenocorticotropic hormone (acth) gel (h.p. acthar®); Ads-5102; Ads-5102, 137 mg; Ads-5102, 274 mg; Aert, (r)-baclofen; Agee cream; Aimspro; Ain457; Alanine; Albumin (human) 25%, united states pharmacopeia (usp); Albuterol; Alcohol; Alemtuzumab; Alemtuzumab (gz402673); Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alfuzosin; Alks 8700; Alks 8700 delayed release (dr); Alks 8700 delayed release (dr) capsule; Allogeneic human umbilical cord tissue-derived mesenchymal stem cells; Alpha lipoic acid; Alpha-lipoic acid; Alpha1-antitrypsin; Altri farmaci del sistema nervoso; Amantadine; American ginseng; American ginseng extract ht-1001; Amiloride; Amiloride hydrochloride; Amiloride hydrochloride, 2 h2o; Amilostad hct; Amilostad hct tablets; Ampyra; An100226; An100226, bg00002; Anakinra; Androgel 1 % topical gel; Androgel 100mg gel; Andrographolides; Anesthetic topical adhesive synera; Anti lp40 antibody, subclass igg4 la294; Anti-cd25 humanized monoclonal antibody; Anti-cd52 monoclonal antibody; Anti-il-12; Anti-thymocyte globulin; Anticholinergic medication; Antihistamine; Antimycotic; Antithymocyte; Antithymocyte immunoglobulin (rabbit); Arbaclofen; Arbaclofen er tablets; Arbaclofen extended release tablets; Arbaclofen placarbil; Arbaclofen placarbil 15 mg bid; Arbaclofen placarbil 30 mg bid; Arbaclofen placarbil 45 mg bid; Aricept; Aricept 10 mg; Aricept 10 mg filmdragerade tabletter; Aricept 5 mg; Aricept 5 mg filmdragerade tabletter; Arm 1 - geh120714 (18f) injection; Armodafinil; Arn-6039; Arzerra; Asb-683699; Aspartate; Aspirin; Aspirin 650mg oral capsule; Ata188; Atacicept; Atacicept 150 mg; Atacicept 25 mg; Atacicept 75 mg; Atl1102; Atomoxetine; Atorvastatin; Atx-ms-1467; Aubagio; Aubagio - 14 mg - compressa rivestita con film - uso orale - blister (alu/alu) - 28 compresse; Aubagio®; Autologous adipose derived mesenchymal cells; Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved; Autologous bone marrow-derived mononuclear stem cells; Autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope; Autologous hematopoietic stem cell; Autologous mesenchymal cell product; Autologous mesenchymal stem cell transplantation; Autologous mesenchymal stem cells; Autologous stem cells; Autologous t-lymphocytes; Autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (toldc-vitd3); Av605; Avonex; Avonex (interferon beta 1a); Avonex (interferon beta-1a), biogen idec ltd; Avonex 30 µg/0,5 ml solution for injection; Avonex and topamax; Avonex im 4sir 30mcg/0,5ml 4ag; Avonex/betaseron/copaxone/rebif; Avonex/zocor; Avonex®; Avonex® monotherapy (6.0 miu administered i.m. each week); Avp-923; Azathioprine; Azatioprina; Azatioprina hex. 50cpr 50mg bl; Azithromycin; Bacille calmette-guerin vaccine; Bacille of calmette-guerin; Baclofen; Baclofen 20 mg; Baclofen ir; Baf312; Baf312 0,25 mg tablet; Baf312 1 mg tablet; Baf312 4 mg tablet; Baf312 hemifumarate; Baf312a; Bafiertam; Balance; Baminercept; Baseline treatment; Bat4406f; Bay 79-4998; Bay86-5046; Bay86-5046_interferon-beta-1b; Bazedoxifene; Bazedoxifene acetate; Bbr 2778; Bcd-033 (interferon beta 1a); Bcd-054 180 mcg; Bcd-054 240 mcg; Bcd-063; Bcd-132; Bcg20-0134; Beam; Beam regimen; Beetainterferoni -1a; Best available therapy (bat); Beta interferon; Beta-1b interferoni; Beta-alanine; Beta-alanine supplementation; Beta-carotene; Beta-interferon; Betacarotene; Betaferon; Betaferon 250 microgram/ml; Betaferon 250 microgram/ml, powder and solvent for solution for injection; Betaferon 250µg; Betaferon 500mcg; Betaferon 500µg; Betaferon sc 15f 0,25mg 15sir; Betaferon*15confez 0,25mg/ml+; Betaferon, bay 86-5046; Betaferon/betaseron; Betaferon®; Betaferon® (interferon beta-1b); Betaseron; Betaseron (interferon beta-1b, bay86-5046); Betaseron (interferon beta-1b, bay86-5046), bayer healthcare ag; Betmiga; Bevacizumab; Bexarotene; Bg00002; Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg00012; Bg00012 (dmf); Bg00012 (dmf) (tecfidera®.); Bg0002 (natalizumab); Bg9418 (interferon beta 1-a); Bg9418 (interferon beta-1a); Bgg492; Bht-3009; Bht-3009 0.5 mg; Bht-3009 1.5 mg; Bht-3009-01; Biib017; Biib017 (peginterferon beta-1a); Biib019; Biib019 (daclizumab); Biib033; Biib033 (anti-lingo); Biib033 (opicinumab); Biib041; Biib041 (fampridine); Biib041 (fampridine-sr); Biib041 (pr fampridine); Biib061; Biotin; Birt 2584 xx; Bisacodyl; Blood sample; Blood samples; Blood sampling; Bmmnc; Bms 188667 (abatacept); Bone marrow autologous mesenchymal stem cells transplantation; Borage oil; Borage oil 20% gla; Bosentan; Boswelan; Boswellia serrata; Boswellia serrata extract; Boswellia serrata extract ps0201bo capsules; Boswellic acids (boswelan); Botox; Botox®; Botulinum toxin a; Botulinum toxin a - haemagglutinin complex; Botulinum toxin type a; Bx-1; C1-esterase inhibitor (cinryze); C105; Calcio; Calcio folinato dc.it; Calcium; Calcium carbonate; Calcium levofolinate; Cannabidiol; Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabis; Cannabis based medicine extract (sativex); Cannabis, medical; Cannador; Caprylic triglyceride; Capsules with 160 mg teavigo (at least 94% egcg); Carbidopa; Carbonate; Carmustine; Carmustine, etoposide, cytarabine, and melphalan (beam); Carnitine; Carnosine; Carnosine, capsulle, 2 g/day, 8 weeks; Cci-779; Cdp323; Cellular therapy with ebv specific autologous ctl infusion; Ceralifimod; Ceralifmod; Cesamet™ (nabilone); Ceterizine; Cetirizina; Cetirizina mylan generics; Cetirizine; Cetirizine hydrochloride; Cgp 77116; Charcoal; Chloride; Cholecalciferol; Cholecalciferol, vitamin d3; Cholestyramine; Chr-1103 / gbr500; Cianocobalamina; Cianocobalamina fu dc.it; Ciclofosfamide; Circadin; Circadin ( inn= melatonin); Cisapride; Cladribine; Cladribine 3.5 mg/kg; Cladribine 5.25 mg/kg; Cladribine tablets; Clemastine; Clostridium botulinum; Clostridium botulinum toxin type a; Cnm-au8; Cnp-ms-0601; Cnto 1275; Co-14; Coconut; Coconut oil; Coconut oil and epigallocatechin gallate; Coenzyme q; Colecalciferol; Colecalciferol concentrate (oily form); Control; Cop-1; Cop-1/copolymer-1; Copaxone; Copaxone 20 mg/ml; Copaxone 20 mg/ml solution for injection, pre-filled syringe; Copaxone 40 mg/ml solution for injection, pre-filled syringe; Copaxone subcutaneous injection syringe; Copaxone-teva; Copaxone®; Copolymer 1; Copolymer-1; Corticosteroid; Corticosteroids & tancart19/20; Corticotropin; Cranberry; Creatine; Cs-0777 tablets; Curcumin; Cyclophosfamide; Cyclophosphamide; Cyclophosphamide (drug); Cyclophosphamide and atg; Cyclophosphamide monohydrate; Cyclophosphamide/glatiramer acetate; Cymbalta; Cysteine; Cytarabine; Cytolytic cd4+ t cells; Células madre mesenquimales; D mannose; D-aspartate; D-biotin; Dac-hyp; Daclizumab; Daclizumab (anti-cd25 humanized monoclonal antibody); Daclizumab high yield process; Daclizumab hyp; Daclizumab hyp (dac hyp); Daclizumab with greek suufix; Dalfampridine; Dalfampridine er; Dalfampridine-er 10mg; Dalfampridine-er 5mg; Darifenacin; Dc-tab; Dekristol; Dekristol 20000 ie; Dekristol® 400-tabletten; Dekristol®-tablette 1 (400 ie); Delta-9-tetrahydrocannabinol; Demestril septem; Dexamethason; Dexamethasone; Dexamethasone soduim phosphate; Dexchlorpheniramine; Dexrazoxane; Dexrazoxane (drz) plus mitoxantrone (mx); Dextromethorphan; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dibase; Diclofenac; Diclofenac sodium topical gel; Dimethyl fumarate; Dimethyl fumarate (dmf); Dimethyl fumarate [dmf]; Dimetilfumarato; Diphenydramine; Diroximel fumarate; Diroximel fumarate (drf); Dirucotide; Dirucotide acetate; Discontinuation of disease modifying therapy; Disease modifying therapy; Dmt continuation; Domperidone; Donepezil; Donepezil hci (drug); Dotarem 0,5mmol/ml,; Doxycycline; Dpa-714 pet/mri; Dronabinol; Dronabinol capsule 2,5 mg; Dtpa; Duloxetine; Duloxetine hydrochloride (hci); Dydrogesterone; Dysport; Dysport®; Early highly effective therapies group; Ebixa; Ecp002a; Eculizumab; Efalizumab; Egb 761® (tanakan®); Egcg; Ek-12; Elezanumab; Elnd002; Emselex 15 mg retardtabletten; Emselex 7,5 mg retardtabletten; Ena713; Encapsulated simvastatin tablets; Endoxan; Endoxan - ciclofosfamide; Endoxan baxter; Enriched hematopoetic stem cell infusion; Eparmefolin 30 cpr 0,1/0,5mg; Epigallocatechin; Epigallocatechin gallate; Epoetin alfa; Epoetin beta; Erypo/erypo fs; Erythropoietin; Escalation therapies group; Escitalopram; Escitalopram oxalate antidepressant; Essential - hydroxytyrosol; Essential fatty acids; Estradiol; Estradiol hemihydrate; Estriol; Estroprogestins; Eszopiclone; Ethinylestradiol; Etifoxine; Etims; Etims (edc-fixed autologous pbmcs coupled with 7 immunodominant myelin peptides in ms patients); Etoposide; Eu/1/08/454/001-002, eu/1/08/454/005-007; Eu/1/95/003/005-010; Eu/1/97/033/002; Eu/1/98/063/001-003; Eu/1/98/063/004-006; Evobrutinib; Exelon; Exelon transdermales pflaster; Experimental glatiramer acetate; Extavia; Extavia (interferon beta-1b), novartis pharma ag; Extavia 250 microgram/ml; Extavia 250 micrograms/ml; Extavia*sc 15fl 250mcg/ml+15si; Extavia®; Extended release fampridine; Extended-release oxycodone; Extended-release quetiapine fumarate; F-18 fedaa1106 (bay85-8101); Fampridine; Fampridine sr; Fampridine-sr; Fampridine-sr b.i.d. (twice daily); Fampyra; Fampyra 10 mg prolonged-release tablets; Fampyra 10mg prolonged release tablets; Febuxostat; Fecal microbial transplant (fmt); Fecal microbial transplants; Fecal microbiota; Femoston 1/10; Femoston 2/10; Feraheme; Ferumoxytol; Filgrastim; Fingolimob (fty); Fingolimod; Fingolimod (fty720); Fingolimod 0.5 mg; Fingolimod 1.25 mg; Fingolimod hydrochloride; Fingolimodi; Fingolmod; Firategrast; Firategrast (usan approved name); Firategrast 150 mg; Firategrast 300 mg; Firategrast gastro-retentive solution; Firategrast immediate release tablet; Firategrast modified release tablet; Fish oil; Fish oil concentrate; Fish oil, rich in omega-3-acids; Fish oil,rich in omega 3 acids; Fludara; Fludarabine; Flumazenil; Fluoxetin; Fluoxetin hexal; Fluoxetine; Fluoxetine hydrochloride; Flupirtin; Flupirtine; Flupirtinmaleat; Flurbiprofen; Fmp30 donor stool; Folate; Folatescan (technetium tc 99mec20); Formulation a; Formulation b; Formulation c; Formulation d; Freshly-pressed extra virgin olive oil; Fty720; Fty720d; Full spectrum vitamin; Fully humanized anti-human il-6 receptor (il-6r) neutralizing monoclonal antibody; Fumaric acid; G-csf; G2-sfm (ifn-beta-1a from clone 484-39,fbs-free process); Ga 20 mg/ml; Ga 40 mg/ml; Ga depot; Ga depot 40 mg; Ga depot 40mg once monthly; Ga depot 80 mg; Gabapentin; Gabapentine; Gabapentine 300mg; Gadobenate; Gadobenate dimeglumine; Gadobutrol; Gadolinium; Gadolinium-based contrast; Gadoteric acid; Gadoteridol; Gadovist 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado; Gadovist 1.0 mmol/ml injektionslösung; Gamma-tocopherol; Gd-dtpa-st; Genotropin; Gilenya; Gilenya / imusera; Gilenya®; Gileyna; Ginkgo; Ginkgo biloba; Ginseng; Glatiramer; Glatiramer acetate; Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Glucose; Glutamate; Glutamate and aspartate; Glycerol; Glycerol-1,3-didecanoate-2-octadeca-(6z,9z,12z)-trienoate; Gnbac1; Gnbac1 monoclonal antibody; Gold; Gold nanocrystals; Granulocyte-colony stimulating factor (g-csf) and prednisone; Growth hormone; Gsk1223249; Gsk1841157; Gsk2018682; Gsk2018682 cd2 capsule; Gsk239512; Gsk2395612; Gtr.ace; Guanabenz; Gw-1000-02; Gz402668; Gz402673; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Helminth ova; Hematopoetic stem cell infusion; Hematopoietic stem cell transplantation; High dose aspirin (1300 mg/day); High/low sodium diet; Histidine; Hmr 1726d; Hmr1726; Hmr1726d; Hookworm larvae; Hp184; Human anti-il-12 igg1 mab; Human anti-il-12 mab; Human anti-lingo-1 monoclonal antibody; Human autologous mesenchymal stem cells; Human fetal-derived neural stem cells (hnscs); Human interferon beta; Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; Human leucocyte interferon-alpha; Human monoclonal antibody (cnto 1275) to interleukin-12p40; Human neural stem cells; Human normal immunoglobulin; Human recombinant growth hormone; Human umbilical cord mesenchymal stem cells; Humax-cd20; Hydrochlorothiazide; Hydroxychloroquine; Hydroxytyrosol; Hydroxyurea; Ibudilast; Ibuprofen; Idebenone; Ifa incomplete freund's adjuvant; Ifn beta 1 a + curcumin (bcm 95); Ifn beta-1a; Ifn-beta-1a (rebif®); Ifn-beta-1a, (avonex®); Ifn-ß-1a (rebif®); Ifn-ß-1a, (avonex®); Il2; Imatinib; Imatinib mesilate; Imatinib mesylate; Immune globulin; Immune globulin iv [human], 10% caprylate/chromatography purified; Immunoglobulin; Immunoglobulin g; Impact; Imu-838 (30 mg/day); Imu-838 (45 mg/day); Incabotulinumtoxina; Inf beta-1a; Influenza vaccine; Inhaled cannabis; Injectable ms dmt; Injection of autologous stem cells; Injection of cell free media; Inn colecalciferol; Inosine; Insulin; Int131; Interferon beta; Interferon beta - 1a (ifn); Interferon beta -1b; Interferon beta 1; Interferon beta 1-a; Interferon beta 1-b (betaferon/betaseron, bay86-5046); Interferon beta 1a; Interferon beta 1a 30 ug im once weekly; Interferon beta 1a, oral doxycycline; Interferon beta 1b; Interferon beta 1b (betaseron, bay86-5046); Interferon beta treatment to add-on atorvastatin treatment; Interferon beta type 1a; Interferon beta-1 a; Interferon beta-1a; Interferon beta-1a (avonex); Interferon beta-1a (avonex®); Interferon beta-1a (current approved manufacturing process invloving fbs); Interferon beta-1a (new process, manufactured without fbs); Interferon beta-1a (rebif); Interferon beta-1a 30 µg; Interferon beta-1a fbs-free/hsa-free, rnf; Interferon beta-1a hsa+ biosimilar; Interferon beta-1a hsa-free biosimilar; Interferon beta-1a original; Interferon beta-1b; Interferon beta-1b (betaferon, bay 86-5046); Interferon beta-1b (betaferon, bay86-5046); Interferon beta-1b (betaferon/betaseron, bay86-5046); Interferon beta-1b (betaferon®, bay 86-5046); Interferon beta-1b (betaseron, bay86-5046); Interferon beta-1b (betaseron, betaferon, bay86-5046); Interferon beta-1b (pf530, betaferon); Interferon beta-1b and tacrolimus; Interferon beta-1b group; Interferon beta-1b, (betaseron bay86-5046); Interferon beta-1b/atorvastatin group; Interferon beta1a; Interferon ß-1a; Interferon ß-1a (avonex®); Interferon ß-1a 30 µg; Interferon ß-1b; Interferon-1beta (betaseron, bay86-5046); Interferon-beta; Interferon-beta (ifn-beta); Interferon-beta 1a; Interferon-beta 1a fbs-free/hsa free, rnf; Interferon-beta 1a fbs-free/hsa-free, rnf; Interferon-beta 1b; Interferon-beta 1b (betaseron); Interferon-beta-1a; Interferon-beta-1a fbs-free/hsa free, rnf; Interferon-beta-1a fbs-free/hsa-free; Interferon-beta-1b; Interferon-beta1; Interferon-ß-1a; Interferon-ß-1b; Intradetrusor injection of botulinum toxin-a; Intratect; Intrathecal administration of autologous msc-np; Intrathecal methotrexate; Intrathecal msc-np injection; Intravenous (iv) infusions; Intravenous injection of mesenchymal stem cells; Intravenous steroid; Ipx056; Ipx056-10 mg; Ipx056-20 mg; Ipx056-30 mg; Ipx056-35 mg; Ipx056-40 mg; Ir902; Iron; Iron oxide; Isentress; Isoxsuprine; Isoxsuprine hydrochloride; Iv methylprednisolone; Iv methylprednisolone (steroids); Ivig; Ixazomib; Ixazomib (ninlaro®) capsules; Jm-4; Kemstro; Kepivance; Keppra; Keppra 250mg; Keppra 500mg; Keppra ®; Ketamine; Ketoconazole; Keyhole limpet hemocyanin; Keyhole limpet hemocyanin (klh); Keyhole limpet hemocyanin (klh) neo-antigen; L acetyl carnitine; L-000124467; L-carnitine; L-histidine; L04aa04 - immunoglobulina antitimocitaria (di coniglio) immunoglobulina di coniglio antitimociti umani thymoglobuline; L04aa31; L04ax01; Lactose; Lactose monohydrate; Lamotrigine; Lamotrigine extended release tablets; Laquinimod; Laquinimod 0.6; Laquinimod 1.2; Laquinimod capsules 0.3 mg; Laquinimod capsules 0.6 mg; Laquinimod sodium (usan); Laquinimod tablets 0.3 mg; Lemtrada; Lemtrada 12 mg konzentrat zur herstellung einer infusionslösung; Levetiracetam; Levitra; Levocarnil; Levofolene; Levofolene 4 mg 30 cpr; Levonorgestrel; Lfb-r603; Lidocaine; Lidocaine patch 5%; Linoleic acid; Linoleic acid/oleic acid; Liothyronine; Liothyronine sodium; Lipoic acid; Lipoic acid (la) with fish oil and la without fish oil; Lipoic acid and omega-3 fatty acids; Lisdexamfetamine; Lisdexamfetamine sulfate; Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; Lithium carbonate; Live hookworm larvae; Live necator americanus larvae; Loperamide; Loratadine; Losartan; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Low dose aspirin (162 mg/day); Low immunogenic interferon-beta-1a; Lubiprostone; Lumbar puncture; Lutenyl; Ly2127399; Ly248686; Lysine; M2951; Mabcampath; Mabcampath ®; Mabthera; Mabthera (rituximab); Mabthera or biosimilar rituximab product; Mabthera®; Magnesium; Maltodextrin; Maltodextrin fiber supplement; Mangafodipir; Mangafodipir (teslascan); Mannose; Mantadan*20cpr 100mg; Marijuana; Masitinb mesylate; Masitinib; Masitinib mesylate; Mastinib; Mavenclad®; Mbp peptide; Mbp8298; Mbp8298 synthetic peptide; Md1003; Md1003 100mg capsule; Medi-551; Medi-551 iv; Medi-551 sc; Medical marijuana; Medrol; Megadose oral methylprednisolone; Melatonin; Melphalan; Memantine; Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent); Menitorix; Mesenchymal stem cells; Mesenchymal stem cells (mscs); Mesenchymal stem/stromal cells; Mesna; Metex; Metformin; Methelphenidate; Methotrexat; Methotrexate; Methyl b12; Methyl folate; Methyloprednisolone; Methylphenidate; Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; Methylprednisolon; Methylprednisolon-21-hydrogensuccinat, natriumsalz; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Microgynon; Microgynon®; Micropirin; Midazolam; Mineral boost (magnesium); Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Mirabegron; Mis416; Mitoquinone; Mitoxantrone; Mk0812; Mln1202; Modafinil; Mog peptide; Monitor; Monoclonal antibody m-t412; Montelukast; Mor103; Msc2015; Msc2304479a; Msc2304480a; Msc2304481a; Msc2304482a; Msc2358825a; Msc2430913a or ono-4641 (to be used as synonyms); Msc2491529a; Msdmds other than betaseron (interferon beta-1b, bay86-5046); Mstc-001 (ms-stat); Mt-1303; Mt-1303-forma; Mt-1303-formb; Mt-1303-high; Mt-1303-low; Mt-1303-middle; Multiferon; Multiple (4 autologous subcutaneous t cell vaccinations with t cell lines reactive to nine myelin peptides); Mutagrip; Mycophenolate; Mycophenolate mofetil; Mycophenolate mofetil (cellcept); N acetylcysteine; N-acetyl cysteine; N-acetylcysteine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N.a.; N02bg10; N03ax12; N06dx01; Nabilone; Naltrexone; Namisol; Nanocort; Nanocurcumin; Naproxen; Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab treatment; Nbi-5788; Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Necator americanus; Neorecormon; Nerispirdine; Nerispirdine (hp184); Nerispirdine hydrochloride; Neupogen; Neuroaspis plp10®; Neurontin; Neurontin 300 mg hard capsule; Neurovax; Neurovax 300ug/ml dose for im injection; New formulation of rebif - human interferon beta-1a; Niacinamide; Nitrofurantoin; Nivolumab; Nomegestrol; Nomegestrol acetate; Non-pegylated interferon; Norethindrone; Normal saline for injection; Novantrone*inf 2mg/ml 5ml; Npb-01; Nt-ko-003; Nu100; Null; Nurown (msc-ntf cells); Ocrelizumab; Ocrelizumab 300 mg; Ocrelizumab 300mg; Ocrelizumab 300mg /10ml; Ocrelizumab 300mg/10ml; Ocrelizumab 600 mg; Ocrelizumab dose 1; Ocrelizumab dose 2 and dose 3; Ocrevus; Octagam 5%; Octagam 50 mg/ml; Ofatumumab; Ofatumumab 100; Ofatumumab 300; Ofatumumab 30mg; Ofatumumab 3mg; Ofatumumab 60mg; Ofatumumab 700; Ofatumumab subcutaneous injection; Oleic acid; Oleovit d3 14.400 iu/ml oral drops, solution; Olesoxime (tro19622); Olive; Olive oil; Omb157; Omega 3; Omega 3 fatty acids; Omega-3; Omega-3 fatty acids; Omeprazole; Onabotulinumtoxina; Ono-4641; Ono-4641/msc2430913a; Opicinumab; Oral lipoic acid (la); Oral thc; Ory2001; Os440; Other disease-modifying therapy; Other h1 antagonist; Other nervous system drugs; Ovastat; Ovastat 1000; Ovastat 5000; Oxcarbazepine; Oxine; Oxycodone; Ozanimod; Ozanimod 0.5 mg; Ozanimod 1 mg; Ozanimod hydrochloride; Palifermin; Pantoprazole; Paracetamol; Paroxetine; Part a: 100 mg/ml gsk2618960; Part b: dose of gsk2618960 decided from part a; Part c: dose of gsk2618960 decided from part a and b; Peg-liposomal prednisolone sodium phosphate; Peginterferon beta-1a; Pegylated intereron beta-1a; Pegylated interferon beta-1a; Pending; Pent; Pet with 11c-flumazenil; Pf-06342674 0.25 mg/kg; Pf-06342674 1.5 mg/kg; Pf-06342674 6.0 mg/kg; Phenylcyclopropylamine derivatives and dual lsd1/mao-b (lysine-specific demethylase 1 and monoamine oxidase-b) inhibitor; Phenytoin; Phosphate; Pi-2301; Pioglitazone; Pixantrone; Pl 04515/0127; Pl 12762/0049; Placebo; Platelet transfusion; Plegridy; Plegridy (peginterferon beta-1a), biogen idec ltd; Plegridy 125 micrograms; Pleneva tm bgc20-0134; Plovamer acetate; Plp peptide; Pneumovax ii; Pnu-215062 sodium salt; Polyphenon e; Ponesimod; Ponesimod 10 mg; Ponesimod 20 mg; Ponesimod 40 mg; Pravastatin; Prebiotics (prebiotin prebiotic fiber stick pac); Prednisolone; Prednisolone sodium phosphate; Prednisone; Pregabalin; Prepulsid; Prn2246; Probiotics (visbiome®); Prohance (gadoteridol); Prolonged-release fampridine; Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis a, hepatitis b, tick-borne encephalitis, meningococcal, pneumococcal); Provigil; Provigil (modafinil); Prucalopride; Ptl201; Quetiapine; Quinidine; R lipoic acid; Rabbit; Rabbit human t lymphocyte immunoglobulin; Ralenova; Raltegravir; Ramatroban; Ranitidine; Raptiva 100 mg/ml powder and solvent for solution for injection; Ratg; Rc18 160 mg; Rebif; Rebif (ifn beta-1a subcutaneous three times per week); Rebif (ifn ß-1a subcutaneous three times per week); Rebif (ifnbeta-1b); Rebif (ifnß-1b); Rebif (interferon beta 1a); Rebif (interferon beta-1a); Rebif (interferon beta-1a), merck serono europe ltd; Rebif 22; Rebif 22 micrograms; Rebif 22 y 44 mcg; Rebif 22®; Rebif 44; Rebif 44 microgramos solución inyectable; Rebif 44 micrograms; Rebif 44 µg; Rebif 44®; Rebif 8,8 µg, rebif 22µg; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; Rebif new formulation 44mcg multidose cartridge; Rebif new formulation non titrated; Rebif new formulation titrated; Rebif sc 12sir 12000000ui44mcg; Rebif sc 12sir 6000000ui 22mcg; Rebif*sc 12sir 12000000ui44mcg; Rebif®; Rebif® (clone 484-39); Rebif® new formulation; Rebif® new formulation (rnf); Rebif® new formulation (rnf) using rebismarttm; Recombinant human alpha b-crystallin; Recombinant human erythropoietin; Recombinant human interferon beta; Recombinant humanized anti-alpha 4 integrin antibody; Recombinant interferon beta-1b; Repository corticotropin injection; Revaxis; Rg2077 (ctla4-igg4m); Rhb-104; Rhepo; Rhifn beta-1b; Rhigf-1 (cep-151); Rhigm22; Rhumab 2h7; Rhumab to il-17a (igg1-k-class); Rhuph20; Riboflavin; Rifampin; Riluzole; Ritalin; Ritalin la 20mg capsules; Ritalin la 30mg capsules; Ritalin la 40mg capsules; Rituximab; Rituximab infusion; Rituximab it; Rituximab iv; Rivastigmin; Rivastigmine; Rivastigmine transdermal patch; Rns60; Rns60 125 ml; Rns60 250 ml; Ro 496-4913/f07; Ro0506997; Ro4964913; Ro4964913 f07; Ro4964913/f03; Ro4964913/f07; Ro4964913/f07-01; Ro4964913/f07-01 (commercial); Ro4964913/f07-01 (development); Rolipram; Rpc-1063; Rpc1063; Rtl1000 (recombinant t cell receptor ligand); S-warfarin; Sa237; Sa237-120 pfs with nsd; Sa237-120/vial; Saline; Sar339658; Sar442168; Sativex; Sativex oromucosal spray; Sativex®; Satralizumab; Satralizumab (r-inn); Sb-683699; Sb683699; Sc interferon beta-1a; Sc interferon beta-1b; Sc peginterferon beta-1a; Sclerolym; Seasonal quadrivalent influenza vaccine; Second-generation fumaric acid; Secukinumab; Selenium; Sendoxan; Serum containing avonex; Serum free avonex; Sh u 555 c; Silodyx; Simethicone; Simvahexal® 40 mg filmtabletten; Simvastatin; Simvastatin 40 mg film-coated tablets; Simvastatin alternova; Simvastatina; Simvastatina sandoz 40 mg comprimidos recubiertos con película efg; Simvastatine; Simvastatine sandoz 40 mg filmomhulde tabletten; Simvastatine sandoz 40mg deelbare filmomhulde tabletten; Sinvastatina sandoz 40 mg comprimidos revestidos por película; Siponimod; Siponimod 0.25 mg tablet; Siponimod 0.5 mg tablet; Siponimod 1 mg tablet; Siponimod 2 mg tablet; Sirolimus; Sivatin 40 mg film-coated tablets; Sivelestat; Smderpept; Smoked cannabis; Sodium chlorid; Sodium chloride; Sodium chloride solution; Soliris; Solu-medrol; Solu-moderin 1 g; Solumedrol; Somatorelin; Spiropent; Sr-fampridine; Ss-interferon; Standard gadolinium contrast; Standard ms dmts; Standard of care; Standard treatment with a conventional drug; Statin; Stem cell transplantation; Study drug; Sub0750mig; Sub22282; Sublingual tizanidine 12 mg; Sulfate; Sunphenon; Sunphenon egcg; Sunphenon egcg tm; Suspension media; Sustained-release oral dalfampridine; Suvorexant; T cell vaccination; T-cell vaccination; Taci-fc5; Tacrolimus; Tanakan; Tarenflurbil; Targretin; Taurine; Tauroursodeoxycholic acid; Tcelna; Tecfidera; Tecfidera (bg12); Tecfidera®; Tecfidera® 120 mg; Tecfidera® 120mg magensaftresistente hartkapseln; Tecfidera® 240 mg; Tecfidera® 240mg magensaftresistente hartkapseln; Tecifdera (dimethyl fumarate); Temsirolimus; Temsirolimus tablets; Teriflunomide; Teriflunomide (hmr1726); Teriflunomide 14 mg; Teriflunomide 14 mg oral tablet [aubagio]; Teriflunomide hmr1726; Teriflunomide orally; Testosterone; Testosterone undecanoate; Tetanus diphtheria toxoid vaccine (td); Tetanus diphtheria toxoids vaccine; Tetanus toxoid (tt) containing vaccine (td, tdap); Tetracycline; Tetracycline - statin - antimycotic; Tetrahydrocannabinol; Tg-1101; Thiamine; Thioplex; Thiotepa; Thymoglobuline; Tissue selective estrogen complex; Tizanidine; Tizanidine (sublingual or oral); Tizanidine hydrochloride capsule; Tmp001; Tocilizumab; Tocilizumab injection; Tocopherol; Tolerogenic dendritic cells (toldc); Tolerogenic dendritic cells loaded with myelin peptides; Tolperisone; Tolperisone hc1; Tolperisone hcl; Tolpersan; Tolposan; Topical preparation h arm; Torvast*10cpr 10mg; Tovaxin; Tovaxin autologous t cell vaccine; Tracleer; Trancopal dolo; Treosulfan; Trichuris suis eggs; Trichuris suis ova; Trichuris suis ova (eggs), embryonated, viable; Trileptal; Triomar™ (omega-3 fatty acids); Tro19622; Tt vaccine; Tv-5010; Tv-5600; Tylenol pill; Tysabri; Tysabri 300 mg concentrate for solution for infusion; Tysabri 300 mg solution à diluer pour perfusion; Tysabri and avonex; Tysabri ® (natalizumab); Tysabri®; Tysabri® (natalizumab); Ublituximab; Ucb l059; Ultra small particles of iron oxide (uspio); Ultrasmall particles of iron oxide; Umbilical cord derived mesenchymal stem cells; Umbilical cord mesenchymal stem cells; Undifferentiated autologous mesenchymal stem cells; Untreated to atorvastatin treatment; Urbason 40 mg; Urbason 40 mg comprimidos; Urbason forte; Urbason solubile forte 1000mg; Urbason® solubile forte 1000 mg; Urine samples; Uvedose 100 000 ui; Uvedose 100 000 ui, solution buvable en ampoule; V08ca02; V08ca09; Vaginal estriol; Vardenafil; Vardenafil (hidrocloride); Vardenafilo; Vardenafilo hidrocloruro; Vatelizumab; Vay736; Vb13s1; Vb5s2; Vb6s5; Venlafaxin hexal; Venlafaxine; Venlafaxine hydrochloride; Verum arm receiving gilenya®; Verum arm receiving vitamin d oil; Vigantol; Vigantol oel; Vigantol oil; Vigantol® öl 20.000 i.e./ml; Vitamin a; Vitamin d; Vitamin d3; Vitamin e; Vitamin e/selenium; Vitamin k; Vitamina d3 kern pharma solución oleosa; Vsn16r; Vsn16r 100mg; Vx15/2503; Warfarin; Water; Way-130799; Xbd173; Xcel-mc-alpha; Xeomin; Zenapax; Zk 157046; Zol446h; Zoledronic acid; Zoledronic acid monohydrate; [11c]flumazenil; [123i]clinde; [14c]-rpc1063 solution (0.1 mg/ml) for oral administration; [18f] pbr06; [18f]-feppa; [18f]dpa-714; [18f]florbetapir and pet imaging; [c-11]methylreboxetine; [f-18]pbr06; [zr-89]oxine-labeled leukocytes pet/mr

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02912897	September 2020	22 October 2019	Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis	An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis	Multiple Sclerosis	Biological: Cellular therapy with EBV specific autologous CTL infusion	Nantes University Hospital		Not recruiting	18 Years	45 Years	All	7	Phase 1	France
2	NCT03404388	April 1, 2020	29 July 2019	Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis	Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis	Multiple Sclerosis	Behavioral: Balance Training	Wayne State University		Recruiting	18 Years	65 Years	All	150	N/A	United States
3	NCT04150549	February 2020	11 November 2019	FMT for MS Patients	Fecal Microbial Transplantation for Relapsing Multiple Sclerosis Patients - a Placebo-controlled, Double-blinded, Randomized Trial	Multiple Sclerosis	Biological: Fecal Microbial Transplants	Lawson Health Research Institute		Not recruiting	18 Years	55 Years	All	34	Phase 2
4	NCT04140305	January 5, 2020	4 November 2019	Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)	A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)	Multiple Sclerosis	Drug: RPC-1063	Celgene		Not recruiting	18 Years	65 Years	All	250	Phase 3
5	NCT04079088	December 23, 2019	7 October 2019	Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) in Relapsing Multiple Sclerosis (RMS)	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 Therapies in Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1	Biogen		Not recruiting	18 Years	55 Years	All	300	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT04075266	December 11, 2019	4 November 2019	A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis	An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche		Not recruiting	10 Years	18 Years	All	12	Phase 2	United States;Italy
7	NCT04130997	December 2019	11 November 2019	An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis	TG1101-RMS303 is an Open-label, Single-arm Extension Study Designed to Evaluate Long-term Safety and Efficacy of Ublituximab in Subjects With Relapsing Multiple Sclerosis. Subjects Who Complete the 96-week, Double-blind Treatment Period o TG1101-RMS301 or TG1101-RMS302 Are Eligible for Participation in This Open Label Extension (OLE) Study.	Relapsing Multiple Sclerosis (RMS)	Biological: Ublituximab	TG Therapeutics, Inc.		Not recruiting	18 Years	N/A	All	1000	Phase 3
8	NCT04025554	November 13, 2019	11 November 2019	Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis	Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis	Multiple Sclerosis	Drug: Anakinra	National Institute of Neurological Disorders and Stroke (NINDS)		Recruiting	18 Years	100 Years	All	10	Phase 1/Phase 2	United States
9	NCT04146285	November 5, 2019	4 November 2019	A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders	A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders	Neuromyelitis Optica Spectrum Disorders	Drug: BAT4406F	Bio-Thera Solutions		Not recruiting	18 Years	65 Years	All	48	Phase 1	China
10	NCT03829566	November 2019	11 November 2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University		Not recruiting	18 Years	65 Years	All	0	Phase 2/Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT03983720	November 2019	28 October 2019	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Sclerosis, Multiple	Other: Evaluation of degree chronic fatigue.;Other: Questionnaires;Biological: Blood sample;Other: Cardiopulmonary evaluation;Device: Capacity of muscular oxygen extraction;Device: Sleep assessment;Device: Metabolic fatigue;Other: Neuromuscular evaluation	Centre Hospitalier Universitaire de Saint Etienne		Not recruiting	18 Years	70 Years	All	60	Phase 2	France
12	NCT04038541	November 2019	28 October 2019	Prebiotic vs Probiotic in Multiple Sclerosis	Prebiotic and Probiotic Treatment Trial in Multiple Sclerosis	Multiple Sclerosis;Clinically Isolated Syndrome (CIS)	Dietary Supplement: Prebiotics (Prebiotin Prebiotic Fiber Stick Pac);Dietary Supplement: Probiotics (Visbiome®)	Columbia University		Recruiting	18 Years	N/A	All	20	N/A	United States
13	NCT04047628	November 2019	4 November 2019	Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)	Relapsing Multiple Sclerosis;Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Procedure: Autologous Hematopoietic Stem Cell Transplantation;Biological: Best Available Therapy (BAT)	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Not recruiting	18 Years	55 Years	All	156	Phase 3	United States;United Kingdom
14	NCT04155424	November 2019	11 November 2019	A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder	A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder	Drug: Eculizumab	Alexion Pharmaceuticals		Not recruiting	2 Years	17 Years	All	15	Phase 2/Phase 3	United States;Canada;Germany;Italy;Japan;Korea, Republic of;Spain
15	NCT03958877	October 31, 2019	22 October 2019	A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis	An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	Multiple Sclerosis, Relapsing-Remitting	Drug: BIIB017 (peginterferon beta-1a);Drug: Interferon beta type 1a	Biogen		Recruiting	10 Years	18 Years	All	142	Phase 3	United States;Bulgaria;Czechia;France;Italy;Spain;Greece
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT04096443	October 14, 2019	30 September 2019	Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis	A Pilot Study of Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis	Multiple Sclerosis	Biological: Fecal microbial transplant (FMT)	Griffin Hospital	Yale-Griffin Prevention Research Center;Multiple Sclerosis Treatment Center, Derby, Connecticut	Recruiting	18 Years	40 Years	All	15	Early Phase 1	United States
17	NCT04129736	October 10, 2019	28 October 2019	Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis	Determination of Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Treated With Teriflunomide 14 mg Daily.	Multiple Sclerosis, Pharmacokinetics	Drug: Teriflunomide 14 MG	Jan Lycke		Recruiting	18 Years	65 Years	All	20	Phase 4	Sweden
18	NCT04115488	October 1, 2019	11 November 2019	Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®	Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Biological: Intravenous (IV) infusions	Polpharma Biologics S.A.		Recruiting	18 Years	60 Years	All	260	Phase 3	Poland
19	NCT03963375	October 2019	14 October 2019	Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis	Cladribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous System Biomarkers in Multiple Sclerosis	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Cladribine	Washington University School of Medicine	EMD Serono	Recruiting	18 Years	65 Years	All	50	Phase 4	United States
20	NCT04121403	October 2019	22 October 2019	Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)	Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) A Prospective Randomized Open-label Blinded Endpoint (PROBE) Multicenter Non-inferiority Study	Relapsing Multiple Sclerosis;Multiple Sclerosis	Biological: Rituximab;Drug: Cladribine	Oslo University Hospital	University of Oslo;Göteborg University;Sykehuset Ostfold;Sykehuset Telemark;Vestre Viken Hospital Trust;Sorlandet Hospital HF;Helse Stavanger HF;Sykehuset Innlandet HF;Sykehuset i Vestfold HF;Helse Forde;University Hospital of North Norway	Recruiting	18 Years	65 Years	All	264	Phase 3	Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT04121468	October 2019	22 October 2019	A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis	A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: Metformin;Other: Placebo	The Hospital for Sick Children	Queen's University;Ontario Institute for Regenerative Medicine	Not recruiting	10 Years	18 Years	All	30	Phase 1/Phase 2
22	NCT04144257	October 2019	4 November 2019	Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue	Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue	Multiple Sclerosis	Drug: [F-18]PBR06;Drug: [C-11]Methylreboxetine	Brigham and Women's Hospital	United States Department of Defense	Not recruiting	18 Years	60 Years	All	12	Phase 1/Phase 2	United States
23	NCT03807973	September 30, 2019	30 September 2019	Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.	Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.	Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy	Drug: [Zr-89]Oxine-labeled leukocytes PET/MR	University of Alabama at Birmingham		Not recruiting	18 Years	65 Years	All	120	Phase 1
24	NCT03996291	September 23, 2019	14 October 2019	Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis	Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: SAR442168	Sanofi		Recruiting	18 Years	55 Years	All	105	Phase 2	United States
25	NCT04035889	September 23, 2019	7 October 2019	Melatonin for Sleep in MS	A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)	Multiple Sclerosis	Dietary Supplement: Placebo;Dietary Supplement: Melatonin	University of California, San Francisco		Recruiting	20 Years	70 Years	All	30	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	NCT04121221	September 19, 2019	22 October 2019	A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS	A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo	Multiple Sclerosis, Relapsing-Remitting	Drug: GA Depot;Other: Placebo	Mapi Pharma Ltd.		Recruiting	18 Years	55 Years	All	960	Phase 3	United States
27	NCT04002934	September 10, 2019	11 November 2019	Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis	A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Delayed-Start Trial to Assess the Efficacy, Safety, and Tolerability of Bazedoxifene Acetate (BZA) as a Remyelinating Agent in Patients With Multiple Sclerosis	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Bazedoxifene Acetate	Riley Bove, MD		Recruiting	40 Years	65 Years	Female	50	Phase 2	United States
28	ChiCTR1900025744	2019-09-01	30 September 2019	Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial	Clinical effectiveness and safety Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial	neuromyelitis optica spectrum disorder (NMOSD)	1:Intravenous 200mg Rituximab, 1/week2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg);2:Oral azathioprine* (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750~3000mg/day);	The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital		Recruiting	18	70	Both	1:30;2:30;	Phase 4	China
29	NCT03993171	September 2019	16 September 2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis (REPAIR-MS)	A Phase 2, Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: gold nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Not recruiting	18 Years	55 Years	All	24	Phase 2	United States
30	NCT04032158	August 26, 2019	11 November 2019	Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety	Relapsing-remitting Multiple Sclerosis	Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	55 Years	All	950	Phase 3	United States;Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	NCT04032171	August 19, 2019	29 July 2019	Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety	Relapsing-remitting Multiple Sclerosis	Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	55 Years	All	950	Phase 3	United States;Germany
32	NCT03961204	August 15, 2019	22 October 2019	Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis (MS)	Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials	Multiple Sclerosis	Drug: Cladribine	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	65 Years	All	971	Phase 4	United States;Georgia;Korea, Republic of;Germany
33	NCT03972306	August 12, 2019	28 October 2019	A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis	A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: Ocrelizumab;Drug: rHuPH20	Hoffmann-La Roche		Recruiting	18 Years	65 Years	All	135	Phase 1	United States
34	NCT04035005	August 12, 2019	22 October 2019	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab;Drug: Placebo	Hoffmann-La Roche		Recruiting	18 Years	65 Years	All	1000	Phase 3	United States;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom
35	JPRN-JapicCTI-194838	31/7/2019	10 September 2019	Investigation for immune response against JC virus in Multiple Sclerosis patients on treatment with fingolimod	A 18-month, multicenter, two-cohort, prospective, observational study to investigate immune response against JC virus in Multiple Sclerosis patients on treatment with 0.5 mg fingolimod (FTY720)	Multiple Sclerosis	Intervention name : Gilenya / Imusera INN of the intervention : Fingolimod Dosage And administration of the intervention : 0.5mg/day Fingolimod orally Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Novartis Pharma K.K.	Mitsubishi Tanabe Pharma Corporation	Recruiting	18		BOTH	280	NA	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	NCT03933202	July 22, 2019	22 October 2019	A Study of Suboptimally Controlled Participants Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)	Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (MASTER-2)	Multiple Sclerosis	Drug: Cladribine Tablets	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	N/A	All	200	N/A	United States
37	NCT04022473	July 7, 2019	29 July 2019	Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers	A Randomized, Double-Blind Study to Compare Gastrointestinal Tolerability Following Oral Administration of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate) to Healthy Male and Female Volunteers	Multiple Sclerosis	Drug: Bafiertam;Drug: Tecfidera	Banner Life Sciences LLC		Recruiting	18 Years	65 Years	All	200	Phase 1	United States
38	NCT03983252	July 2019	24 June 2019	Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis	Effect of Alemtuzumab on Microglial Activation Assessed Using Novel [F-18]-Based Positron Emission Tomography (PET) Ligand in Multiple Sclerosis	Multiple Sclerosis	Drug: [F-18]PBR06	Brigham and Women's Hospital	Genzyme, a Sanofi Company	Not recruiting	18 Years	60 Years	All	10	Phase 1/Phase 2	United States
39	NCT03656627	June 27, 2019	22 October 2019	Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Autoimmune Diseases;Non-small Cell Lung Cancer;Rheumatoid Arthritis;Psoriasis;Giant Cell Arteritis;Polymyalgia Rheumatica;Systemic Lupus Erythematosus;Crohn Disease;Multiple Sclerosis;Ulcerative Colitis	Drug: Nivolumab	Alliance Foundation Trials, LLC.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	72	Phase 1	United States
40	NCT03774407	June 20, 2019	2 September 2019	Vaginal Estriol in Multiple Sclerosis	Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis;Neurogenic Bladder	Drug: vaginal estriol	Texas Tech University Health Sciences Center		Recruiting	40 Years	65 Years	Female	20	Phase 2/Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	NCT03887065	June 15, 2019	20 May 2019	Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients	Magnetic Resonance Imaging 12 Day Study for Multiple Sclerosis/Clinically Isolated Syndrome Trial of JM-4 Novel Human Peptide	Multiple Sclerosis	Drug: JM-4	Cook, Stuart, MD		Not recruiting	18 Years	55 Years	All	15	Early Phase 1
42	NCT03995810	June 15, 2019	15 July 2019	Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis	Oral Carnosine for Neuromuscular Performance, Brain Biomarkers of Carnosine Metabolism and Health-related Quality of Life in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Carnosine, capsulle, 2 g/day, 8 weeks	University of Novi Sad, Faculty of Sport and Physical Education	CarnoMed	Recruiting	18 Years	65 Years	All	3	N/A	Serbia
43	NCT03873389	June 12, 2019	15 July 2019	Ocrelizumab Effects on the Metabolome in MS	Evaluating the Effects of Ocrelizumab on the Circulating Metabolome in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Ocrelizumab	Johns Hopkins University	Genentech, Inc.	Recruiting	18 Years	75 Years	All	50	Phase 1	United States
44	NCT03783416	June 1, 2019	21 January 2019	SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis	Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.	Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules	Queen Mary University of London	Takeda Pharmaceuticals International, Inc.	Not recruiting	18 Years	65 Years	All	72	Phase 1	United Kingdom
45	NCT03910738	June 2019	23 April 2019	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disability	University Hospital, Strasbourg, France	Bayer;Fédération Hospitalo-Universitaire NEUROGENYCS	Not recruiting	18 Years	55 Years	Male	40	Phase 2	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	NCT03933215	May 21, 2019	22 October 2019	A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)	Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (CLICK-MS)	Multiple Sclerosis	Drug: Cladribine Tablets	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	N/A	All	200	N/A	United States
47	NCT03824938	April 30, 2019	15 July 2019	Aspirin for Exercise in Multiple Sclerosis (ASPIRE)	Aspirin for Exercise in Multiple Sclerosis (ASPIRE): A Double-Blind RCT of Aspirin or Acetaminophen Pretreatment to Improve Exercise Performance in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Aspirin 650mg Oral Capsule;Drug: Acetaminophen Tab 650mg;Other: Placebo	Columbia University	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	18 Years	65 Years	All	60	Phase 1/Phase 2	United States
48	NCT03816345	April 4, 2019	11 November 2019	Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer	A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	Advanced Malignant Neoplasm;Autoimmune Disease;Crohn Disease;Dermatomyositis;Inflammatory Bowel Disease;Metastatic Malignant Neoplasm;Multiple Sclerosis;Rheumatoid Arthritis;Sjogren Syndrome;Systemic Lupus Erythematosus;Systemic Scleroderma;Ulcerative Colitis;Unresectable Malignant Neoplasm	Biological: Nivolumab	National Cancer Institute (NCI)		Recruiting	18 Years	N/A	All	264	Phase 1	United States
49	NCT03025269	April 2, 2019	29 April 2019	Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis	Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	University at Buffalo		Recruiting	18 Years	60 Years	All	30	N/A	United States
50	NCT03853746	April 1, 2019	27 May 2019	Short-term B-cell Depletion in Relapsing Multiple Sclerosis	Evaluating the Effects of Short-term B-cell Depletion on Long-term Disease Activity and Immune Tolerance in Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	Johns Hopkins University	National Multiple Sclerosis Society	Recruiting	18 Years	99 Years	All	10	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	NCT03888924	April 1, 2019	1 April 2019	Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)	Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)	Multiple Sclerosis	Drug: Placebo;Drug: Bacille Calmette-Guerin vaccine	S. Andrea Hospital		Not recruiting	18 Years	N/A	All	100	Phase 2	Italy
52	NCT02466074	April 2019	19 November 2018	Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis	Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis	Multiple Sclerosis	Drug: Acetazolamide;Drug: Placebo	The University of Texas Health Science Center, Houston		Not recruiting	18 Years	55 Years	All	60	Phase 2	United States
53	NCT03856619	March 27, 2019	15 April 2019	To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis	A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: TERIFLUNOMIDE HMR1726	Sanofi		Recruiting	18 Years	N/A	All	193	Phase 4	India
54	NCT03945006	March 25, 2019	20 May 2019	Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence	An Investigation of Balance, Trunk Impairment, and Fear of Falling in Multiple Sclerosis Patients With Incontinence	Multiple Sclerosis;Physical Therapy;Incontinence	Other: Incontinence Severity;Other: Balance;Other: Trunk impairment;Other: Fear of falling	Ankara Yildirim Beyazit University		Not recruiting	24 Years	58 Years	All	36	N/A	Turkey
55	NCT03870763	March 19, 2019	28 October 2019	Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl Fumarate;Drug: Peginterferon Beta-1a;Drug: Placebo	Biogen		Recruiting	10 Years	17 Years	All	340	Phase 3	United States;Colombia;Estonia;Hungary;Korea, Republic of;Taiwan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	EUCTR2018-003927-12-SK	18/03/2019	30 April 2019	Dose-finding study for SAR442168 in relapsing multiple sclerosis	A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR442168 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not available CAS Number: 1971920-73-6 Current Sponsor code: SAR442168 Other descriptive name: PRN2246 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- INN or Proposed INN: Not available CAS Number: 1971920-73-6 Current Sponsor code: SAR442168 Other descriptive name: PRN2246 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Authorised			Female: yes Male: yes	160	Phase 2	France;United States;Estonia;Czech Republic;Slovakia;Canada;Spain;Ukraine;Russian Federation;Norway;Netherlands;Sweden
57	NCT03799718	March 13, 2019	26 August 2019	Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS	A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS	Multiple Sclerosis, Chronic Progressive	Biological: NurOwn (MSC-NTF cells)	Brainstorm-Cell Therapeutics		Recruiting	18 Years	65 Years	All	20	Phase 2	United States
58	EUCTR2018-000516-22-HU	04/03/2019	30 April 2019	Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	340	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Taiwan;Estonia;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of
59	NCT03896217	March 2019	8 April 2019	Simvastatin in Secondary Progressive Multiple Sclerosis	A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage	Secondary Progressive Multiple Sclerosis	Drug: Simvastatin	University College, London	MS Society	Not recruiting	18 Years	65 Years	All	40	Phase 2	United Kingdom
60	NCT03737812	February 27, 2019	4 November 2019	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie		Recruiting	18 Years	65 Years	All	90	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	NCT03808142	February 20, 2019	4 November 2019	PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon	PROmyBETAappGame: Ascertaining Medication Usage & Patient Reported Outcomes Via the myBETAapp and Exploring Gamification in Patients With Multiple Sclerosis Treated With Betaferon	Multiple Sclerosis	Other: myBETAapp;Other: PEAK;Drug: Betaferon, BAY 86-5046;Device: BETACONNECT	Bayer		Recruiting	18 Years	N/A	All	200	Phase 2	Germany
62	NCT03756974	February 18, 2019	11 November 2019	BX-1 in Spasticity Due to Multiple Sclerosis	A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Investigate the Efficacy and Safety of BX-1 for the Symptomatic Relief of Spasticity in Patients With Multiple Sclerosis (MS)	Spasticity Due to Multiple Sclerosis	Drug: BX-1;Drug: Placebo	Bionorica SE		Recruiting	18 Years	65 Years	All	384	Phase 3	Czechia;Germany;Hungary;Poland;Spain
63	NCT03752307	February 15, 2019	13 May 2019	Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses	Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse	Multiple Sclerosis	Drug: Isoxsuprine Hydrochloride;Drug: Placebo;Drug: Corticosteroid	University of New Mexico		Recruiting	18 Years	50 Years	All	20	Phase 1/Phase 2	United States
64	NCT03623243	February 14, 2019	8 April 2019	Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Advancing RMS Patients.	Exploring the Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study	Multiple Sclerosis, Relapsing MS, Advancing Multiple Sclerosis	Drug: Siponimod	Novartis Pharmaceuticals		Recruiting	18 Years	65 Years	All	300	Phase 3	United States
65	NCT03822858	February 12, 2019	30 September 2019	Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis	Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally	Multiple Sclerosis	Drug: Intrathecal MSC-NP injection	Tisch Multiple Sclerosis Research Center of New York		Not recruiting	18 Years	70 Years	All		Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	NCT03759522	February 3, 2019	8 April 2019	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy	Drug: DPA-714 PET/MRI	University of Alabama at Birmingham		Recruiting	18 Years	65 Years	All	120	Phase 1	United States
67	NCT03784547	February 1, 2019	26 August 2019	Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM	Real-world Patient Profile and Treatment Persistence of Ocrelizumab in Multiple Sclerosis: A Retrospective Analysis in Latin America	Multiple Sclerosis	Drug: Ocrelizumab	Hospital Italiano de Buenos Aires		Recruiting	N/A	N/A	All	100	N/A	Argentina
68	NCT03825601	February 1, 2019	11 February 2019	PET With [18F]Flumazenil as an Index of Neurodegeneration in MS	PET With [18F]Flumazenil as an Index of Neurodegeneration in MS: Sensitivity at an Early Disease Stage and Pathophysiological Meaning	Multiple Sclerosis;Relapsing-Remitting Multiple Sclerosis	Diagnostic Test: PET with [11C]Flumazenil	Institut National de la Santé Et de la Recherche Médicale, France		Not recruiting	18 Years	55 Years	All	45	N/A
69	NCT03846219	January 28, 2019	4 March 2019	MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)	Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: IMU-838 (30 mg/day);Drug: IMU-838 (45 mg/day);Drug: Placebo	Immunic AG		Recruiting	18 Years	55 Years	All	195	Phase 2	Bulgaria
70	NCT03653273	January 24, 2019	18 March 2019	Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)	Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years	Multiple Sclerosis	Drug: DMT continuation;Other: DMT withdrawal	Rennes University Hospital		Recruiting	50 Years	N/A	All	250	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	NCT03745144	January 17, 2019	28 October 2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck KGaA, Darmstadt, Germany		Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
72	NCT04086225	January 17, 2019	16 September 2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany		Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
73	EUCTR2018-000516-22-EE	14/01/2019	28 February 2019	Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	340	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Estonia;Taiwan;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of
74	EUCTR2017-004886-29-IE	11/01/2019	28 February 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial	A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL	Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden
75	NCT03803800	January 9, 2019	28 January 2019	Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis	Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis	Multiple Sclerosis	Other: Classic, progressive endurance training;Other: Periodized exercise training;Dietary Supplement: beta-alanine	Hasselt University		Recruiting	18 Years	75 Years	All	80	N/A	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	NCT03535298	January 3, 2019	26 August 2019	Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS	Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Early Highly Effective Therapies Group;Drug: Escalation Therapies Group	The Cleveland Clinic	University of Nottingham	Recruiting	18 Years	60 Years	All	800	Phase 4	United States;United Kingdom
77	NCT04106830	January 1, 2019	22 October 2019	Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)	Prospective Cohort Study of Clinical and Imaging Patterns of Neuroinflammation Diseases (CLUE)	NMO Spectrum Disorder;MRI;Multiple Sclerosis	Drug: Intravenous steroid	Beijing Tiantan Hospital		Recruiting	16 Years	80 Years	All	1000	N/A	China
78	NCT03650114	December 28, 2018	14 October 2019	Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS	An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Biological: Ofatumumab;Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);Biological: Seasonal Quadrivalent influenza vaccine;Biological: Keyhole limpet hemocyanin (KLH) neo-antigen	Novartis Pharmaceuticals		Recruiting	18 Years	N/A	All	2010	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom
79	NCT03847545	December 12, 2018	11 March 2019	Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique	Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking	Multiple Sclerosis	Drug: Fampridine	University of Southern Denmark	Odense University Hospital;Sygehus Lillebaelt;University of Miami;Region of Southern Denmark;The Augustinus Foundation, Denmark.;The Lounkaer Foundation;Fonden for scleroseramte paa Fyn;The Danish Multiple Sclerosis Society;The Lily Benthine Lunds Foundation	Recruiting	18 Years	100 Years	All	60	N/A	Denmark
80	NCT03737851	December 11, 2018	4 November 2019	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie		Recruiting	18 Years	65 Years	All	165	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	EUCTR2018-002315-98-DK	06/12/2018	30 April 2019	The effect of cannabis products on nerve pain and muscle stiffness in patients with multiple sclerosis and in patients with spinal cord injury.	The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial - The effect of medical cannabis on neuropathic pain and spasticity in patients with MS and SCI	Central neuropathic pain and spasticity MedDRA version: 20.0 Level: PT Classification code 10028335 Term: Muscle spasticity System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10077975 Term: Central neuropathic pain System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol capsule 5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: Cannabidiol CAS Number: 13956-29-1 Other descriptive name: CBD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Dronabinol capsule 2,5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3 Other descriptive name: THC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Cannabidiol / Dronabinol capsule 5 mg+2,5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3 Other descriptive name: THC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- INN or Proposed INN: Cannabidiol CAS Number: 13956-29-1 Other descriptive name: CBD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Aarhus Universitetshospital		Authorised			Female: yes Male: yes	448	Phase 2	Denmark
82	NCT03944447	December 1, 2018	7 October 2019	Outcomes Mandate National Integration With Cannabis as Medicine	Outcomes Mandate National Integration With Cannabis as Medicine	Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder	Drug: Cannabis, Medical	OMNI Medical Services, LLC		Recruiting	7 Years	N/A	All	100000	Phase 2	United States
83	NCT03689972	November 28, 2018	7 October 2019	A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment	A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab	Biogen		Not recruiting	18 Years	60 Years	All	480	Phase 3	United States;Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom
84	NCT03536559	November 23, 2018	28 January 2019	Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis	A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis;Optic Neuropathy;Optic; Neuritis, With Demyelination	Drug: CNM-Au8;Drug: Placebo	Clene Nanomedicine	Clene Australia Pty Ltd	Recruiting	18 Years	50 Years	All	150	Phase 2	Australia
85	EUCTR2017-004703-51-SK	21/11/2018	14 January 2019	Long-term safety, tolerability and effectiveness study of ofatumumab in subjects with relapsing multiple sclerosis	An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Novartis Pharma AG		Authorised			Female: yes Male: yes	2233	Phase 3	Portugal;United States;Taiwan;Estonia;Slovakia;Greece;Thailand;Spain;Russian Federation;Israel;Italy;Switzerland;India;France;Peru;Australia;Denmark;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Croatia;Bulgaria;Norway;Germany;Japan;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
86	NCT03594487	November 16, 2018	18 December 2018	Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis	Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function	Relapsing Remitting Multiple Sclerosis	Drug: FMP30 Donor Stool;Procedure: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool;Other: Observational Control	University of California, San Francisco		Recruiting	18 Years	60 Years	All	30	Phase 1	United States
87	NCT03621761	November 15, 2018	4 November 2019	Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue	A Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis	Multiple Sclerosis	Behavioral: Telephone-based Cognitive Behavioral Therapy;Drug: Modafinil	University of Michigan	University of Washington;Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society	Recruiting	18 Years	N/A	All	330	Phase 4	United States
88	NCT03691077	November 11, 2018	18 December 2018	Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714	A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714	Multiple Sclerosis;Relapse;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab	Assistance Publique - Hôpitaux de Paris	Roche Pharma AG;Institut du Cerveau et de la Moelle épinière	Recruiting	18 Years	60 Years	All	51	Phase 3	France
89	NCT04120675	November 9, 2018	22 October 2019	Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis	Randomized, Double Blind, Controlled Prospective Study, to Evaluate the Therapeutic Effects of Early Harvest Olive Oil in Cognitive Functions of Patients With Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis.	Progressive Multiple Sclerosis	Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil	Aristotle University Of Thessaloniki	Greek Alzheimer's Association and Related Disorders;YANNI'S OLIVE GROVE	Recruiting	18 Years	65 Years	All	150	N/A	Greece
90	EUCTR2018-000001-23-ES	06/11/2018	7 January 2019	Clinical study to investigate the efficacy and safety of the test substance BX-1 (dronabinol) for the symptomatic relief of spasticity in patients with multiple sclerosis	A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patients with multiple sclerosis - BX-1 in spasticity due to MS	Symptomatic relief of spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dronabinol Product Code: BX-1 Pharmaceutical Form: Oral solution INN or Proposed INN: Dronabinol CAS Number: 1972-08-3 Current Sponsor code: BX-1 Other descriptive name: Dronabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Bionorica SE		Authorised			Female: yes Male: yes	548	Phase 3	Hungary;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
91	NCT03283397	November 4, 2018	16 December 2017	A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS	A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Drug: EK-12;Drug: INF beta-1a	Bosnalijek D.D	MonitorCRO	Not recruiting	18 Years	55 Years	All	400	Phase 3
92	NCT03593590	November 2, 2018	11 November 2019	Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis	A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche		Recruiting	18 Years	N/A	All	1250	Phase 3	Austria;Belgium;Bulgaria;Colombia;Dominican Republic;Egypt;Italy;Kuwait;Montenegro;Netherlands;Panama;Paraguay;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Slovakia;Spain;Turkey;United Arab Emirates;United Kingdom;Israel
93	EUCTR2018-000001-23-HU	25/10/2018	6 November 2018	Clinical study to investigate the efficacy and safety of the test substance BX-1 (dronabinol) for the symptomatic relief of spasticity in patients with multiple sclerosis	A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patients with multiple sclerosis - BX-1 in spasticity due to MS	Symptomatic relief of spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dronabinol Product Code: BX-1 Pharmaceutical Form: Oral solution INN or Proposed INN: Dronabinol CAS Number: 1972-08-3 Current Sponsor code: BX-1 Other descriptive name: Dronabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Bionorica SE		Authorised			Female: yes Male: yes	548	Phase 3	Hungary
94	EUCTR2017-004702-17-CZ	23/10/2018	28 February 2019	A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.	A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Novartis Pharma AG		Authorised			Female: yes Male: yes	284	Phase 2	United States;Estonia;Czech Republic;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy
95	EUCTR2018-003231-30-ES	19/10/2018	7 January 2019	EFFECTIVENESS OF REPEATED INJECTIONS OF BOTULINUM TOXIN IN THE GAIT AND QUALITY OF LIFE OF ADULT PATIENTS WITH WEAKNESS AND MUSCLE RIGIDITY DUE TO MULTIPLE ESCLEROSIS	EFFECTIVENESS OF THE REPEATED INFILTRATIONS OF BOTULINUM TOXIN A IN THE GAIT AND QUALITY OF LIFE IN ADULTS WITH SPASTIC PARAPARESIA SECONDARY TO MULTIPLE SCLEROSIS - BOTULINUM TOXIN IN PATIENTS WITH SPASTIC PARAPARESIA ASSOCIATED WITH ESCLEROSIS MULTIPLE	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Dysport Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: Dysport Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: range Concentration number: 250-1000	Aránzazu Vázquez Doce		Authorised			Female: yes Male: yes	84	Phase 3	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
96	NCT03740295	October 5, 2018	11 November 2019	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Coconut oil and epigallocatechin gallate;Other: Placebo	Fundación Universidad Católica de Valencia San Vicente Mártir	Valencian Institute of Neurorehabilitation Foundation	Not recruiting	19 Years	65 Years	All	60	Phase 2	Spain
97	NCT03674099	October 1, 2018	26 August 2019	Imatinib for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study	Multiple Sclerosis	Drug: Imatinib Mesylate;Drug: Methylprednisolone	Tomas Olsson	The Swedish Research Council	Recruiting	18 Years	55 Years	All	200	Phase 2	Denmark;Norway;Sweden
98	NCT03396822	September 24, 2018	7 October 2019	Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis	Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis	Multiple Sclerosis	Drug: Gadoteridol	University of Maryland, Baltimore	Genentech, Inc.	Recruiting	18 Years	65 Years	All	22	Phase 1	United States
99	NCT03355365	September 21, 2018	11 June 2019	Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis	Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally	Multiple Sclerosis	Biological: Intrathecal MSC-NP injection;Other: Intrathecal saline injection	Tisch Multiple Sclerosis Research Center of New York		Recruiting	18 Years	65 Years	All	50	Phase 2	United States
100	EUCTR2017-004702-17-EE	17/09/2018	1 October 2018	A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.	A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Novartis Pharma AG		Authorised			Female: yes Male: yes	284	Phase 2	United States;Czech Republic;Estonia;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
101	NCT03166800	September 15, 2018	15 July 2019	MitoQ for Fatigue in Multiple Sclerosis	MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial	Multiple Sclerosis;Fatigue	Drug: Mitoquinone	Oregon Health and Science University	MitoQ Ltd	Recruiting	18 Years	70 Years	All	60	Phase 1/Phase 2	United States
102	NCT03606460	September 14, 2018	30 September 2019	A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)	A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab Dose 1;Drug: Ocrelizumab Dose 2 and Dose 3	Genentech, Inc.		Not recruiting	18 Years	55 Years	All	140	Phase 3	United States
103	EUCTR2017-004158-40-FR	11/09/2018	30 April 2019	NA	A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 - INN-MS	Patients with Relapsing MS or primary progressive MS MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrevus Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab Other descriptive name: ocrelizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)		Authorised			Female: yes Male: yes	71	Phase 3	France
104	EUCTR2017-004702-17-AT	01/09/2018	19 November 2018	A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.	A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Novartis Pharma AG		Authorised			Female: yes Male: yes	284	Phase 2	United States;Estonia;Czech Republic;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy
105	NCT03605238	August 15, 2018	30 September 2019	Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20	Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Biological: Corticosteroids & tanCART19/20	Chinese PLA General Hospital		Not recruiting	12 Years	75 Years	All	0	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
106	NCT03500289	August 10, 2018	16 September 2019	Ketamine for Treatment of MS Fatigue	Ketamine for Treatment of Multiple Sclerosis-related Fatigue	Multiple Sclerosis;Fatigue	Drug: Ketamine;Drug: Midazolam	Johns Hopkins University	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	All	18	Phase 1/Phase 2	United States
107	EUCTR2017-004886-29-CZ	08/08/2018	7 January 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial	A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL	Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden
108	NCT03589105	August 6, 2018	30 September 2019	A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting	An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab 300 mg;Drug: Ocrelizumab 600 mg	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	423	Phase 4	France
109	NCT03584672	August 5, 2018	23 July 2018	The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.	The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.	Multiple Sclerosis	Other: One-leg Stance Test;Other: Functional Reach Test;Other: Four Square Step Test;Other: Timed Up an Go Test;Other: Berg Balance Scale;Other: Static Balance Test	Gazi University		Not recruiting	18 Years	N/A	All	30	N/A
110	NCT03562975	July 23, 2018	4 November 2019	Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus	A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus™	Multiple Sclerosis;Pathologic Processes;Demyelinating Diseases;Nervous System Diseases;Autoimmune Diseases;Immune System Diseases;Primary Progressive Multiple Sclerosis;Relapsing Remitting Multiple Sclerosis	Drug: Ocrelizumab	University of South Florida	Genentech, Inc.	Recruiting	18 Years	70 Years	All	35	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
111	NCT03567057	July 18, 2018	10 September 2018	A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Multiple Sclerosis;Walking Impairment	Drug: ADS-5102	Adamas Pharmaceuticals, Inc.		Recruiting	18 Years	70 Years	All	540	Phase 3	United States
112	NCT03979456	July 4, 2018	24 June 2019	RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS	RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Rituximab	Karolinska Institutet		Recruiting	20 Years	52 Years	All	200	Phase 3	Sweden
113	NCT03000127	July 1, 2018	11 November 2019	Testosterone for Fatigue in Men With MS	A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis	Multiple Sclerosis	Drug: AndroGel 1 % Topical Gel;Drug: Placebos	University of California, Los Angeles	Washington University School of Medicine	Not recruiting	18 Years	60 Years	Male	0	Phase 2	United States
114	NCT03161028	July 1, 2018	11 November 2019	Lipoic Acid for Progressive Multiple Sclerosis (MS)	Lipoic Acid for the Treatment of Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Lipoic acid;Drug: Placebo	VA Office of Research and Development		Recruiting	18 Years	70 Years	All	118	Phase 2	United States;Canada
115	EUCTR2017-004886-29-DK	21/06/2018	19 November 2018	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial	A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL	Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
116	NCT03369665	June 20, 2018	22 October 2019	Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS)	A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®	Multiple Sclerosis	Drug: Mavenclad®	Merck KGaA, Darmstadt, Germany		Not recruiting	18 Years	N/A	All	486	Phase 4	Austria;Belgium;Czechia;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;Germany
117	NCT03423121	June 19, 2018	26 August 2019	A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis	A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients	Progressive Multiple Sclerosis	Drug: Tauroursodeoxycholic Acid;Drug: Placebo oral capsule	Johns Hopkins University		Recruiting	18 Years	N/A	All	60	Phase 1/Phase 2	United States
118	EUCTR2017-000635-13-DE	08/06/2018	30 April 2019	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Multiple Sclerosis (MS), acute episode MedDRA version: 20.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Pharmaceutical Form: Powder and solution for solution for injection INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2000-	Universität Leipzig		Authorised			Female: yes Male: yes	140	Phase 3	Germany
119	NCT03493841	June 8, 2018	1 April 2019	Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis	Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial	Multiple Sclerosis;Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Alpha Lipoic Acid	Rebecca Spain		Not recruiting	18 Years	N/A	All	20	Phase 1	United States
120	NCT03526224	June 4, 2018	22 October 2018	Teriflunomide Tecfidera LMCE	Effect of Teriflunomide on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective Observational Case-control Pilot Study	Tecfidera;Teriflunomide	Drug: Dimethyl Fumarate;Drug: Teriflunomide	University at Buffalo		Not recruiting	18 Years	65 Years	All	120	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
121	NCT03364036	May 28, 2018	2 September 2019	Evaluation of the Onset of Action in Highly Active Multiple Sclerosis (MS)	A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Mavenclad®	Merck KGaA, Darmstadt, Germany		Not recruiting	18 Years	N/A	All	270	Phase 4	Australia;Austria;Canada;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;Belgium
122	NCT03523858	May 28, 2018	22 October 2019	A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis	An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis (PMS)	Drug: Ocrelizumab	Hoffmann-La Roche		Recruiting	18 Years	65 Years	All	600	Phase 3	United States;Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czechia;Denmark;Egypt;France;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Saudi Arabia;Spain;United Arab Emirates
123	NCT03610139	May 21, 2018	24 September 2018	Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients	Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical Trial	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome;Clinically Isolated Syndrome, CNS Demyelinating;Vitamin D3 Deficiency	Dietary Supplement: Vitamin D3	American University of Beirut Medical Center		Recruiting	18 Years	N/A	All	162	N/A	Lebanon
124	EUCTR2017-001313-93-ES	11/05/2018	18 June 2018	A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis	AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30-	Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD		Authorised			Female: yes Male: yes	600	Phase 3	United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria
125	NCT03498131	May 9, 2018	7 October 2019	Melatonin in Patients With Multiple Sclerosis (MS).	Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)	Relapsing Remitting Multiple Sclerosis	Drug: 3 mg Melatonin;Drug: 5 mg Melatonin	Providence Health & Services		Recruiting	18 Years	65 Years	All	30	Early Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
126	NCT03574428	May 8, 2018	3 June 2019	Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers	A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers	Multiple Sclerosis	Drug: GNbAC1;Other: GNbAC1 Placebo	GeNeuro Australia PTY Ltd		Not recruiting	18 Years	55 Years	Male	24	Phase 1	Australia
127	EUCTR2017-001313-93-IE	03/05/2018	7 January 2019	A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis	AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07-01 (development) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 (commercial) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	600	Phase 3	United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria
128	NCT03585569	May 1, 2018	23 July 2018	Treating MS Patients With Lower Extremity Spasticity Using Dysport	A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity Who Are Treated With Dysport	Multiple Sclerosis;Spasticity, Muscle	Biological: Abobotulinumtoxin A	Neurology Center of New England P.C.	Ipsen	Recruiting	N/A	N/A	All	30	Phase 3	United States
129	EUCTR2018-000620-34-SE	24/04/2018	3 September 2018	Imatinib treatment for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study - Imatinib MS	Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where there are radiological and/or cerebrospinal fluid signs consistent with MS), which display an acute relapse MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10028247 Term: Multiple sclerosis like syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Pharmaceutical Form: Film-coated tablet INN or Proposed INN: IMATINIB MESILATE CAS Number: 220127-57-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Trade Name: Solu-Medrol Product Name: Solu-Medrol Pharmaceutical Form: Injection INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: g gram(s) Concentration type: equal Concentration number: 1-	Department of Clinical Neuroscience, Karolinska Institutet		Authorised			Female: yes Male: yes	200	Phase 2	Sweden
130	EUCTR2017-000426-35-AT	17/04/2018	10 September 2018	The efficacy of treatment of patients with multiple sclerosis, a chronic, inflammatory, autoimmune, disease that leads to neurologic deficits and aggravates with flairs, with low doses of rituximab, an antibody directed against the CD20 epitope on B Lymphocytes, specific cells of the immune system contributing to the progression of the disease - a pilot trial	Efficacy of Rituximab at low doses in Multiple Sclerosis – A prospective, randomized, double-blind, active controlled, pilo trial - Low-dose Rituximab in MS	Relapse Remitting Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera or biosimilar rituximab product Product Name: Rituximab Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Mabthera or biosimilar rituximab product Product Name: Rituximab Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Medical University of Vienna - Department of Neurology		Authorised			Female: yes Male: yes	70	Phase 2	Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
131	NCT03464448	April 17, 2018	16 September 2019	Mechanistic Studies of Teriflunomide in RRMS	Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS	Relapsing Remitting Multiple Sclerosis	Drug: Teriflunomide	University of Michigan		Recruiting	18 Years	65 Years	All	30	Phase 3	United States
132	NCT03501342	April 9, 2018	22 October 2018	Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis	Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis	Multiple Sclerosis	Other: Dynamic Balance Training;Other: Virtual reality group	Gazi University		Not recruiting	18 Years	65 Years	All	39	N/A	Turkey
133	EUCTR2017-001313-93-DK	04/04/2018	30 April 2019	A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis	AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	600	Phase 3	United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria
134	NCT03319732	April 3, 2018	28 January 2019	A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS	An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)	Multiple Sclerosis;Spasticity, Muscle	Drug: Arbaclofen	Osmotica Pharmaceutical US LLC		Not recruiting	18 Years	65 Years	All	323	Phase 3	United States
135	JPRN-UMIN000031135	2018/04/01	2 April 2019	Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients		Neuromyelitis Optica	Mycophenolate mofetil treatment for 1 year	Kobe University Hospital		Recruiting	20years-old	80years-old	Male and Female	10	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
136	NCT03850301	April 1, 2018	18 March 2019	Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target	An Experimental Medicine Study to Validate the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target in Multiple Sclerosis	Multiple Sclerosis	Drug: XBD173;Drug: Etifoxine	Imperial College London		Recruiting	35 Years	65 Years	All	44	N/A	United Kingdom
137	NCT03436199	March 29, 2018	20 August 2018	Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment	A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment	Walking Impairment;Multiple Sclerosis	Other: Placebo;Drug: ADS-5102, 274 mg;Drug: ADS-5102, 137 mg	Adamas Pharmaceuticals, Inc.		Recruiting	18 Years	70 Years	All	540	Phase 3	United States
138	NCT03387046	March 26, 2018	26 August 2019	A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)	Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)	Multiple Sclerosis, Relapsing-Remitting	Dietary Supplement: D-aspartate;Drug: Placebo;Biological: IFN beta-1a;Drug: Methylprednisolone	Merck KGaA, Darmstadt, Germany		Not recruiting	18 Years	55 Years	All	7	Phase 2	Italy;Germany
139	NCT03266965	March 23, 2018	2 September 2019	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Multiple Sclerosis	Drug: Carbidopa;Dietary Supplement: L-Histidine	University of Miami	United States Department of Defense	Recruiting	18 Years	60 Years	All	15	Phase 1	United States
140	EUCTR2017-004100-22-PL	21/03/2018	28 February 2019	Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004)	Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use	Osmotica Pharmaceutical US LLC		Not Recruiting			Female: yes Male: yes	510	Phase 3	Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
141	EUCTR2017-004101-40-PL	21/03/2018	28 February 2019	Long-Term Study of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity	An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005).	Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	Osmotica Pharmaceutical US LLC		Authorised			Female: yes Male: yes	300	Phase 3	Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
142	NCT03477500	March 21, 2018	17 June 2019	RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS	Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab for Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab	Haukeland University Hospital		Recruiting	18 Years	50 Years	All	100	Phase 3	Denmark;Netherlands;Norway;Sweden
143	EUCTR2017-004100-22-BG	16/03/2018	7 January 2019	Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004)	Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use	Osmotica Pharmaceutical US LLC		Not Recruiting			Female: yes Male: yes	510	Phase 3	Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
144	JPRN-JapicCTI-173711	15/3/2018	10 September 2019	Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab	A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab	Relapsing Multiple Sclerosis	Intervention name : Ofatumumab INN of the intervention : - Dosage And administration of the intervention : Ofatumumab 20 mg subcutaneous injections every 4 weeks Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo subcutaneous injection matching to ofatumumab every 4 weeks	Novartis Pharma K.K.		Not Recruiting	18	55	BOTH	30	Phase 2	Japan, Russia
145	NCT03249714	March 15, 2018	4 November 2019	Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab	A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab	Relapsing Multiple Sclerosis	Drug: Ofatumumab subcutaneous injection;Drug: Placebo subcutaneous injection matching ofatumumab	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	64	Phase 2	Japan;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
146	NCT03005119	March 1, 2018	16 December 2017	Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms	A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms	Multiple Sclerosis	Drug: PTL201;Drug: Placebo Oral Capsule	PhytoTech Therapeutics, Ltd.		Not recruiting	18 Years	65 Years	All	70	Phase 2	Israel
147	EUCTR2016-004414-10-SE	23/02/2018	12 March 2018	Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.	Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.	Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aubagio Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14-	MS Centrum, Department of Neurology, Sshlgrenska University Hospital		Authorised			Female: yes Male: yes	20	Phase 4	Sweden
148	NCT03551275	February 22, 2018	20 August 2018	Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis	A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Biological: BCD-132	Biocad		Not recruiting	18 Years	60 Years	All	48	Phase 1	Russian Federation
149	EUCTR2017-001224-22-BE	02/02/2018	28 February 2019	Efficacy and Safety of BIIB033 as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies - Efficacy and Safety of BIIB033 as an Add-on Therapy to DMTs in RMS	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Opicinumab Product Code: BIIB033 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Opicinumab Other descriptive name: BIIB033 (ANTI-LINGO) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	240	Phase 2	United States;Spain;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Netherlands;Germany;Sweden
150	EUCTR2017-003008-30-GB	31/01/2018	21 May 2018	Simvastatin in Secondary Progressive Multiple Sclerosis	A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage - MS-OPT Version 1.0 dated 12/10/17	Multiple Sclerosis (Secondary Progressive) MedDRA version: 20.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets Product Code: Not applicable Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	University College London		Authorised			Female: yes Male: yes	40	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
151	NCT03290131	January 28, 2018	9 September 2019	A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis	Multiple Sclerosis;Spasticity, Muscle	Drug: Arbaclofen;Drug: Placebo	Osmotica Pharmaceutical US LLC		Not recruiting	18 Years	65 Years	All	536	Phase 3	Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Serbia;United States
152	NCT03399981	January 24, 2018	24 June 2019	Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries	An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri	Progressive Multifocal Leukoencephalopathy	Biological: Tysabri	Biogen		Not recruiting	N/A	N/A	All	72600	N/A	United States
153	NCT03560739	January 18, 2018	11 November 2019	A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients	A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients	Multiple Sclerosis	Drug: OMB157	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	284	Phase 2	United States;Austria;Bulgaria;Czechia;Estonia;Latvia;Lithuania;Russian Federation;Spain
154	NCT03135249	January 1, 2018	22 October 2019	Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis	Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)	Multiple Sclerosis (MS)	Drug: Alemtuzumab	University of Texas Southwestern Medical Center	Genzyme, a Sanofi Company	Not recruiting	18 Years	60 Years	All	40	Phase 4	United States
155	EUCTR2018-000516-22-PT		30 April 2019	Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Biogen Idec Research Limited		Not Available			Female: yes Male: yes	340	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Taiwan;Estonia;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
156	NCT03670459	December 31, 2017	24 September 2018	Forty Five Patients With Multiple Sclerosis Recieved Vestibular Rehabilitation and Balance Training	Cawthorne Cooksey Versus Vestibular Habituation Exercises on Trunk Kinetics and Velocity of Gait in Patients With Multiple Sclerosis	Neurologic Disorder	Other: Cawthorne Cooksey exercises;Other: Vestibular habituation exercises;Other: Balance exercises	October 6 University		Not recruiting	35 Years	55 Years	All	45	N/A	Egypt
157	EUCTR2017-003328-56-GB	19/12/2017	26 November 2018	MS-STAT2 - Multiple Sclerosis – Simvastatin Trial 2	A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability - MS-STAT2	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Simvastatine Sandoz 40 mg filmomhulde tabletten Product Name: Simvastatine Sandoz 40 mg filmomhulde tabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: SimvaHEXAL® 40 mg Filmtabletten Product Name: SimvaHEXAL® 40 mg Filmtabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG Product Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película Product Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Sivatin 40 mg film-coated tablets Product Name: Sivatin 40 mg film-coated tablets Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten Product Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal	University College London Comprehensive Clinical Trials Unit		Authorised			Female: yes Male: yes	1180	Phase 3	United Kingdom
158	NCT03385356	December 19, 2017	1 April 2019	Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis	Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Vitamin D Deficiency	Drug: Vitamin D	University Medical Centre Maribor	Medical Faculty Maribor	Not recruiting	18 Years	60 Years	All	89	Phase 4	Slovenia
159	EUCTR2017-004846-31-SI	14/12/2017	8 January 2018	Vitamin D supplementation in patients with multiple sclerosis	Impact of vitamin D supplementation in patients with multiple sclerosis	Relapsing remitting multiple sclerosis MedDRA version: 20.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Oleovit D3 14.400 IU/ml oral drops, solution	University medical centre Maribor		Authorised			Female: yes Male: yes	95	Phase 4	Slovenia
160	EUCTR2017-000638-75-PL	13/12/2017	23 July 2018	UbLiTuximab In Multiple Sclerosis Treatment Effects	Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) - ULTIMATE I STUDY	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	TG Therapeutics, Inc.		Authorised			Female: yes Male: yes	440	Phase 3	United Kingdom;Georgia;Russian Federation;Ukraine;Poland;Spain;United States;Belarus;Serbia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
161	NCT03362294	December 11, 2017	16 September 2019	Safety and Efficacy of Monthly Long-acting IM Injection of 40 mg GA Depot in Subjects With PPMS	A Prospective, Multicenter, Single Arm, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)	Primary Progressive Multiple Sclerosis	Drug: GA Depot 40mg once monthly	Mapi Pharma Ltd.		Recruiting	18 Years	65 Years	All	24	Phase 2	Israel
162	EUCTR2017-000638-75-ES	05/12/2017	26 March 2018	UbLiTuximab In Multiple Sclerosis Treatment Effects	Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) - ULTIMATE I STUDY	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	TG Therapeutics		Authorised			Female: yes Male: yes	440	Phase 3	Serbia;Belarus;United States;Poland;Spain;Ukraine;Russian Federation;Georgia;United Kingdom
163	EUCTR2017-000639-15-ES	05/12/2017	26 March 2018	UbLiTuximab In Multiple Sclerosis Treatment Effects	Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY) - ULTIMATE II STUDY	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	TG Therapeutics		Authorised			Female: yes Male: yes	440	Phase 3	Belarus;United States;Poland;Spain;Ukraine;Romania;Croatia;Russian Federation;United Kingdom
164	NCT02988401	December 1, 2017	25 February 2019	Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis	Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: Insulin;Drug: Placebo (Sterile diluent)	Johns Hopkins University	United States Department of Defense	Recruiting	18 Years	70 Years	All	105	Phase 1/Phase 2	United States
165	NCT03315923	December 1, 2017	3 June 2019	Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients	Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate	Secondary Progressive Multiple Sclerosis	Drug: Glatiramer Acetate;Drug: Rituximab	Isfahan University of Medical Sciences		Not recruiting	18 Years	55 Years	All	84	Phase 2/Phase 3	Iran, Islamic Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
166	NCT03353974	December 1, 2017	22 October 2018	Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.	The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial.	Multiple Sclerosis	Device: Video game therapy;Device: Balance platform therapy	University Hospital of Ferrara		Recruiting	18 Years	80 Years	All	40	N/A	Italy
167	NCT03347370	November 27, 2017	7 October 2019	A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis	Subcutaneous (SC) Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms Under Daily Practice Setting	Multiple Sclerosis, Relapsing-Remitting	Drug: SC Peginterferon beta-1a;Drug: SC interferon beta-1a;Drug: SC interferon beta-1b	Biogen	AMS Advanced Medical Services GmbH	Not recruiting	18 Years	N/A	All	626	N/A	Germany
168	NCT03222973	November 14, 2017	13 May 2019	Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies	Multiple Sclerosis	Drug: BIIB033 (opicinumab);Drug: Placebo	Biogen		Not recruiting	18 Years	58 Years	All	263	Phase 2	United States;Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom
169	NCT03342638	November 8, 2017	26 August 2019	Maximizing Outcome of Multiple Sclerosis Transplantation	Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial	Multiple Sclerosis, Relapsing-Remitting	Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University		Not recruiting	18 Years	58 Years	All	200	Phase 3	United States
170	EUCTR2017-001176-31-GB	06/11/2017	28 February 2019	A long term follow up study to look at the progress of patients with symptoms suggestive of MS who took part in previous studies with Betaferon®/Betaseron®	BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies	Clinically-isolated syndrome (CIS) and multiple sclerosis (MS) MedDRA version: 20.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10071068 Term: Clinically isolated syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Betaferon 250 microgram/ml, powder and solvent for solution for injection Product Name: Betaferon Product Code: BAY86-5046 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: RECOMBINANT INTERFERON BETA-1B CAS Number: 145155-23-3 Current Sponsor code: BAY86-5046 Other descriptive name: RECOMBINANT INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250-	Bayer AG,		Not Recruiting			Female: yes Male: yes	300	Phase 4	Portugal;Slovenia;Finland;Spain;Austria;Israel;Italy;United Kingdom;Switzerland;France;Czech Republic;Hungary;Canada;Poland;Belgium;Denmark;Norway;Germany;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
171	NCT03244696	November 2, 2017	11 February 2019	Behavior and Activity Monitoring in MS	Behavior and Activity Monitoring in Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Behavioral: Step Tracking;Behavioral: Water Tracking	Ohio State University	National Multiple Sclerosis Society	Recruiting	30 Years	59 Years	All	200	N/A	United States
172	NCT03350633	November 1, 2017	4 November 2019	Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders	Safety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 Trial	Neuromyelitis Optica Spectrum Disorders;Neuromyelitis Optica	Drug: Tocilizumab Injection;Drug: Azathioprine	Tianjin Medical University General Hospital		Not recruiting	18 Years	N/A	All	118	Phase 2/Phase 3	China
173	NCT02200718	November 2017	14 March 2016	A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis	A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis	Multiple Sclerosis	Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant	Immune Response BioPharma, Inc.	Oregon Health and Science University	Not recruiting	5 Years	17 Years	Both	12	Phase 1	United States
174	EUCTR2017-002838-23-ES	27/10/2017	13 November 2017	Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)	Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)	patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS) MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ORY2001 Product Code: ORY2001 Pharmaceutical Form: Capsule INN or Proposed INN: Not yet requested Current Sponsor code: ORY2001 Other descriptive name: PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0.6-1.2 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Oryzon Genomics S. A		Authorised			Female: yes Male: yes	24	Phase 2	Spain
175	NCT03368664	October 24, 2017	28 October 2019	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)	Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: Glatiramer acetate;Drug: Beta-Interferon;Drug: Methylprednisolone;Drug: Ranitidine;Drug: Ceterizine;Drug: Dexchlorpheniramine;Drug: Paracetamol;Drug: Acyclovir;Drug: Prednisolone;Drug: Diphenydramine;Drug: Other H1 antagonist	Genzyme, a Sanofi Company		Recruiting	10 Years	17 Years	All	50	Phase 3	Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
176	NCT03283826	October 19, 2017	14 October 2019	Phase 1 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis	A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Biological: ATA188;Drug: Placebo	Atara Biotherapeutics		Recruiting	18 Years	65 Years	All	72	Phase 1	United States;Australia
177	EUCTR2015-005431-41-PL	16/10/2017	10 October 2018	A late stage clinical trial to investigate the efficacy and safety of SA237 monotherapy in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SA237 Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: FULLY HUMANIZED ANTI-HUMAN IL-6 RECEPTOR (IL-6R) NEUTRALIZING MONOCLONAL ANTIBODY Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SA237 Product Code: SA237-120 PFS with NSD Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: FULLY HUMANIZED ANTI-HUMAN IL-6 RECEPTOR (IL-6R) NEUTRALIZING MONOCLONAL ANTIBODY Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120-	Chugai Pharmaceutical Co. Ltd		Authorised			Female: yes Male: yes	90	Phase 3	United States;Taiwan;Ukraine;Turkey;Russian Federation;Italy;Canada;Poland;Malaysia;Croatia;Romania;Bulgaria;Georgia;Korea, Republic of
178	NCT03344094	October 12, 2017	16 December 2017	Mechanism of Action of Ocrelizumab in Multiple Sclerosis	Mechanism of Action of Ocrelizumab in Multiple Sclerosis	Multiple Sclerosis;Immune System Diseases	Drug: ocrelizumab	University of Chicago		Recruiting	18 Years	65 Years	All	30	N/A	United States
179	NCT03207464	October 10, 2017	16 July 2018	Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis	Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis	Multiple Sclerosis	Drug: [C-11]Methylreboxetine	Brigham and Women's Hospital		Recruiting	18 Years	60 Years	All	19	Phase 1/Phase 2	United States
180	EUCTR2017-002636-16-NL	09/10/2017	23 October 2017	Understanding problems with attention, memory and concentration in persons with multiple sclerosis	Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate - GABA and glutamate in cognitive impairment in MS	Multiple Sclerosis (MS). And specifically cognitive problems in MS.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [11C]flumazenil Pharmaceutical Form: Solution for injection in administration system	VU University medical center Amsterdam		Authorised			Female: yes Male: yes		Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
181	NCT03185065	October 4, 2017	1 April 2019	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Fatigue in Multiple Sclerosis	Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos	Johns Hopkins University	Patient-Centered Outcomes Research Institute	Not recruiting	18 Years	N/A	All	140	Phase 3	United States
182	EUCTR2016-004719-10-ES	02/10/2017	16 October 2017	A research study to look at the long term benefits and risks of ponesimod 20 mg treatment for patients with relapsing multiple sclerosis.	Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis - OPTIMUM LT	relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Product Name: Ponesimod Product Code: ACT-128800	Actelion Pharmaceuticals Ltd.		Authorised			Female: yes Male: yes	800	Phase 3	Bulgaria;Georgia;Germany;Sweden;Croatia;Romania;Poland;Canada;Mexico;Hungary;Czech Republic;United Kingdom;Lithuania;Turkey;Finland;Bosnia and Herzegovina;Latvia;France;Italy;Israel;Russian Federation;Ukraine;Spain;Greece;Portugal;United States;Belarus;Serbia
183	EUCTR2017-002634-24-SE	29/09/2017	6 November 2017	MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis.	MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients. - MultipleMS	Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Trade Name: Tysabri Pharmaceutical Form: Infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Tecfidera Pharmaceutical Form: Capsule INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Gilenya Pharmaceutical Form: Tablet INN or Proposed INN: FINGOLIMOD CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Copaxone Pharmaceutical Form: Injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 20-40 Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7	Karolinska Institutet		Authorised			Female: yes Male: yes	150	Phase 4	Sweden
184	NCT03122652	September 25, 2017	23 April 2019	Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome	Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study	Multiple Sclerosis	Drug: Teriflunomide 14 MG Oral Tablet [Aubagio];Drug: Placebo Oral Tablet	Centre Hospitalier Universitaire de Nice	Genzyme, a Sanofi Company	Recruiting	18 Years	N/A	All	200	Phase 3	France;Germany;Martinique;Switzerland;Turkey;United Kingdom;Sweden
185	NCT03326505	September 25, 2017	16 December 2017	Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment	The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study.	Multiple Sclerosis	Biological: Umbilical cord derived Mesenchymal Stem Cells;Other: Supervised physical therapy	University of Jordan		Recruiting	18 Years	65 Years	All	60	Phase 1/Phase 2	Jordan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
186	NCT03424733	September 25, 2017	26 August 2019	Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects	A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a	Multiple Sclerosis	Drug: Plegridy;Drug: Prednisone;Drug: Tylenol Pill	Holy Name Medical Center, Inc.	Biogen	Recruiting	18 Years	N/A	All	50	Phase 4	United States
187	EUCTR2017-001294-16-PL	22/09/2017	30 April 2019	A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate	A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate	Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: N/A Product Code: ALKS 8700 Delayed Release (DR) Pharmaceutical Form: Capsule INN or Proposed INN: Not available Current Sponsor code: RDC-5108-00, ALKS8700 Other descriptive name: Diroximel Fumarate (DRF) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 231- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Tecfidera® 120 mg Product Name: Tecfidera® 120 mg Pharmaceutical Form: Capsule INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Tecfidera® 240 mg Product Name: Tecfidera® 240 mg Pharmaceutical Form: Capsule INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Alkermes, Inc.		Authorised			Female: yes Male: yes	420	Phase 3	United States;Poland;Germany
188	NCT03330418	September 21, 2017	28 January 2019	A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders	A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.	Neuromyelitis Optica Spectrum Disorders	Biological: Placebo;Biological: RC18 160 mg	RemeGen		Recruiting	18 Years	65 Years	All	118	Phase 3	China
189	EUCTR2016-003622-16-FI	19/09/2017	2 October 2017	The effect of teriflunomide on brain microglial cell activation in multiple sclerosis.	Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.	Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: AUBAGIO Product Name: Teriflunomide Product Code: L04AA31 Pharmaceutical Form: Film-coated tablet	Turku University Hospital		Authorised			Female: yes Male: yes		Phase 4	Finland
190	NCT03257358	September 19, 2017	2 September 2019	A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod	A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]	Relapsing Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	N/A	All	370	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
191	NCT03134573	September 15, 2017	8 April 2019	Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study	PROmyBETAapp: Ascertaining Medication Usage & Documentation of Patient Reported Outcomes Utilizing the myBETAapp® in Patients With Multiple Sclerosis Treated With Betaferon®: a Pilot Study	Multiple Sclerosis	Drug: Interferon beta-1b (Betaferon, BAY86-5046);Device: Betaconnect auto-injector;Device: myBETAapp	Bayer		Not recruiting	18 Years	N/A	All	96	Phase 2	Germany
192	NCT03282760	September 9, 2017	28 January 2019	Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients	A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients	Secondary-progressive Multiple Sclerosis	Biological: Human Neural Stem Cells	Casa Sollievo della Sofferenza IRCCS	Associazione Revert ONLUS;Neurocenter of Southern Switzerland;Fondazione Cellule Staminali	Not recruiting	18 Years	60 Years	All	24	Phase 1	Italy;Switzerland
193	NCT03183869	August 24, 2017	16 December 2017	Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients	Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients	Autoimmune Diseases;Relapsing Multiple Sclerosis	Drug: Fecal microbiota	Lawson Health Research Institute		Recruiting	18 Years	N/A	All	40	Phase 2	Canada
194	EUCTR2017-001253-13-BE	23/08/2017	20 August 2018	Does decresaed perfusion of the brain play a role in the reduced function of axons and the clinical disability and fatigue in patients with multiple sclerosis ?	Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? - ROCHIMS (Role of Cerebral Hypoperfusion In Multiple Sclerosis)	Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be any clinical evidence of an MS relpase within the 3 months prior to inclusion.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Tracleer Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	UZ Brussel		Authorised			Female: yes Male: yes	30	Phase 2	Belgium
195	NCT03109288	August 11, 2017	4 November 2019	Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)	Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)	Multiple Sclerosis	Drug: Pioglitazone;Drug: Montelukast;Drug: Losartan;Drug: Hydroxychloroquine	National Institute of Allergy and Infectious Diseases (NIAID)		Recruiting	18 Years	99 Years	All	250	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
196	NCT02744222	August 10, 2017	20 August 2018	Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis	An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 µg and 240 µg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: BCD-054 180 mcg;Biological: Avonex®;Biological: BCD-054 240 mcg;Other: Placebo	Biocad		Not recruiting	18 Years	60 Years	All	399	Phase 2/Phase 3	Russian Federation
197	EUCTR2016-000700-29-SE	07/08/2017	28 February 2019	Effect of MD1003 in progressive multiple sclerosis with walking impairment	Effect of MD1003 in progressive multiple sclerosis: a randomized-double blind placebo-controlled study. - SPI2	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: D-Biotin Product Code: MD1003 Pharmaceutical Form: Capsule, hard INN or Proposed INN: D-BIOTIN CAS Number: 58-85-5 Current Sponsor code: MD1003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	MEDDAY PHARMACEUTICALS SA		Authorised			Female: yes Male: yes	754	Phase 3	United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Germany;Netherlands;Sweden
198	NCT03138421	August 1, 2017	4 February 2019	Central Pain Study for ABX-1431	A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain	Neuromyelitis Optica Spectrum Disorder;Transverse Myelitis;Multiple Sclerosis;Longitudinally Extensive Transverse Myelitis	Drug: ABX-1431 HCl;Drug: Placebo	Abide Therapeutics		Not recruiting	18 Years	N/A	All	9	Phase 1	United Kingdom
199	NCT03277248	August 1, 2017	11 November 2019	A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)	ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)	Relapsing Multiple Sclerosis (RMS)	Biological: Ublituximab;Drug: Teriflunomide	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	500	Phase 3	United States
200	NCT03277261	August 1, 2017	11 November 2019	A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)	UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)	Relapsing Multiple Sclerosis (RMS)	Biological: Ublituximab;Drug: Teriflunomide	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	500	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
201	NCT03232073	July 17, 2017	14 October 2019	Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis	Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ponesimod	Actelion		Not recruiting	18 Years	65 Years	All	800	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom
202	EUCTR2016-002937-31-BE	10/07/2017	28 February 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis	Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	1078	Phase 3	Portugal;United States;Slovakia;Spain;Lebanon;Switzerland;Italy;France;Australia;Denmark;Kuwait;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Norway;Germany;Sweden
203	NCT02903537	July 6, 2017	11 June 2018	Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)	Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS)	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Chronic Progressive	Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);Drug: Interferon-beta	Fundació Institut Germans Trias i Pujol	Clinica Universidad de Navarra, Universidad de Navarra	Recruiting	18 Years	60 Years	All	16	Phase 1	Spain
204	NCT03250169	July 1, 2017	16 December 2017	Neurofilaments for NEDA Assessing in MS	Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study	Multiple Sclerosis	Drug: Alemtuzumab	Queen Mary University of London		Recruiting	18 Years	55 Years	All	60	N/A	United Kingdom
205	EUCTR2016-002937-31-SE	19/06/2017	28 February 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis	Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	1078	Phase 3	Portugal;United States;Slovakia;Spain;Lebanon;Switzerland;Italy;France;Australia;Denmark;Kuwait;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Norway;Germany;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
206	NCT03239860	June 6, 2017	18 December 2018	Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis	A Long-Term International, Extension of Study GNC-003 With GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: GNbAC1 Monoclonal Antibody	GeNeuro SA	Les Laboratoires Servier;Worldwide Clinical Trials;Institut de Recherches Internationales Servier	Not recruiting	18 Years	55 Years	All	220	Phase 2	Bulgaria;Croatia;Czechia;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine
207	NCT03381170	June 1, 2017	11 November 2019	An Extension of the TG1101-RMS201 Trial	An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Biological: Ublituximab	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	48	Phase 2	United States
208	NCT02618902	May 30, 2017	11 June 2018	A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial	A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial	Multiple Sclerosis	Biological: tolerogenic dendritic cells (tolDC)	University Hospital, Antwerp		Recruiting	18 Years	60 Years	All	9	Phase 1	Belgium
209	NCT02901106	May 23, 2017	21 January 2019	Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate	Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP	Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl fumarate	Fondation Ophtalmologique Adolphe de Rothschild		Not recruiting	18 Years	N/A	All	11	Phase 4	France
210	EUCTR2016-003587-39-SE	22/05/2017	4 December 2018	This is a long-term study of the safety, efficacy and patient satisfaction of the drug rituximab in comparison with other immunomodulatory treatments for multiple sclerosis. The study will use a national registry for both retrospective and prospective data retrieval.	COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) A prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in relapsing-remitting multiple sclerosis - COMparison Between All immunoTherapies for Multiple Sclerosis (COMBAT-MS)	Relapsing-remitting multiple sclerosis (RRMS) that has started on their first or second immunomodulatory drug at the earliest 2011-01-01 and at the latest 2018-06-30. The clinical course and response to treatment is thereafter followed until 2021-06-30;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Trade Name: Tysabri Pharmaceutical Form: Infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Tecfidera Pharmaceutical Form: Capsule INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Gilenya Pharmaceutical Form: Tablet INN or Proposed INN: FINGOLIMOD CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Copaxone Pharmaceutical Form: Injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 20-40 Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7	Karolinska Institutet		Authorised			Female: yes Male: yes	3700	Phase 4	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
211	NCT03126760	May 22, 2017	18 March 2019	Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	Relapsing, Remitting Multiple Sclerosis	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt		Recruiting	18 Years	N/A	All	66	Phase 4	United States
212	NCT03269071	May 17, 2017	11 March 2019	Neural Stem Cell Transplantation in Multiple Sclerosis Patients	Neural Stem Cell Transplantation in Multiple Sclerosis Patient: a Phase I Study	Progressive Multiple Sclerosis	Drug: human fetal-derived Neural Stem Cells (hNSCs)	IRCCS San Raffaele	Fondazione Italiana Sclerosi Multipla	Recruiting	18 Years	55 Years	All	4	Phase 1	Italy
213	NCT03028675	May 1, 2017	22 October 2019	pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress	pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress	Multiple Sclerosis	Drug: Gd-DTPA-ST;Drug: Control	NYU Langone Health		Not recruiting	18 Years	65 Years	All	4	Phase 4	United States
214	NCT03345940	April 30, 2017	4 November 2019	Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis	A Multicentric Randomized PRAGmatic Trial to Compare the Effectiveness of Fingolimod Versus Dimethyl-Fumarate on Patient Overall Disease Experience in Relapsing Remitting Multiple Sclerosis: Novel Data to Inform Decision-makers	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Dimethyl Fumarate	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	Patient-Centered Outcomes Research Institute;Universita degli Studi di Genova	Not recruiting	18 Years	N/A	All	55	Phase 4	Italy
215	NCT03073603	April 20, 2017	22 July 2019	Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)	Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Discontinuation of disease modifying therapy;Drug: Standard of Care	University of Colorado, Denver	Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society;University of Alabama at Birmingham	Recruiting	55 Years	N/A	All	250	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
216	NCT02881567	April 18, 2017	7 October 2019	Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: Daclizumab	Biogen	AbbVie	Not recruiting	18 Years	55 Years	All	41	Phase 3	United States;Canada;Germany;Italy;Puerto Rico;France;United Kingdom
217	EUCTR2016-004935-18-HU	12/04/2017	23 October 2017	A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis	A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis - ANGEL-MS	Multiple Sclerosis (MS) MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not Available CAS Number: 1393641-34-3 Current Sponsor code: GNbAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	GeNeuro SA		Authorised			Female: yes Male: yes	240	Phase 2	Serbia;Estonia;Czech Republic;Hungary;Poland;Spain;Ukraine;Croatia;Russian Federation;Bulgaria;Germany;Italy
218	EUCTR2016-003100-30-ES	04/04/2017	10 April 2017	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)	Multiple Sclerosis MedDRA version: 19.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Authorised			Female: yes Male: yes	65	Phase 3	Portugal;Greece;Spain;Turkey;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Czech Republic;Poland;Belgium;Bulgaria;Norway;Netherlands;Germany;Sweden
219	NCT03085810	April 4, 2017	11 November 2019	Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)	An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Ocrelizumab	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	1233	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Finland
220	NCT02907177	March 30, 2017	30 September 2019	Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)	Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)	Multiple Sclerosis	Drug: Ponesimod;Other: Placebo	Actelion		Recruiting	18 Years	55 Years	All	600	Phase 3	United States;Australia;Austria;Belgium;Bulgaria;Canada;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;Croatia;Czech Republic;Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
221	NCT03091400	March 28, 2017	25 June 2018	Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)	Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis	Memory Disorders;Multiple Sclerosis	Drug: Atomoxetine;Drug: Placebo	Icahn School of Medicine at Mount Sinai		Not recruiting	21 Years	60 Years	All	11	Phase 2	United States
222	NCT03110315	March 28, 2017	29 April 2019	A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia	A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia	Multiple Sclerosis;Fatigue;Insomnia	Drug: Suvorexant;Drug: Placebo	Theodore R. Brown, MD MPH	Merck Sharp & Dohme Corp.	Recruiting	18 Years	75 Years	All	30	Phase 4	United States
223	NCT03093324	March 15, 2017	2 September 2019	A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2	A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate	Relapsing Remitting Multiple Sclerosis	Drug: ALKS 8700;Drug: Dimethyl Fumarate	Alkermes, Inc.		Not recruiting	18 Years	65 Years	All	506	Phase 3	United States;Germany;Poland
224	NCT03091569	March 10, 2017	11 June 2018	Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy	Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY)	Relapsing-Remitting Multiple Sclerosis	Other: Vitamin K Cream;Other: Placebo Cream	Biogen		Not recruiting	18 Years	N/A	All	23	Phase 4	Italy
225	EUCTR2016-000700-29-DE	08/03/2017	28 February 2019	Effect of MD1003 in progressive multiple sclerosis with walking impairment	Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study. - SPI2	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: D-Biotin Product Code: MD1003 Pharmaceutical Form: Capsule, hard INN or Proposed INN: D-BIOTIN CAS Number: 58-85-5 Current Sponsor code: MD1003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	MEDDAY PHARMACEUTICALS SA		Authorised			Female: yes Male: yes	754	Phase 3	United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Germany;Netherlands;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
226	NCT02975349	March 7, 2017	28 January 2019	A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.	Relapsing-remitting Multiple Sclerosis	Drug: M2951;Drug: Placebo;Drug: Tecfidera	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	65 Years	All	267	Phase 2	Bulgaria;Czechia;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;Germany;United States
227	NCT03164018	March 7, 2017	25 February 2019	Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis	Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis	Multiple Sclerosis	Drug: Fampridine	Genesis Pharma CNS & Specialty		Not recruiting	18 Years	N/A	All	111	Phase 2	Greece
228	NCT03806387	March 1, 2017	28 January 2019	Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment	Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment - a Prospective Observational Study	Multiple Sclerosis	Drug: Alemtuzumab	University of Aarhus	Genzyme, a Sanofi Company	Recruiting	18 Years	65 Years	All	60	N/A	Denmark
229	NCT02149706	March 2017	14 March 2016	A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination	Multiple Sclerosis	Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant	Immune Response BioPharma, Inc.	Oregon Health and Science University	Not recruiting	18 Years	70 Years	Both	150	Phase 2	United States
230	EUCTR2016-001448-21-SK	16/02/2017	28 February 2019	A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.	Relapsing Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: M2951 Product Code: M2951 Pharmaceutical Form: Tablet INN or Proposed INN: M2951 Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240-	Merck KGaA		Authorised			Female: yes Male: yes	250	Phase 2	Serbia;United States;Czech Republic;Slovakia;Poland;Spain;Ukraine;Croatia;Turkey;Russian Federation;Bulgaria;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
231	NCT02949908	February 9, 2017	16 December 2017	MEasuring Satisfaction of Treatment With REbif After Initial Treatment of MS (MESTRE-MS)	A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study to Measure Treatment Satisfaction of Multiple Sclerosis (MS) Patients on Rebif® After Discontinuing Initial First-line Treatment	Multiple Sclerosis	Drug: Rebif (IFNß-1b)	Merck KGaA	Merck B.V., Netherlands	Not recruiting	18 Years	65 Years	All	2	N/A	Germany
232	NCT03193866	February 1, 2017	29 April 2019	COMparison Between All immunoTherapies for Multiple Sclerosis.	COMparison Between All immunoTherapies for Multiple Sclerosis. An Observational Long-term Prospective Cohort Study of Safety, Efficacy and Patient's Satisfaction of MS Disease Modulatory Treatments in Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Rituximab	Karolinska Institutet	Patient-Centered Outcomes Research Institute;Kaiser Foundation Research Institute	Recruiting	18 Years	N/A	All	3700	N/A	Sweden
233	NCT03418376	February 1, 2017	21 January 2019	Carnosine Loading in MS and HC	The Impact of Carnosine Loading and Rehabilitation Therapy on Exercise Capacity in Multiple Sclerosis.	Multiple Sclerosis;Exercise Therapy;Dietary Supplement	Dietary Supplement: Beta-alanine supplementation;Other: Exercise intervention	Hasselt University		Not recruiting	18 Years	75 Years	All	45	N/A	Belgium
234	NCT02057159	February 2017	14 March 2016	A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	Secondary Progress Multiple Sclerosis;Multiple Sclerosis	Biological: NeuroVax;Biological: IFA Placebo	Immune Response BioPharma, Inc.	Oregon Health and Science University	Not recruiting	18 Years	50 Years	Both	200	Phase 2/Phase 3	United States
235	NCT03021317	February 2017	16 December 2017	Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses	Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses	Multiple Sclerosis	Drug: ACTHar	University of Chicago		Not recruiting	18 Years	N/A	All	18	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
236	NCT03177083	January 30, 2017	24 September 2018	Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy	Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	Relapsing Remitting Multiple Sclerosis	Drug: peginterferon beta-1a;Drug: interferon beta-1a;Drug: interferon beta-1b	Biogen		Recruiting	18 Years	65 Years	All	140	Phase 4	Portugal
237	NCT03051646	January 13, 2017	26 November 2018	Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis	A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis	Overheating;Fatigue	Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit;Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit	Columbia University	National Multiple Sclerosis Society	Not recruiting	18 Years	60 Years	All	12	Early Phase 1	United States
238	NCT03032601	January 5, 2017	23 April 2019	Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis	Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: N-acetyl Cysteine	Thomas Jefferson University		Not recruiting	30 Years	80 Years	All	25	N/A	United States
239	NCT03193086	January 1, 2017	16 December 2017	The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients	The Effect of Alemtuzumab on the Blood-brain-barrier and Cerebral Metabolism in Multiple Sclerosis Patients; a New MRI Method for Treatment Response Evaluation in Multiple Sclerosis	Multiple Sclerosis	Drug: Alemtuzumab	Glostrup University Hospital, Copenhagen	Genzyme, a Sanofi Company	Recruiting	18 Years	60 Years	All	35	N/A	Denmark
240	NCT02481882	January 2017	22 October 2018	Baseline Cortical Haemodynamics in MS	Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis	Multiple Sclerosis	Device: Magnetic Resonance Imaging;Drug: Prohance (Gadoteridol)	University of Nottingham		Recruiting	21 Years	80 Years	All	80	N/A	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
241	NCT02980042	January 2017	29 April 2019	Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis	Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Rituximab	University of Colorado, Denver		Recruiting	18 Years	65 Years	All	200	Phase 3	United States
242	NCT03172741	January 2017	20 August 2018	The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis	The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis	Multiple Sclerosis	Drug: Medical Marijuana;Drug: Placebo	Colorado State University		Not recruiting	21 Years	74 Years	All	0	Phase 2/Phase 3
243	NCT04082260	January 2017	30 September 2019	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Multiple Sclerosis	Drug: Alemtuzumab Injection [Lemtrada]	University Hospital Muenster		Recruiting	18 Years	N/A	All	150	N/A	Germany
244	EUCTR2017-005129-18-IT		17 September 2018	Clinical trial to evaluate the effectiveness and safety of IFN beta-1a (IFN beta-1a), injected once a week via intramuscolar (i.m.), and glatiramer-acetate (GA) in children/adolescent patients with multiple sclerosis.	Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affected by multiple sclerosis.	Relapsing-remitting multiple sclerosis with paediatric onset MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Copaxone 40 mg/ml solution for injection, pre-filled syringe Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: Glatiramer Acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Trade Name: AVONEX 30 µg/0,5 ml solution for injection Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: Interferon beta-1a CAS Number: 145258-61-3 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30-	Università degli Studi Aldo Moro		Not Available			Female: yes Male: yes	142	Phase 3	Italy
245	NCT02969304	December 30, 2016	16 December 2017	Study of Utilization Patterns of Dimethyl Fumarate in Germany	Claims Database Study of Utilization Patterns of Dimethyl Fumarate in Germany	Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	N/A	N/A	All	930	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
246	NCT03186664	December 28, 2016	26 August 2019	The Role of SAtivex® in Robotic-Rehabilitation	The Role of SAtivex® Associated With Robotic-Rehabilitation in Improving the Motor Performances of Multiple Sclerosis Patients (SARR)	Rehabilitation	Device: Lokomat training;Drug: Sativex	IRCCS Centro Neurolesi Bonino-Pulejo		Not recruiting	18 Years	65 Years	All	40	N/A	Italy
247	NCT02977533	December 1, 2016	11 June 2018	A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: GZ402668;Drug: Placebo;Drug: Acyclovir	Sanofi		Not recruiting	18 Years	65 Years	All	20	Phase 1	Germany
248	NCT03561402	December 1, 2016	20 August 2018	Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)	Association of Possible Biomarkers With Disease Activity in Patients Treated With Teriflunomide (Aubagio)	Multiple Sclerosis, Relapsing-Remitting	Drug: Teriflunomide	McGill University		Recruiting	18 Years	55 Years	All	75	Early Phase 1	Canada
249	NCT02936037	December 2016	20 May 2019	Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)	Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule;Drug: PLACEBO	MedDay Pharmaceuticals SA		Not recruiting	18 Years	65 Years	All	642	Phase 3	United States;Australia;Belgium;Canada;Czechia;Germany;Hungary;Italy;Poland;Spain;Sweden;Turkey;United Kingdom;Czech Republic;Netherlands
250	NCT02959658	December 2016	4 March 2019	Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis	Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis	Drug: Dimethyl Fumarate;Drug: Placebo Oral Capsule	Rigshospitalet, Denmark	Biogen	Not recruiting	18 Years	65 Years	All	90	Phase 2	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
251	EUCTR2015-005431-41-HR	30/11/2016	7 January 2019	A late stage clinical trial to investigate the efficacy and safety of SA237 monotherapy in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SA237 Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SA237-120 PFS with NSD Product Code: L04AX01 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120-	Chugai Pharmaceutical Co. Ltd		Authorised			Female: yes Male: yes	90	Phase 3	United States;Taiwan;Ukraine;Turkey;Italy;Canada;Malaysia;Poland;Croatia;Romania;Bulgaria;Georgia;Korea, Republic of
252	EUCTR2016-002180-33-PL	16/11/2016	29 January 2018	Multiple sclerosis therapy with transdermal myelin peptide stimulation.	Multiple sclerosis therapy with transdermal myelin peptide stimulation.	relapsing-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SMderpept Pharmaceutical Form: Powder for cutaneous solution INN or Proposed INN: PLP peptide Current Sponsor code: PLP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: MBP peptide Current Sponsor code: MBP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: MOG peptide Current Sponsor code: MOG peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Product Name: SMderpept Pharmaceutical Form: Powder for cutaneous solution INN or Proposed INN: PLP peptide Current Sponsor code: PLP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- INN or Proposed INN: MBP peptide Current Sponsor code: MBP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- INN or Proposed INN: MOG peptide Current Sponsor code: MOG peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Avonex Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1-A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Centrum Neurologii Krzysztof Selmaj		Authorised			Female: yes Male: yes	220	Phase 2	Poland
253	EUCTR2012-000541-12-DE	15/11/2016	6 November 2018	Clinical study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®)	Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) - POINT	Relapsing multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s)	Actelion Pharmaceuticals Ltd.		Authorised			Female: yes Male: yes	600	Phase 3	Greece;Finland;United States;Portugal;Spain;Austria;Israel;Italy;France;Czech Republic;Hungary;Canada;Belgium;Poland;Australia;Denmark;Bulgaria;Germany
254	EUCTR2016-000434-21-PT	14/11/2016	30 April 2019	PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	Relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Plegridy 125 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Peginterferon beta-1a CAS Number: 1211327-92-2 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 125- Trade Name: Rebif 22 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Trade Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Trade Name: Betaferon 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Recombinant Interferon Beta-1b Other descriptive name: RECOMBINANT INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia 250 micrograms/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Recombinant Interferon Beta-1b Other descriptive name: RECOMBINANT INTERFERON BETA-1B	Biogen Portugal		Authorised			Female: yes Male: yes	140	Phase 4	Portugal
255	NCT03516526	November 3, 2016	22 July 2019	Towards Personalized Dosing of Natalizumab in Multiple Sclerosis	Towards Personalized Dosing of Natalizumab in Multiple Sclerosis	Multiple Sclerosis	Drug: Natalizumab	VU University Medical Center	Sanquin Plasma Products BV;Erasmus Medical Center;St. Antonius Hospital;OLVG;Rijnstate Hospital	Not recruiting	18 Years	N/A	All	61	Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
256	NCT02913157	November 2016	29 April 2019	Hydroxychloroquine in Primary Progressive Multiple Sclerosis	Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)	Multiple Sclerosis, Primary Progressive	Drug: Hydroxychloroquine	University of Calgary		Recruiting	18 Years	65 Years	All	35	Phase 2	Canada
257	EUCTR2016-001515-20-IT	20/10/2016	12 February 2018	nd	EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS - nd	RELAPSING-REMITTING MULTIPLE SCLEROSIS MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE Product Name: teriflunomide Product Code: nd Pharmaceutical Form: Film-coated tablet	UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI		Authorised			Female: yes Male: yes	30	Phase 4	Italy
258	NCT02587065	October 19, 2016	11 June 2018	Plegridy Satisfaction Study in Participants	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: peginterferon beta-1a	Biogen		Not recruiting	18 Years	65 Years	All	199	Phase 4	Italy
259	NCT02601885	October 18, 2016	11 June 2018	A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis	An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ABT-555;Other: Placebo	AbbVie		Not recruiting	18 Years	60 Years	All	20	Phase 1	United States
260	NCT01649050	October 2016	16 December 2017	Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis	A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis	Muscle Spasticity Due to Multiple Sclerosis	Drug: BGG492;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	0	Phase 2	Germany;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
261	NCT02807285	October 2016	16 December 2017	Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis	An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	Genentech, Inc.		Not recruiting	18 Years	55 Years	All		N/A	United States
262	EUCTR2016-000345-31-NL	30/09/2016	10 October 2016	Reduce the number of natalizumab infusions in patients with multiple sclerosis	Towards personalized dosing of natalizumab in multiple sclerosis - Personalised Dosing of Natalizumab in Multiple Sclerosis (The PDNMS trial)	multiple sclerosis MedDRA version: 18.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: tysabri Product Name: natalizumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	VU medical center		Authorised			Female: yes Male: yes	60	Phase 4	Netherlands
263	EUCTR2016-003073-18-GB	29/09/2016	3 April 2017	A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body	A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults - ADME study of [14C]-RPC1063 in healthy male subjects (QCL117686)	The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for adult patients with moderately to severely active inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856 MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration Pharmaceutical Form: Oral solution INN or Proposed INN: Ozanimod hydrochloride CAS Number: 1618636-37-5 Current Sponsor code: RPC1063HCL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.1-	Celgene International II Sàrl		Authorised			Female: no Male: yes	6	Phase 1	United Kingdom
264	NCT03101735	September 23, 2016	20 August 2018	Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece	A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study	RRMS	Drug: Dimethyl Fumarate (DMF)	Genesis Pharma CNS & Specialty		Not recruiting	18 Years	65 Years	All	455	N/A	Greece
265	JPRN-UMIN000024312	2016/09/20	2 April 2019	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.		Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic		Not Recruiting	20years-old	80years-old	Male and Female	12	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
266	NCT02792218	September 20, 2016	16 September 2019	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis	A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Placebo subcutanous injection matching to ofatumumab;Drug: Teriflunomide orally;Drug: Placebo orally matching to teriflunomide;Drug: Ofatumumab subcutaneous injection	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	929	Phase 3	Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;Slovakia;Spain
267	EUCTR2015-005418-31-EE	12/09/2016	28 February 2019	Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosis	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis	multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Current Sponsor code: OMB157 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Aubagio Product Name: Teriflunomide Pharmaceutical Form: Capsule, hard INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	900	Phase 3	United States;Estonia;Slovakia;Greece;Thailand;Spain;Russian Federation;Israel;Switzerland;India;France;Australia;Denmark;Netherlands;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Belgium;Poland;Croatia;Bulgaria;Germany;Sweden
268	EUCTR2016-000283-41-DK	12/09/2016	6 November 2018	Treatment with dimethyl fumarate in patients with primary progressive multiple sclerosis	Dimethyl fumarate treatment of primary progressive multiple sclerosis - FUMAPMS	Primary progressive multiple sclerosis (PPMS) MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Product Name: dimethyl fumarate Product Code: dimethyl fumarate Pharmaceutical Form: Capsule, hard INN or Proposed INN: dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Finn Sellebjerg		Authorised			Female: yes Male: yes	90	Phase 2	Denmark
269	NCT02861014	September 9, 2016	22 October 2019	A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)	An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment	Multiple Sclerosis, Relapsing-Remitting	Biological: Ocrelizumab	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	681	Phase 3	Australia;Belgium;Czechia;Denmark;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;Czech Republic;Hong Kong
270	NCT02898974	September 2016	22 January 2018	Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis	Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study	Multiple Sclerosis	Behavioral: Medical Marijuana	Colorado State University	William R. Shaffer, M.D.	Not recruiting	30 Years	60 Years	All	19	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
271	NCT02792231	August 26, 2016	16 September 2019	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.	A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.	Relapsing Multiple Scelrosis	Drug: Ofatumumab subcutaneous injection;Drug: Placebo orally matching to teriflunomide;Drug: Teriflunomide orally;Drug: Placebo subcutaneous injection matching to ofatumumab	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	900	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Finland;France;Germany;Hungary;India;Italy;Latvia;Lithuania;Mexico;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom
272	EUCTR2015-003147-19-GR	18/07/2016	8 August 2016	To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).	Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo	Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NEUROASPIS PLP10® Pharmaceutical Form: Oral liquid INN or Proposed INN: FISH OIL,RICH IN OMEGA 3 ACIDS Other descriptive name: FISH OIL, RICH IN OMEGA-3-ACIDS Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 42.1- INN or Proposed INN: BORAGE OIL 20% GLA CAS Number: 8000051-62-9 Other descriptive name: BORAGE OIL Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 43.7- INN or Proposed INN: beta-Carotene Other descriptive name: BETACAROTENE Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 0.04- INN or Proposed INN: Gamma-tocopherol CAS Number: 54 28 4 Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 4.2- Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use	PALUPA Medical Ltd		Authorised			Female: yes Male: yes	220	Phase 3	Greece
273	NCT03436927	July 15, 2016	26 February 2018	Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis	Comparison of the Effects of Two Different Virtual Reality Treatment Methods in Patients With Multiple Sclerosis: A Randomized Controlled Trial	Multiple Sclerosis	Other: Nintendo Wii Fit Balance exercises;Other: Balance Trainer Balance Exercises	Biruni University	Istanbul University	Not recruiting	25 Years	60 Years	All	51	N/A
274	NCT02660359	July 8, 2016	11 November 2019	Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2	A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis	Urinary Incontinence;Overactive Bladder	Biological: Botulinum toxin type A;Drug: Placebo	Ipsen		Not recruiting	18 Years	80 Years	All	258	Phase 3	Argentina;Australia;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;Peru;Russian Federation;Spain;Ukraine;United Kingdom;New Zealand
275	NCT02760056	July 2016	5 September 2016	Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study	Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study	Multiple Sclerosis	Drug: Liothyronine sodium;Drug: Placebo	Oregon Health and Science University		Recruiting	18 Years	50 Years	Both	24	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
276	NCT02833142	July 2016	9 January 2017	Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes	A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers	Multiple Sclerosis;Acute Optic Neuritis	Drug: BIIB033 (opicinumab)	Biogen		Not recruiting	18 Years	55 Years	Both	28	Phase 1	United States
277	NCT02869425	July 2016	9 September 2019	To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS	A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis	Multiple Sclerosis;Sperm	Drug: arbaclofen ER Tablets;Drug: Placebo for arbaclofen ER tablets	Osmotica Pharmaceutical US LLC		Not recruiting	18 Years	55 Years	Male	0	Phase 3	United States
278	NCT03069170	July 2016	18 June 2018	Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.	Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis.	Multiple Sclerosis	Biological: Stem Cell Transplantation	Stem Cells Arabia		Not recruiting	N/A	N/A	All	50	Phase 1	Jordan
279	NCT02921035	June 30, 2016	30 September 2019	Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis	A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With Relapsing Multiple Sclerosis (RMS) Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a	Relapsing Multiple Sclerosis	Drug: Rebif (Interferon beta-1a)	Merck KGaA, Darmstadt, Germany	Merck Serono Middle East FZ LLC	Not recruiting	18 Years	60 Years	All	594	N/A	Algeria;Argentina;Bahrain;Bulgaria;Egypt;Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Germany;Tunisia;United Arab Emirates
280	EUCTR2015-000507-44-DE	29/06/2016	21 May 2018	A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosis	A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT® FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS	Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10046543 Term: Urinary incontinence System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Not possible to specify	Trade Name: Dysport® Product Name: Dysport® Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: 52120 Other descriptive name: BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX Concentration unit: U unit(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intravesical use Trade Name: Dysport® Product Name: Dysport® Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: 52120 Other descriptive name: BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX Concentration unit: U unit(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intravesical use	Ipsen Innovation		Authorised			Female: yes Male: yes	330	Phase 3	Spain;Ukraine;Lithuania;Russian Federation;Chile;Israel;Colombia;United Kingdom;France;Mexico;Argentina;Belgium;Brazil;Peru;Germany;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
281	NCT02797015	June 23, 2016	11 June 2018	Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS	A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: RPC1063	Celgene		Not recruiting	18 Years	55 Years	All	22	Phase 1	United States
282	EUCTR2016-000464-42-DE	13/06/2016	11 June 2018	The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab	A Prospective, Open-label, Interventional Phase IIIb Clinical Trial to Investigate the Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab - LemCourse	Relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Other descriptive name: ALEMTUZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme GmbH		Authorised			Female: yes Male: yes	100	Phase 3	Germany
283	NCT02424396	June 13, 2016	11 February 2019	Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis	Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study	Relapsing Remitting Multiple Sclerosis	Drug: IL2;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	Fondation ARSEP/AFM	Recruiting	18 Years	65 Years	All	30	Phase 2	France
284	NCT03150966	June 8, 2016	24 September 2018	The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients	The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients	Multiple Sclerosis	Drug: Nanocurcumin;Drug: Placebo	Tabriz University of Medical Sciences		Not recruiting	18 Years	65 Years	All	41	Phase 2	Iran, Islamic Republic of
285	EUCTR2015-005160-41-PL	07/06/2016	28 February 2019	an Open Label Study of ALKS 8700 in Adults with Multiple Sclerosis	A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis - EVOLVE-MS-1	Relapsing Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: N/A Product Code: ALKS 8700 Delayed Release (DR) Capsule Pharmaceutical Form: Capsule INN or Proposed INN: Not available CAS Number: Not availabl Current Sponsor code: RDC-5108-00, ALKS 8700 Other descriptive name: ALKS 8700 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 231-	Alkermes, Inc.		Authorised			Female: yes Male: yes	800	Phase 3	Serbia;United States;Canada;Belgium;Spain;Poland;Ukraine;Russian Federation;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
286	NCT02446886	June 2016	14 January 2019	Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS	Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS	Multiple Sclerosis	Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)	Weill Medical College of Cornell University	Mallinckrodt	Recruiting	18 Years	N/A	All	30	Phase 4	United States
287	NCT02609607	June 2016	18 December 2018	Treating Anorectal Dysfunction in MS	Treating Anorectal Dysfunction Associated With Multiple Sclerosis	Constipation;Fecal Incontinence;Multiple Sclerosis	Drug: Bisacodyl;Other: Placebo	David Levinthal	Consortium of Multiple Sclerosis Centers	Not recruiting	18 Years	80 Years	All	11	Phase 2	United States
288	NCT02870023	June 2016	4 March 2019	How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?	How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?	Multiple Sclerosis	Other: Balance training;Other: Strength training	University of Aarhus	VIA University College;TrygFonden, Denmark;Fondazione Don Carlo Gnocchi Onlus	Not recruiting	18 Years	N/A	All	71	N/A	Denmark
289	NCT02784210	May 26, 2016	23 April 2019	Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques	The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study	Multiple Sclerosis	Drug: Methylprednisolone	National Institute of Neurological Disorders and Stroke (NINDS)		Recruiting	25 Years	55 Years	All	10	Phase 2	United States
290	NCT02676739	May 20, 2016	1 April 2019	Adderall XR and Cognitive Impairment in MS	A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS	Multiple Sclerosis	Drug: Adderall XR	Sarah Morrow		Recruiting	18 Years	59 Years	All	180	Phase 2/Phase 3	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
291	EUCTR2015-005597-38-GB	19/05/2016	7 January 2019	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis	An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment - CASTING	Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Greece;Finland;Spain;Ireland;Turkey;Italy;United Kingdom;Switzerland;France;Czech Republic;Belgium;Denmark;Norway;Netherlands;Germany;Sweden
292	NCT03237832	May 16, 2016	16 December 2017	A Phase 1 Study of ARN-6039	A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Oral Doses of ARN-6039 in Healthy Adult Subjects.	Multiple Sclerosis	Drug: ARN-6039;Other: Placebo	Arrien Pharmaceuticals	Worldwide Clinical Trials	Not recruiting	18 Years	50 Years	All	60	Phase 1
293	EUCTR2015-004059-29-HU	04/05/2016	19 February 2018	Clinical study to assess efficacy, safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis	An international, double-blind, randomised, placebo-controlled phase IIb trial to assess the efficacy, safety, and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis - CHANGE-MS	Multiple Sclerosis (MS) MedDRA version: 19.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNbAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNBAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNBAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	GeNeuro SA		Not Recruiting			Female: yes Male: yes	260	Phase 2	Serbia;Estonia;Spain;Ukraine;Russian Federation;Italy;France;Hungary;Czech Republic;Poland;Croatia;Bulgaria;Germany
294	NCT02749396	May 2, 2016	26 August 2019	EPID Multiple Sclerosis Pregnancy Study	Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon ß - a Register-based Study in the Nordic Countries	Multiple Sclerosis	Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG;Drug: Extavia (interferon beta-1b), Novartis Pharma AG;Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd;Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd;Drug: Avonex (interferon beta-1a), Biogen Idec Ltd;Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046);Other: No MSDMDs therapy (control)	Bayer	EPID Research;Biogen;Merck Serono Europe Ltd;Novartis Pharmaceuticals	Not recruiting	N/A	N/A	Female	2089	Early Phase 1	Finland
295	NCT03566251	May 1, 2016	2 July 2018	Core Stability, Trunk Position Sense, Balance and Functional Mobility in Patients With Multiple Sclerosis	The Investigation of the Relationship Between Core Stability and Trunk Position Sense With Balance and Functional Mobility in Patients With Multiple Sclerosis	Physical Therapy	Other: Balance;Other: Functional mobility;Other: Core stability;Other: Trunk position sense	Ankara Yildirim Beyazit University		Not recruiting	18 Years	65 Years	All	74	N/A	Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
296	NCT02428218	May 2016	25 April 2016	Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)	A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Relapsing Forms of Multiple Sclerosis	Drug: Placebo;Drug: dimethyl fumarate	Biogen		Not recruiting	10 Years	17 Years	Both	0	Phase 3
297	NCT02670161	May 2016	26 August 2019	Quality Improvement and Practice Based Research in Neurology Using the EMR	Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record	Brain Tumors;Epilepsy;Migraine;Mild Cognitive Impairment;Concussion;Multiple Sclerosis;Neuropathy;Parkinson's;Restless Legs Syndrome;Stroke	Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)	NorthShore University HealthSystem		Recruiting	18 Years	100 Years	All	3300	Phase 4
298	NCT02746744	May 2016	17 June 2019	RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.	RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.	Multiple Sclerosis, Relapsing-Remitting	Drug: Rituximab;Drug: Dimethyl fumarate;Drug: Sodium Chloride solution	Anders Svenningsson		Not recruiting	18 Years	50 Years	All	200	Phase 3	Sweden
299	NCT02688985	April 29, 2016	11 November 2019	Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)	An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis	Relapsing Multiple Sclerorsis;Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab;Procedure: Lumbar Puncture;Drug: Methyloprednisolone;Drug: Antihistamine	Genentech, Inc.		Recruiting	18 Years	55 Years	All	120	Phase 3	United States;Canada;Germany;Sweden
300	NCT02675413	April 2016	8 August 2016	Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS	Mechanisms of Action of Dimethyl Fumarate in Relapsing MS	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl Fumarate	Washington University School of Medicine	Biogen	Not recruiting	18 Years	N/A	Both	0	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
301	NCT02769689	April 2016	23 May 2016	Methylprednisolone During the Switch Between Natalizumab and Fingolimod	Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY)	Multiple Sclerosis	Drug: Methylprednisolone;Drug: Placebo;Drug: natalizumab (NTZ);Drug: fingolimob (FTY)	University Hospital, Clermont-Ferrand		Recruiting	18 Years	65 Years	Both	56	Phase 4	France
302	NCT02739542	March 19, 2016	27 May 2019	Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)	Multi-center, Randomized, Double-blinded Assessment of Tecfidera® in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)	Multiple Sclerosis (MS)	Drug: Tecfidera;Drug: Placebo	University of Texas Southwestern Medical Center	Biogen	Recruiting	18 Years	N/A	All	90	Phase 4	United States
303	NCT02738775	March 18, 2016	11 November 2019	Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis	A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.	Multiple Sclerosis	Biological: Ublituximab;Drug: Placebo	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	48	Phase 2	United States
304	NCT02636829	March 2016	26 September 2016	Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis	Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Chronic Inflammatory Arthritis	Multiple Sclerosis;Rheumatoid Arthritis	Other: QALCIMUM questionnaire;Other: Determination of calcium intake by a dietician interview	Centre Hospitalier Universitaire de Nimes		Not recruiting	18 Years	69 Years	Both	100	N/A	France
305	NCT02660138	March 2016	11 November 2019	Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1	A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis	Urinary Incontinence;Overactive Bladder	Biological: Botulinum toxin type A;Drug: Placebo	Ipsen		Not recruiting	18 Years	80 Years	All	227	Phase 3	United States;Canada;Czechia;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Turkey;Czech Republic;Malaysia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
306	NCT02555215	February 22, 2016	18 December 2018	Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)	A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: dimethyl fumarate	Biogen		Not recruiting	10 Years	17 Years	All	20	Phase 3	United States;Belgium;Bulgaria;Czechia;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;Czech Republic
307	EUCTR2015-004451-40-CZ	17/02/2016	3 July 2017	SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS	SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL - SAVANT	Moderate to severe spasticity due to MS (multiple sclerosis). MedDRA version: 19.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SATIVEX Pharmaceutical Form: Oromucosal spray Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use	Almirall Hermal GmbH		Not Recruiting			Female: yes Male: yes	228	Phase 4	Czech Republic;Austria
308	NCT02575365	February 16, 2016	16 December 2017	Effect of Fingolimod on Neurodegeneration	Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients	Cognition;Brain Volume Loss	Drug: 0,5 mg Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	4	Phase 4	Turkey
309	NCT02637856	February 11, 2016	30 September 2019	A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)	An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment	Multiple Sclerosis, Relapsing-Remitting	Drug: Ocrelizumab	Genentech, Inc.		Not recruiting	18 Years	55 Years	All	611	Phase 3	United States;Canada
310	NCT02652091	February 5, 2016	17 September 2018	Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction	Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta-1b (Betaseron, BAY86-5046);Device: BETACONNECT device	Bayer		Not recruiting	18 Years	N/A	All	146	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
311	EUCTR2015-002820-20-NL	03/02/2016	7 January 2019	Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?	Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? - Alpha blockers and Multiple Sclerosis (MS)	Bladder dysfunction in Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10069632 Term: Bladder dysfunction System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Silodyx Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Erasmus MC Dept. Urology		Authorised			Female: yes Male: no	30	Phase 3	Netherlands
312	NCT02601131	February 2016	12 December 2016	Post-transfusion Platelet Count	Post-transfusion Platelet Count	Leukemia;Multiple Sclerosis	Biological: Platelet transfusion	Region Skane		Not recruiting	18 Years	N/A	Both	80	N/A	Sweden
313	NCT02641041	February 2016	17 October 2016	Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants	A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects	Central Nervous System (CNS) Demyelinating Disease;Multiple Sclerosis	Biological: BIIB033;Other: Placebo	Biogen		Not recruiting	20 Years	55 Years	Both	24	Phase 1	United Kingdom
314	NCT02644083	February 2016	10 September 2018	Tecfidera and MRI for Brain Energy in MS	Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate	Multiple Sclerosis	Drug: Dimethyl fumarate	Oregon Health and Science University	Biogen	Not recruiting	18 Years	55 Years	All	4	N/A	United States
315	NCT02710214	February 2016	15 July 2019	A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis	Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.	Menopause;Multiple Sclerosis	Drug: Tissue Selective Estrogen Complex;Drug: Placebo	University of California, San Francisco	National Multiple Sclerosis Society	Not recruiting	18 Years	62 Years	Female	24	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
316	NCT02823951	February 2016	12 March 2018	Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®	Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)	Relapsing-remitting Multiple Sclerosis	Drug: Rebif;Drug: Tecfidera	IMS HEALTH GmbH & Co. OHG	EMD Serono	Not recruiting	18 Years	55 Years	All	479	N/A	United States;Canada
317	JPRN-UMIN000022201	2016/01/10	2 April 2019	The efficacy and safety of tocilizumab in patients with neuromyelitis optica		neuromyelitis optica	Tocilizumab it to be infused every 4weeks at 8mg/kg of body weight for 2 years.	Department of Neurology, Shimane University Hospital		Recruiting	20years-old	74years-old	Male and Female	3	Not selected	Japan
318	ChiCTR-OPB-16007730	2016-01-01	18 April 2017	Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA)	Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA)	Neuromyelitis optica	Case series:Mycophenolate Mofetil;	The third affiliated hospital,Sun Yat-sen university		Recruiting	18	65	Both	Case series:100;	Post-market	China
319	NCT02276963	January 2016	17 June 2019	Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses	Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder	Drug: Ublituximab	Johns Hopkins University		Not recruiting	18 Years	100 Years	All	6	Phase 1	United States
320	NCT02644044	January 2016	18 January 2016	Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study	Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study	To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS	Drug: Intrathecal methotrexate	Tel-Aviv Sourasky Medical Center		Not recruiting	18 Years	75 Years	Both	30	Phase 0
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
321	NCT02649985	January 2016	11 June 2018	Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease	Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease	Multiple Sclerosis;Alzheimer's Disease	Drug: [F-18]PBR06	Brigham and Women's Hospital		Recruiting	18 Years	70 Years	All	50	Phase 1/Phase 2	United States
322	NCT02809079	January 2016	27 June 2016	Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients	Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients	Neuromyelitis Optica Spectrum Disorders;Mycophenolate Mofetil;Efficacy and Safety	Drug: Mycophenolate mofetil;Drug: Prednisone	Third Affiliated Hospital, Sun Yat-Sen University	Zhongshan Ophthalmic Centre, Sun Yat-sen University;Nangfang Hospital, Southern Medical University	Recruiting	18 Years	65 Years	Both	100	Phase 4
323	EUCTR2016-003100-30-BG		28 February 2019	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)	Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Not Available			Female: yes Male: yes	65	Phase 3	Norway;Netherlands;Germany;Bulgaria;Poland;Belgium;France;Italy;United Kingdom;Switzerland;Russian Federation;Austria;Turkey;Spain;Greece;Portugal
324	NCT02677077	December 31, 2015	14 January 2019	Clinical Disease Activity With Long Term Natalizumab Treatment	MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab	Relapsing-Remitting Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	277	Phase 2	Belgium;Czechia;Czech Republic
325	EUCTR2015-004116-38-SE	18/12/2015	22 January 2018	A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis.	RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis Objective: To compare the efficacy of rituximab on the ability to prevent relapses in early RRMS and CIS compared with dimethyl fumarate (DMF), which is an approved first-line medication for RRMS today, using a phase 3 design. Population: Patients with newly diagnosed RRMS or CIS with no more than 10 years disease duration (since diagnosis), 18 – 50 years of age and previously not treated with immunomodulating drugs OR treated with first-line injectables. Patients should display protocol-defined clinical or radiological disease activity during the preceding year before screening for inclusion. Intervention: Treatment with rituximab (Mabthera®) with an initial dose of 1000 mg intravenously (iv) followed by 500 mg iv every six months. Control: Treatment with DMF (Tecfidera®) 240 mg twice daily. The two treatments are randomised in a 1:1 proportion. Outcome: Primary outcome is the relative risk of experiencing a relapse during the two–year period for either compound. As secondary endpoints worsening on neurological disability, magnetic-resonance imaging-defined disease activity and effect on cerebrospinal fluid biomarkers will be analysed. In addition, health-economic evaluations of using rituximab as first-line treatment for RRMS will be performed.	Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use Trade Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 480-	Department of Clinical Sciences, Danderyd Hospital		Authorised			Female: yes Male: yes	200	Phase 3	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
326	NCT02587195	December 18, 2015	11 June 2018	A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period	A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period	Multiple Sclerosis	Drug: Teriflunomide	Centre Hospitalier Universitaire de Nice		Not recruiting	18 Years	55 Years	All	5	Phase 3	France
327	NCT02583594	December 6, 2015	5 November 2018	A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis	A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: Acyclovir;Drug: Methylprednisolone;Drug: alemtuzumab GZ402673;Drug: Paracetamol;Drug: Loratadine;Drug: Ceterizine;Drug: Dexchlorpheniramine	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	All	24	Phase 1	Spain
328	NCT02011451	December 2015	3 October 2016	Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis	Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis	Multiple Sclerosis	Drug: 95% Pure ECGC capsules 200mg;Drug: Placebo Comparator:	Louisiana State University Health Sciences Center in New Orleans	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	Both	0	Phase 2	United States
329	NCT02634307	December 2015	14 October 2019	A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1	A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: ALKS 8700	Alkermes, Inc.		Not recruiting	18 Years	65 Years	All	1057	Phase 3	United States;Belgium;Bulgaria;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine
330	NCT02471560	November 30, 2015	12 February 2018	Tecfidera and the Gut Microbiota	The Effect of Tecfidera® (Dimethyl Fumarate, BG00012) on the Gut Microbiota as a Causal Factor for Gastro Intestinal Associated Adverse Events.	Multiple Sclerosis, Relapsing-Remitting	Drug: dimethyl fumarate;Drug: injectable MS DMT	Biogen		Not recruiting	18 Years	N/A	All	37	Phase 4	Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
331	NCT02545959	November 30, 2015	14 October 2019	Intrathecal Rituximab in Progressive Multiple Sclerosis	Intrathecal Rituximab in Progressive Multiple Sclerosis	Multiple Sclerosis, Chronic Progressive;Nervous System Diseases	Drug: Rituximab IT;Drug: methylprednisolone IV;Drug: Rituximab IV	Centre Hospitalier de PAU	University Hospital, Bordeaux	Not recruiting	45 Years	N/A	All	10	Phase 2	France
332	JPRN-JapicCTI-153058	24/11/2015	16 July 2019	Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis	Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis	Multiple sclerosis	Intervention name : Copaxone subcutaneous injection syringe Dosage And administration of the intervention : For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily.Participants will receive interventions as part of routine medical care.	TAKEDA PHARMACEUTICAL COMPANY LTD.		Recruiting			BOTH	1000	NA
333	NCT02633033	November 24, 2015	4 February 2019	Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse	A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse	Multiple Sclerosis, Relapsing-Remitting	Drug: H.P. Acthar® Gel (repository corticotropin injection)	Mallinckrodt		Not recruiting	18 Years	N/A	All	160	Phase 3	United States;Puerto Rico
334	EUCTR2012-003735-32-GR	19/11/2015	23 July 2018	Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.	A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment	Relapsing-remitting multiple sclerosis (RR MS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinb mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	AB Science		Not Recruiting			Female: yes Male: yes	450	Phase 3	Slovakia;Greece;Spain;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Argentina;Belgium;Brazil;Bulgaria;Germany
335	EUCTR2015-002500-91-BE	10/11/2015	28 February 2019	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Label Extension (OLE) study	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: 0.25mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: 1.0mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0-	Celgene International II Sàrl (CIS II)		Authorised			Female: yes Male: yes	2496	Phase 3	Serbia;Belarus;United States;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Lithuania;United Kingdom;Hungary;Belgium;Poland;Croatia;Romania;Bulgaria;Georgia;Germany;New Zealand;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
336	NCT02490982	November 2015	16 December 2017	Teriflunomide Observational Effectiveness Study	Teriflunomide Observational Effectiveness Study	Relapsing Remitting Multiple Sclerosis	Drug: Teriflunomide	Centre hospitalier de l'Université de Montréal (CHUM)	Genzyme, a Sanofi Company;Montreal Neurological Institute and Hospital	Recruiting	18 Years	N/A	All	300	N/A	Canada
337	NCT02686684	November 2015	7 November 2016	Tecfidera Diffusion Tensor Imaging	An Open-label, Observational, Single-blinded, Longitudinal Study to Evaluate the Effect of Dimethyl Fumarate on Gray and White Matter Pathology in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging	Drug: Dimethyl fumarate	University at Buffalo		Not recruiting	18 Years	N/A	Both	115	N/A
338	NCT02743312	November 2015	24 October 2016	Long-Term Effects of Torso-Weighting	Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study	Multiple Sclerosis	Device: Balance-Based Torso-Weighting (WT);Device: Sham Weights (SW);Device: Fitbit Flex	San Francisco State University	Samuel Merritt University;Samuel Merritt University	Not recruiting	18 Years	N/A	Both	5	N/A	United States
339	NCT02545868	October 27, 2015	11 November 2019	A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis	A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: 23-PPV;Biological: 13-PCV Booster;Biological: Influenza Vaccine;Biological: KLH;Drug: OCR;Biological: TT Vaccine	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	102	Phase 3	United States;Canada
340	EUCTR2015-002500-91-HU	12/10/2015	28 February 2019	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Label Extension (OLE) study	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: 0.25mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: 1.0mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0-	Celgene International II Sàrl (CIS II)		Authorised			Female: yes Male: yes	2496	Phase 3	Belgium;Serbia;Belarus;United States;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Lithuania;United Kingdom;Hungary;Poland;Croatia;Romania;Bulgaria;Georgia;Germany;New Zealand;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
341	NCT02529839	October 2015	31 August 2015	Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)	Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis	Multiple Sclerosis	Procedure: Autologous bone marrow transplantation;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Alemtuzumab	Hadassah Medical Organization		Not recruiting	18 Years	65 Years	Both	20	N/A
342	NCT02606630	October 2015	16 December 2017	[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis	A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ABT-555	AbbVie		Not recruiting	18 Years	60 Years	All	4	Phase 1	United Kingdom
343	EUCTR2012-000540-10-DE	23/09/2015	25 June 2018	International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis	Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis - OPTIMUM	relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Capsule INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Aubagio® Product Name: Aubagio® Pharmaceutical Form: Tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod	Actelion Pharmaceuticals Ltd		Authorised			Female: yes Male: yes	1100	Phase 3	Serbia;Portugal;Belarus;United States;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Latvia;Bosnia and Herzegovina;Finland;Turkey;Lithuania;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Romania;Croatia;Bulgaria;Georgia;Germany;Sweden
344	EUCTR2014-003498-41-AT	22/09/2015	28 September 2015	Effects of dalfampridine on mobility in the context of daily life	Effects of dalfampridine on mobility in the context of daily life - Fampridine Study in Activities of Daily Living	Motor behaviour and cognition in multiple sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Medical University of Vienna		Authorised			Female: yes Male: yes			Austria
345	NCT02486640	September 8, 2015	11 November 2019	Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon	BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence	Multiple Sclerosis	Drug: Interferon beta-1b (Betaferon, BAY86-5046);Device: Betaconnect Autoinjector	Bayer		Not recruiting	18 Years	N/A	All	162	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
346	NCT03774914	September 1, 2015	26 August 2019	LEMTRADA Pregnancy Registry in Multiple Sclerosis	International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis	Multiple Sclerosis	Drug: Alemtuzumab (GZ402673)	Genzyme, a Sanofi Company		Recruiting	18 Years	55 Years	Female	204	Phase 2	United States;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;Sweden;United Kingdom
347	NCT02283671	September 2015	25 February 2019	Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B		Multiple Sclerosis;Neuromyelitis Optica	Biological: Tolerogenic Dendritic cells loaded with myelin peptides	Sara Varea		Recruiting	18 Years	65 Years	All	22	Phase 1	Spain
348	NCT03002038	September 2015	9 January 2017	Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients	Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders	Neuromyelitis Optica Spectrum Disorder	Drug: Azathioprine;Drug: Rituximab	Isfahan University of Medical Sciences		Not recruiting	18 Years	50 Years	Both	76	Phase 2/Phase 3	Iran, Islamic Republic of
349	NCT02499900	August 31, 2015	16 December 2017	Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®	A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily	Multiple Sclerosis	Drug: Copaxone®	Teva Pharmaceutical Industries, Ltd.		Not recruiting	18 Years	N/A	All	861	Phase 4	United States;Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Spain;Turkey
350	NCT02525874	August 31, 2015	3 December 2018	Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).	An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	65 Years	All	218	Phase 3	United States;Belgium;Bulgaria;Kuwait;Lithuania;Poland;Turkey;Croatia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
351	EUCTR2014-000395-26-DE	07/08/2015	30 October 2017	Description ofchanges in that part of the nervous sstem that is processing visual information over an extended perion of time in patients with relapsing remitting multiple sclerosis who take Tecfidera	A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate - VISION	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240-	Biogen GmbH		Not Recruiting			Female: yes Male: yes	600	Phase 4	Germany
352	NCT01532154	August 2015	31 October 2016	Fampridine Pregnancy Exposure Registry	Fampridine Pregnancy Exposure Registry	Multiple Sclerosis;Pregnancy	Drug: Fampridine	Biogen		Not recruiting	N/A	N/A	Female	1	N/A	France;Germany;United Kingdom;United States
353	NCT02493049	August 2015	22 October 2019	Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)	Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Domperidone	University of Calgary	Alberta Innovates Health Solutions	Not recruiting	18 Years	60 Years	All	17	Phase 2	Canada
354	NCT02542787	August 2015	12 March 2018	Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis	A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis	Spasticity in People With Multiple Sclerosis	Drug: VSN16R;Other: Placebo	Canbex Therapeutics Ltd		Not recruiting	18 Years	70 Years	All	160	Phase 2	United Kingdom
355	NCT02632591	August 2015	28 December 2015	Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment	Use on Human Being of a Mix Between Very Well Known Drugs, Tested Upon Registered Trial n° NCT02606929, to Consider Effectiveness of Improvement After 45 Days	Multiple Sclerosis;Autoimmune Disease;Disseminated or Multiple Sclerosis Nos;Multiple Sclerosis, Acute Relapsing;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive	Drug: Tetracycline;Drug: statin;Drug: antimycotic;Drug: Fingolimod;Drug: copaxone	Università Popolare Homo & Natura		Not recruiting	18 Years	65 Years	Both	90	Phase 1	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
356	NCT02683863	August 2015	16 December 2017	Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers	An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: BG00012 (DMF) (Tecfidera®.)	Multiple Sclerosis Center of Northeastern New York	Biogen	Not recruiting	25 Years	65 Years	All	20	Phase 4	United States
357	NCT02686788	August 2015	3 December 2018	TMP001 in Relapsing-remitting Multiple Sclerosis	TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial	Remitting-Relapsing Multiple Sclerosis	Drug: TMP001	Dr. Frank Behrens	SocraMetrics GmbH	Not recruiting	18 Years	55 Years	All	9	Phase 2	Germany
358	NCT03046251	August 2015	26 August 2019	Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis	Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis	Multiple Sclerosis	Drug: Natalizumab	State University of New York at Buffalo		Recruiting	18 Years	N/A	Female	100	Phase 4	United States
359	NCT02511028	July 28, 2015	1 April 2019	In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging	In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging	Multiple Sclerosis	Other: Ferumoxytol	National Institutes of Health Clinical Center (CC)	National Institute of Neurological Disorders and Stroke (NINDS)	Not recruiting	18 Years	70 Years	All	14	Early Phase 1	United States
360	EUCTR2014-004483-38-DE	16/07/2015	7 May 2018	TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial	TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial	Patients with defined diagnosis of relapsing-remitting multiple sclerosis and at least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years. MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tarenflurbil Product Code: TMP001 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tarenflurbil CAS Number: 5104-49-4 Other descriptive name: FLURBIPROFEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)		Not Recruiting			Female: yes Male: yes	55	Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
361	JPRN-UMIN000018154	2015/07/01	2 April 2019	11C-acetate PET for Multiple sclerosis	11C-acetate PET for Multiple sclerosis - 11C-acetate PET for Multiple sclerosis	Multiple Sclerosis, NMO	Withdraw blood before and after the injection of 11C-acetate	department of neurology, Osaka university school of medicine		Recruiting	20years-old	75years-old	Male and Female	30	Not applicable	Japan
362	NCT02472938	July 2015	4 January 2016	Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis	Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: dimethyl fumarate;Other: Placebo	Biogen	GB Pharma Services & Consulting S.r.l. Unipersonale	Not recruiting	18 Years	50 Years	Both	0	Phase 4
363	NCT02506751	July 2015	19 February 2018	Open-label Study of Liothyronine in MS	A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: liothyronine	Johns Hopkins University		Not recruiting	18 Years	58 Years	All	20	Phase 1	United States
364	NCT02519413	July 2015	5 September 2016	Tecfidera Lymphocyte Chart Review	A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis (REALIZE)	Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	483	N/A	United States
365	NCT02521545	July 2015	14 September 2015	Single-Dose Study of a New Formulation of BIIB061	A Single-Dose Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of a New Formulation of BIIB061	Multiple Sclerosis	Drug: BIIB061	Biogen		Not recruiting	20 Years	55 Years	Both	8	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
366	NCT02665221	July 2015	16 December 2017	Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY	Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.	Multiple Sclerosis	Other: No Treatment Arm;Drug: Topical Preparation H arm	New York University School of Medicine		Not recruiting	18 Years	70 Years	All	32	Phase 4	United States
367	NCT02696590	July 2015	11 April 2016	High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients	Isfahan University of Medical Sciences	Relapsing Remitting Multiple Sclerosis	Dietary Supplement: Vitamin D3	Isfahan University of Medical Sciences		Not recruiting	23 Years	59 Years	Both	200	N/A	Iran, Islamic Republic of
368	NCT02410278	June 29, 2015	11 June 2018	Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera	A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules	Multiple Sclerosis	Drug: dimethyl fumarate;Drug: montelukast;Drug: Placebo	Biogen		Not recruiting	18 Years	N/A	All	63	Phase 4	United States
369	EUCTR2015-000303-21-IT	24/06/2015	11 April 2016	Experimental clinical trial regarding relapsing-remitTing Multiple Sclerosis newly diagnosed patients, not yet treated for the evaluation of the onset, the efficacy and speed of action of the treatment with BG00012	A Phase IV, interventional, multicenteR, double-blind, randomized, placebo-controlled study tO explore the onset of efficacy on Magnetic resonance disease activity of BG00012 (dimethyl fumarate) in Patients with relapsing-remitTing Multiple Sclerosis (PROMPT) - PROMPT	Relapsing-remitting Multiple Sclerosis patients MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera® Product Name: Tecfidera® Product Code: BG00012 Pharmaceutical Form: Capsule INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Current Sponsor code: BG00012 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Biogen Idec Italia S.r.l.		Not Recruiting			Female: yes Male: yes		Phase 4	Italy
370	EUCTR2014-004562-22-BE	10/06/2015	30 April 2018	Study to evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis	A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis	Multiple Sclerosis MedDRA version: 17.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	300	Phase 3	France;United States;Hungary;Czech Republic;Canada;Spain;Belgium;Australia;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
371	NCT02425644	June 4, 2015	16 September 2019	Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis	Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: ponesimod;Drug: teriflunomide	Actelion		Not recruiting	18 Years	55 Years	All	1133	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;Argentina;Czech Republic
372	EUCTR2014-005003-24-LV	01/06/2015	24 October 2016	A study of BG00012 on MRI lesions and Pharmacokinetics in children from 10 to less than 18 years old with a type of Multiple Sclerosis called 'Relapsing, Remitting Multiple Sclerosis'	Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years	Relapsing-Remitting Multiple Sclerosis MedDRA version: 17.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	20	Phase 2	Finland;Lebanon;Lithuania;Turkey;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Australia;Bulgaria;Latvia;Germany;Kuwait
373	NCT02090348	June 2015	14 September 2015	Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate	A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	0	Phase 4
374	NCT02239393	June 2015	1 April 2019	Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study	MEsenchymal Stem Cell Therapy for CAnadian MS Patients	Multiple Sclerosis	Biological: Mesenchymal Stem Cells	Ottawa Hospital Research Institute		Not recruiting	18 Years	50 Years	All	40	Phase 2	Canada
375	NCT03113162	May 29, 2015	16 December 2017	Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis	Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous Hematopoietic Stem Cell;Drug: BEAM Regimen	Makati Medical Center		Recruiting	18 Years	60 Years	All	15	Phase 1	Philippines
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
376	EUCTR2013-001055-12-IT	28/05/2015	10 July 2015	Study to evaluate the efficacy of cetirizine in the treatment of Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß.	Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß. - FLU-LIGHT	Patients with relapsing remitting multiple sclerosis (RRMS) treated with interferoneß, suffering from flu-like syndrome (FLS). MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Cetirizina Mylan Generics Product Name: Cetirizina Mylan Generics Pharmaceutical Form: Tablet INN or Proposed INN: Cetirizina CAS Number: 83881-52-1 Other descriptive name: CETIRIZINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Biogen Idec Italia S.r.l.		Not Recruiting			Female: yes Male: yes			Italy
377	NCT02315872	May 22, 2015	9 September 2019	ACTH for Fatigue in Multiple Sclerosis Patients	The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.	Multiple Sclerosis, Relapsing-Remitting	Drug: ACTH;Drug: Placebo	Providence Health & Services	Mallinckrodt	Not recruiting	18 Years	65 Years	All	8	Phase 3	United States
378	EUCTR2015-001197-18-NO	20/05/2015	25 June 2018	The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.	The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.	multiple sclerosis;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21]	Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: IU/mg international unit(s)/milligram Concentration type: range Concentration number: 240-480	Biogen Idec Norway		Authorised			Female: yes Male: yes	70	Phase 4	Norway
379	EUCTR2014-003481-25-DE	13/05/2015	20 August 2018	Investigation of the effect of Dimethyl fumarate on T cells in patients with relapsing remitting Multiple Sclerosis	A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis - DIMAT-MS	relapsing remitting multiple sclerosis MedDRA version: 19.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera® 120mg magensaftresistente Hartkapseln Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera® 240mg magensaftresistente Hartkapseln Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240-	Universitätsklinikum Münster		Not Recruiting			Female: yes Male: yes	67	Phase 4	Germany
380	NCT02495766	May 11, 2015	22 July 2019	Autologous Mesenchymal Stromal Cells for Multiple Sclerosis	Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: XCEL-MC-ALPHA;Drug: Placebo	Banc de Sang i Teixits	Vall d'Hebron Research Institute (VHIR)	Not recruiting	18 Years	60 Years	All	8	Phase 1/Phase 2	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
381	NCT02461069	May 6, 2015	22 October 2018	Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis	A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)	Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl fumarate	University Hospital Muenster	Biogen	Not recruiting	18 Years	60 Years	All	67	Phase 4	Germany
382	NCT02323269	May 2015	18 April 2016	Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)	A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing-Remitting Multiple Sclerosis, Who Are Either Treatment-Naïve or Switching From an Interferon or Glatiramer Acetate After Suboptimal Response (ImPROve)	Multiple Sclerosis, Relapsing-Remitting;Relapsing-Remitting Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	24	N/A	Canada
383	NCT02419378	May 2015	27 June 2016	Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential	Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential	Multiple Sclerosis, Relapsing-Remitting	Drug: Alemtuzumab	University Hospital Muenster	Genzyme, a Sanofi Company	Recruiting	18 Years	55 Years	Both	15	Phase 4	Germany
384	NCT02419638	May 2015	14 March 2016	Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS		Multiple Sclerosis	Drug: Rebif (IFN ß-1a subcutaneous three times per week);Drug: Tecifdera (dimethyl fumarate)	Brigham and Women's Hospital	EMD Serono	Not recruiting	18 Years	65 Years	Both	0	N/A	United States
385	NCT02471222	May 2015	16 December 2017	Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102;Other: Placebo	Adamas Pharmaceuticals, Inc.		Not recruiting	18 Years	70 Years	All	60	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
386	NCT02736279	May 2015	14 November 2016	Impact of Tecfidera on Gut Microbiota	Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate With Gastrointestinal Disturbances Following Therapy Initiation?	Multiple Sclerosis	Drug: Dimethyl fumarate	Virginia Simnad	Biogen	Recruiting	18 Years	N/A	Both	25	N/A	United States
387	EUCTR2014-005548-17-FR	28/04/2015	3 April 2017	TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY	TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY	PENDULAR NYSTAGMUS IN PATIENTS WITH MULTIPLE SCLEROSIS OR OCULOPALATAL TREMOR MedDRA version: 18.0 Level: PT Classification code 10029864 Term: Nystagmus System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: NEURONTIN Product Name: Gabapentine Product Code: N03AX12 Pharmaceutical Form: Capsule CAS Number: 60142-96-3 Other descriptive name: GABAPENTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: EBIXA Product Name: MEMANTINE Product Code: N06DX01 Pharmaceutical Form: Coated tablet INN or Proposed INN: MEMANTINE CAS Number: 19982-08-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	HOSPICES CIVILS DE LYON		Not Recruiting			Female: yes Male: yes		Phase 2	France
388	JPRN-UMIN000017217	2015/04/21	23 April 2019	An open-label extension study following the RIN-1 study to investigate the efficacy of rituximab against a relapse of neuromyelitis optica	An open-label extension study following the RIN-1 study to investigate the efficacy of rituximab against a relapse of neuromyelitis optica - RIN-2	Neuromyelitis optica	Rituximab intravenous infusion	Clinical Research Center, Utano National Hospital, National Hospital Organization	Zenyaku Kogyo Co., Ltd.	Not Recruiting	16years-old	80years-old	Male and Female	40	Phase 2,3	Japan
389	NCT02423083	April 21, 2015	11 November 2019	Oral Guanabenz for Multiple Sclerosis	Phase I Study of Oral Guanabenz for Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis	Drug: Guanabenz	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	55 Years	All	2	Phase 1	United States
390	EUCTR2014-002592-29-CZ	17/04/2015	17 May 2016	Administration of Mirabegron 50mg in patients with neurogenic bladder	A randomized, double blind, placebo controlled study to evaluate the efficacy and safety of mirabegron 50 mg versus placebo in patients with neurogenic detrusor overactivity - MIRAGE	Spinal cord injury Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Betmiga Product Name: Betmiga Pharmaceutical Form: Coated tablet INN or Proposed INN: mirabegron CAS Number: 223673-61-8 Other descriptive name: MIRABEGRON Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Fakultní nemocnice Ostrava		Authorised			Female: yes Male: yes		Phase 3	Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
391	EUCTR2012-003735-32-SK	01/04/2015	12 November 2018	Study to compare the efficacy and/or safety of masitinib at 3 mg/kg/day with switch to 4.5 then to 6 mg/kg/day to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.	A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment	Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day as single agent first line treatment.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	AB Science		Not Recruiting			Female: yes Male: yes	450	Phase 3	Slovakia;Greece;Spain;Colombia;Switzerland;United Kingdom;Italy;Mexico;Canada;Argentina;Belgium;Brazil;Bulgaria;Germany
392	NCT02391961	April 1, 2015	29 April 2019	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Multiple Sclerosis;Internuclear Ophthalmoplegia;Fatigue	Drug: Dalfampridine;Drug: Placebo	VA Office of Research and Development		Not recruiting	18 Years	65 Years	All	20	Phase 2	United States
393	NCT02398461	April 2015	3 September 2018	An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse	A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse	Multiple Sclerosis, Acute Relapsing	Drug: rHIgM22;Drug: Placebo	Acorda Therapeutics	PRA Health Sciences	Not recruiting	18 Years	70 Years	All	27	Phase 1	United States
394	NCT02939079	April 2015	31 October 2016	Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients	Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-a , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Fingolimod;Dietary Supplement: Fish Oil;Drug: Placebo (for Fish Oil)	Isfahan University of Medical Sciences	Shiraz University of Medical Sciences	Not recruiting	18 Years	45 Years	Both	50	Phase 2/Phase 3
395	NCT02373098	March 31, 2015	16 December 2017	Fingolimod Effect on Cytokine and Chemokine Levels	Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod 0.5 mg	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	66	Phase 4	Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
396	EUCTR2014-003021-18-SE	25/03/2015	7 December 2015	A safety and efficacy study of BG00012 in slowing the progression of disability in patients with Secondary Progressive Multiple Sclerosis.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis MedDRA version: 17.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl Fumarate CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: Dimethyl Fumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	1170		Serbia;United States;Slovakia;Finland;Spain;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Denmark;Australia;Bulgaria;Norway;Netherlands;Germany;Sweden
397	NCT02386566	March 20, 2015	24 September 2018	Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab	A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab	Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	48	Phase 1	Switzerland
398	EUCTR2014-003145-99-GB	19/03/2015	17 August 2015	A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis.	A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial - CCMR One	Relapsing-remitting multiple sclerosis already on interferon-beta therapy MedDRA version: 17.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Targretin Product Name: Bexarotene Pharmaceutical Form: Capsule, hard INN or Proposed INN: Bexarotene CAS Number: 153559-49-0 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: range Concentration number: 100-300 Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge		Authorised			Female: yes Male: yes	50	Phase 2a	United Kingdom
399	NCT02474134	March 2015	23 November 2015	Comparison Study of PF530 and Betaferon in Healthy Subjects	A Phase 1 Double-Blind, Randomised, Two-Treatment Cross-over Study Comparing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF530 and Betaferon Administered by Subcutaneous Injection in Healthy Adult Volunteers	Multiple Sclerosis	Drug: Interferon beta-1b (PF530, Betaferon)	Pfenex, Inc		Not recruiting	18 Years	50 Years	Both	12	Phase 1	Australia
400	NCT02097849	February 28, 2015	16 December 2017	Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.	An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.	Relapsing Forms of Multiple Sclerosis	Drug: dimethyl fumarate;Biological: tetanus diphtheria toxoids vaccine;Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent);Drug: non-pegylated interferon	Biogen		Not recruiting	18 Years	55 Years	All	71	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
401	NCT02343159	February 28, 2015	16 December 2017	Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.	A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients.	Multiple Sclerosis	Drug: dimethyl fumarate;Device: Medication Event Monitoring System (MEMS);Behavioral: Adherence counseling	Biogen		Not recruiting	18 Years	65 Years	All	84	Phase 4	United States
402	EUCTR2015-000182-31-NL	11/02/2015	23 February 2015	Study to evaluate the effects of fampridine in patients with multiple sclerosis and eye movement abnormality	A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)	Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra 10 mg prolonged-release tablets Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	CHDR		Authorised			Female: yes Male: yes			Netherlands
403	EUCTR2014-001643-20-DE	10/02/2015	13 February 2017	Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple Sclerosis	A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)	Nervous System Diseases MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR339658 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	168	Phase 2	United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
404	EUCTR2013-003884-71-BE	05/02/2015	10 July 2015	Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409	A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) - TOPAZ	Relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Authorised			Female: yes Male: yes	799	Phase 3B	Serbia;Spain;Ukraine;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Netherlands;Germany;Sweden
405	NCT02306811	February 2015	9 January 2017	Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839	A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839	Relapsing-remitting Multiple Sclerosis	Drug: Vatelizumab	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	Both	62	Phase 2	United States;Canada;Poland;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
406	NCT02308137	February 2015	29 April 2019	Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)	Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis, Secondary Progressive	Drug: Domperidone	University of Calgary	Alberta Innovates Health Solutions	Recruiting	18 Years	60 Years	All	62	Phase 2	Canada
407	NCT02403947	February 2015	10 December 2018	MEsenchymal StEm Cells for Multiple Sclerosis	Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study	Multiple Sclerosis	Drug: Mesenchymal stem cells;Drug: Suspension media	University Hospital, Toulouse		Not recruiting	18 Years	50 Years	All	1	Phase 1/Phase 2	France
408	NCT02418325	February 2015	17 November 2015	A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy	Genesis Limited		Not recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	Trinidad and Tobago
409	NCT02418351	February 2015	17 November 2015	A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	Multiple Sclerosis, Relapsing-Remitting	Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy	Genesis Limited		Not recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	India;Trinidad and Tobago
410	NCT02490046	February 2015	3 August 2015	D-mannose for the Prevention of UTIs in Multiple Sclerosis	Single Centre Open-label Feasibility Study Evaluating the Use of D-mannose in Multiple Sclerosis	Multiple Sclerosis;Recurrent Urinary Tract Infections	Dietary Supplement: D Mannose	University College, London	UCLH	Recruiting	18 Years	65 Years	Both	20	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
411	NCT02587715	February 2015	17 November 2015	A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy	Novo Cellular Medicine Institute LLP		Recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	Trinidad and Tobago
412	NCT02587806	February 2015	17 November 2015	A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	Multiple Sclerosis, Relapsing-Remitting	Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy	Novo Cellular Medicine Institute LLP		Recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	India;Trinidad and Tobago
413	NCT02638038	February 2015	12 March 2018	This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for = 3 Years	A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing Remitting	Drug: INT131	InteKrin Therapeutics, Inc.		Not recruiting	18 Years	50 Years	All	228	Phase 2
414	NCT03092544	February 2015	11 June 2018	Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients	Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients	Multiple Sclerosis	Drug: dimethyl fumarate	Multiple Sclerosis Center of Northeastern New York	Icahn School of Medicine at Mount Sinai;Biogen	Not recruiting	18 Years	65 Years	All	57	Phase 4	United States
415	EUCTR2013-005586-39-DE	29/01/2015	16 November 2015	Natalizumab (BG00002) as an Efficacy Switch in Subjects with Relapsing Multiple Sclerosis (MS) after Failure on Other Therapies	A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS)	Multiple Sclerosis (MS) MedDRA version: 17.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri® Product Name: AN100226, BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	200	Phase 4	United States;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
416	NCT02166021	January 29, 2015	26 August 2019	Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis	Phase 2 Trial to Investigate the Clinical Efficacy & the Optimal Administration (Based on the Immunological, Clinical & Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis	Multiple Sclerosis (MS)	Biological: Mesenchymal stem cells	Dimitrios Karussis		Not recruiting	18 Years	65 Years	All	48	Phase 2	Israel
417	EUCTR2014-005129-10-FI	27/01/2015	2 February 2015	Multiple Sclerosis, menopause and hormone replacement therapy	Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis	Multiple sclerosis MedDRA version: 17.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis System Organ Class: 100000004852 MedDRA version: 17.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Femoston 2/10 Product Name: Femoston 2/10 Pharmaceutical Form: Tablet INN or Proposed INN: ESTRADIOL HEMIHYDRATE CAS Number: 35380-71-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- INN or Proposed INN: DYDROGESTERONE CAS Number: 152-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: Femoston 1/10 Product Name: Femoston 1/10 Pharmaceutical Form: Tablet INN or Proposed INN: ESTRADIOL HEMIHYDRATE CAS Number: 35380-71-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: DYDROGESTERONE CAS Number: 152-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Irina Elovaara		Authorised			Female: yes Male: no			Finland
418	EUCTR2014-004412-11-GB	16/01/2015	23 May 2016	The purpose of this study is to examine the safety and efficacy of VSN16R and the performance in treating spasticity (tightness, stiffness or pull of muscles) in patients with Multiple Sclerosis (MS).	A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects with Multiple Sclerosis	Multiple Sclerosis MedDRA version: 19.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: VSN16R 100mg Product Code: VSN16R Pharmaceutical Form: Capsule INN or Proposed INN: VSN16R Other descriptive name: (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Canbex Therapeutics Ltd		Authorised			Female: yes Male: yes		Phase 2	United Kingdom
419	NCT02284568	January 12, 2015	11 June 2018	A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo	A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)	Primary Progressive Multiple Sclerosis	Drug: Laquinimod;Drug: Placebo	Teva Branded Pharmaceutical Products, R&D Inc.		Not recruiting	25 Years	55 Years	All	374	Phase 2	United States;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom
420	NCT02255656	January 7, 2015	15 April 2019	Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409	A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)	Relapsing Remitting Multiple Sclerosis	Drug: alemtuzumab GZ402673	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	All	812	Phase 4	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Ukraine;United Kingdom;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
421	NCT02200770	January 6, 2015	24 June 2019	A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders	A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders	Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders	Biological: MEDI-551;Other: Placebo	MedImmune LLC		Not recruiting	18 Years	N/A	All	231	Phase 2/Phase 3	United States;Australia;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;China;Czech Republic;India;Netherlands;Portugal;Ukraine
422	NCT02335450	January 2015	11 April 2016	Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series	Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series	Multiple Sclerosis	Behavioral: Motivational Interviewing;Device: Wristband physical activity monitor	Oakland University		Not recruiting	19 Years	N/A	Both	5	N/A	United States
423	NCT02364986	January 2015	13 June 2016	Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis	Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Rebif®;Drug: Avonex	PD Dr. Marcus Müller	BfARM, Bonn;DZNE, Bonn	Recruiting	18 Years	65 Years	Both	50	Phase 1	Germany
424	NCT02427776	January 2015	16 December 2017	A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis	A Clinical Trial to Document Safety and Radiological Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Treated With Autologous CD4+ T Cells, Stimulated and Expanded ex Vivo by a Myelin Oligodendrocyte Glycoprotein Peptide Modified by the Introduction of a Thioreductase Motif Into the Flanking Residues of the Cell Epitope - A First-in-human Trial (SCLEROLYM TRIAL)	Multiple Sclerosis, Relapsing-Remitting	Biological: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope	Imcyse SA		Not recruiting	18 Years	50 Years	All	2	Phase 1/Phase 2	Belgium
425	NCT02606929	January 2015	23 November 2015	Use of Well Known Drugs for New Destination - MS Improvement (MSNT)	Expanded Access Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Multiple Sclerosis Not Responding With Commonly Used Treatments	Multiple Sclerosis;Autoimmune Diseases;Disseminated or Multiple Sclerosis Nos;Multiple Sclerosis, Acute Relapsing;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive	Drug: Tetracycline - Statin - Antimycotic	Università Popolare Homo & Natura		Not recruiting	18 Years	65 Years	Both		Phase 0	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
426	EUCTR2015-000137-78-AT		14 March 2016	Mesenchymal stem cells therapy for patients with multiple sclerosis	Randomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria)	multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Human autologous mesenchymal stem cells Pharmaceutical Form: Infusion INN or Proposed INN: MSC2015 Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS Concentration unit: Other Concentration type: equal Concentration number: 2 mio cells /kg - Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use	SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU		Authorised			Female: yes Male: yes		Phase 2	Austria
427	NCT02254304	December 31, 2014	11 June 2018	Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™	Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart™	Relapsing Multiple Sclerosis;Clinically Isolated Syndrome	Drug: Rebif	Merck KGaA	Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	65 Years	All	106	Phase 4	Germany
428	EUCTR2014-000709-10-DE	19/12/2014	18 June 2018	Investigation on how alemtuzumab acts in patients with relapsing remitting multiple sclerosis.	Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential - ALAIN01	relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Alemtuzumab CAS Number: 216503-57-0 Other descriptive name: ALEMTUZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Universitätsklinikum Münster		Authorised			Female: yes Male: yes	15	Phase 4	Germany
429	EUCTR2014-002547-17-NL	18/12/2014	14 March 2016	Imaging of inflammation in the cortex of the brain in progressive MS patients	Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS	Progressive multiple sclerosis, both primary and secondary progressive MedDRA version: 17.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [18F]DPA-714 Pharmaceutical Form: Radiopharmaceutical precursor INN or Proposed INN: [18F]DPA-714 Other descriptive name: [18F]DPA-714 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 250-	VU University Medical Center		Not Recruiting			Female: yes Male: yes			Netherlands
430	NCT01910259	December 18, 2014	16 December 2017	MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial	A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.	Secondary Progressive Multiple Sclerosis	Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo	University College, London	Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick	Not recruiting	25 Years	65 Years	All	445	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
431	EUCTR2014-001012-19-NL	17/12/2014	12 January 2015	Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosis	Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis - Effect of fingolimod on brain and cognition	Relapsing-remitting (RR) multiple sclerosis (MS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Pharmaceutical Form: Capsule INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Product Name: Interferon Beta Pharmaceutical Form: INN or Proposed INN: interferon beta-1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0-0.25 INN or Proposed INN: interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0-0.044 Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 20-	VU University Medical Center		Authorised			Female: yes Male: yes			Netherlands
432	EUCTR2014-001081-99-BE	16/12/2014	8 August 2016	A first in human trial for evaluating both safety and preliminary efficacy of a single infusion of stimulated autologous CD4+ cells in patients with Relapsing- Remitting multiple sclerosis	A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by a myelin oligodendrocyte glycoprotein (MOG) peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope (SCLEROLYM trial). First-in-human trial - SCLEROLYM Trial	Multiple sclerosis is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system. MS is characterized initially by episodes of reversible neurologic deficits. In most patients, these episodes are followed by progressive neurologic deterioration over time. Relapsing-remitting multiple sclerosis is characterized by recurrent attacks of neurologic dysfunction (relapses) followed by periods of complete or incomplete recovery (remission) MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: SCLEROLYM Pharmaceutical Form: Suspension for injection INN or Proposed INN: Cytolytic CD4+ T cells Other descriptive name: AUTOLOGOUS T-LYMPHOCYTES Concentration unit: million organisms/ml million organisms/millilitre Concentration type: range Concentration number: 5-50	ImCyse S.A		Not Recruiting			Female: yes Male: yes		Phase 1;Phase 2	Belgium
433	NCT02294058	December 3, 2014	16 December 2017	Phase 3 Study of RPC1063 in Relapsing MS	A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients	Multiple Sclerosis	Drug: RPC1063;Drug: Beta interferon	Celgene		Not recruiting	18 Years	55 Years	All	1346	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;Argentina;Austria;Colombia;Czech Republic;Mexico;Peru
434	NCT02087631	December 2014	22 October 2019	Safety and Tolerability of Quetiapine in Multiple Sclerosis	A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Extended-release quetiapine fumarate	University of Calgary	Multiple Sclerosis Society of Canada	Not recruiting	18 Years	65 Years	All	14	Phase 1/Phase 2	Canada
435	NCT02142192	December 2014	10 October 2016	Natalizumab Subcutaneous Immunogenicity and Safety Study	A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	Both	2	Phase 2	Belgium;Denmark;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
436	NCT02317263	December 2014	15 August 2016	A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis		Multiple Sclerosis	Drug: testosterone;Drug: placebo gel	University of California, Los Angeles		Not recruiting	18 Years	60 Years	Male	0	Phase 2
437	NCT02389426	December 2014	28 April 2015	Transcranial Doppler in Multiple Sclerosis	Evaluation of Cerebrovascular Hemodynamics With Transcranial Doppler and Near-infrared Spectroscopy in Patients With Multiple Sclerosis	Multiple Sclerosis	Device: TCD baseline;Device: TCD after bosentan administration;Device: NIRS baseline;Device: NIRS after bosentan administration	Universitair Ziekenhuis Brussel		Not recruiting	18 Years	N/A	Both	30	N/A	Belgium
438	EUCTR2014-001579-30-GB	27/11/2014	24 October 2016	A Phase 2 clinical study in subjects with Progressive Multiple Sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.5mg/day (experimental drug) as compared to placebo	A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis (PPMS) - ARPEGGIO	Primary Progressive Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Laquinimod Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Laquinimod Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Teva Pharmaceutical Industries Ltd.		Authorised			Female: yes Male: yes	375	Phase 2	United States;Canada;Poland;Spain;Ukraine;Russian Federation;Netherlands;Germany;Italy;United Kingdom
439	EUCTR2013-002378-26-SE	13/11/2014	25 June 2018	Switch To RItuXimab in MS extension An extension study of an ongoing clinical trial where people with multiple sclerosis switch therapy from interferon or glatiramere injections to rituximab, a monoclonal antibody that eliminate B lymphocytes	Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach - STRIX-MSext	The original trial (EudraCT 2010-023021-38) recruited 74 patients with relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (DMDs), eg beta-interferons or glatiramere acetate. This extension study involves the same patients, those that consent to participate in this extension trial. MedDRA version: 16.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera® Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion	Västerbottens Läns Landsting		Not Recruiting			Female: yes Male: yes	74	Phase 2	Sweden
440	NCT02230969	November 12, 2014	6 May 2019	Plegridy Observational Program	Plegridy™ (Peginterferon ß-1a) Real World Effectiveness and Safety Observational Program	Relapsing Forms of Multiple Sclerosis	Drug: peginterferon beta-1a	Biogen		Not recruiting	18 Years	N/A	All	1210	N/A	United States;Australia;Austria;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
441	EUCTR2013-004622-29-IT	10/11/2014	11 April 2016	Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Subjects	A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects	Multiple Sclerosis (MS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri® Product Name: AN100226, BG00002 Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- Trade Name: Gilenya Product Name: Fingolimod Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	540		France;United States;Czech Republic;Canada;Spain;Denmark;Australia;Germany;United Kingdom;Italy;Sweden
442	NCT02142764	November 2014	9 January 2017	Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients	Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS).	Multiple Sclerosis	Biological: Blood samples	University Hospital, Bordeaux	Merck Serono International SA;ADERA	Not recruiting	18 Years	N/A	Both	30	N/A	France
443	NCT02253264	November 2014	16 December 2017	A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients	A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Rituximab	Johns Hopkins University		Not recruiting	18 Years	N/A	All	8	Phase 1	United States
444	NCT02259361	November 2014	19 February 2015	Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS	Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study	Multiple Sclerosis	Drug: Sustained-release oral dalfampridine;Drug: Placebo	Sheba Medical Center		Not recruiting	18 Years	70 Years	Both	30	Phase 4	Israel
445	NCT02310048	November 2014	23 March 2015	Comparative Oral Bioavailability Study of MT-1303	A Randomised, Open-Label, Single-Dose, Parallel Group Study to Assess the Comparative Oral Bioavailability of Two Capsule Formulations of MT-1303 in Healthy Male Subjects	Relapsing-remitting Multiple Sclerosis	Drug: MT-1303-FormA;Drug: MT-1303-FormB	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	55 Years	Male	34	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
446	NCT02326935	November 2014	11 June 2018	Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis	Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous adipose derived mesenchymal cells	American CryoStem Corporation		Not recruiting	18 Years	65 Years	All	2	Phase 1	Cayman Islands
447	EUCTR2014-002335-34-GB	30/10/2014	22 May 2017	Intravenous immunoglobulin vs standard therapy for treatment of transverse myelitis	A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children - STRiVE	Transverse myelitis (TM) (acute, first onset cases), including first presentation of neuromyelitis optica (NMO) MedDRA version: 17.1 Level: PT Classification code 10028527 Term: Myelitis transverse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Intratect Product Name: Intratect Pharmaceutical Form: Solution for infusion	Guy's and St Thomas NHS Foundation Trust		Not Recruiting			Female: yes Male: yes	0	Phase 3	United Kingdom
448	EUCTR2014-003669-97-BE	27/10/2014	30 April 2018	A safety study for patients with Relapsing Forms of Multiple Sclerosis who participated STRATA.	A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA.	Relapsing Forms of Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri Product Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	Biogen Idec		Not Recruiting			Female: yes Male: yes	10	Phase 4	Belgium
449	EUCTR2014-000221-20-AT	23/10/2014	23 July 2018	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: RNS60 Product Code: RNS60 Pharmaceutical Form: Infusion	University Hospital Zürich		Not Recruiting			Female: yes Male: yes	16	Phase 2	Austria;Switzerland
450	NCT02247310	October 20, 2014	16 December 2017	BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon	BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®	Multiple Sclerosis, Relapsing Remitting	Drug: Interferon beta-1b (Betaferon®, BAY 86-5046);Device: BETACONNECT	Bayer		Not recruiting	N/A	N/A	All	498	N/A	Austria;Belgium;Bosnia and Herzegovina;Croatia;Czechia;France;Greece;Hungary;Italy;Spain;Switzerland;Czech Republic;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
451	NCT02096133	October 13, 2014	16 December 2017	Vitamin D3 and the Stress-axis in MS	Regulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled Study	Multiple Sclerosis	Drug: Cholecalciferol;Other: Placebo comparator	Academic MS Center Limburg		Not recruiting	18 Years	N/A	Female	54	Phase 2	Netherlands
452	NCT02104661	October 2014	11 June 2018	Protective Role of Oxcarbazepine in Multiple Sclerosis	OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial	Multiple Sclerosis	Drug: Oxcarbazepine;Drug: Placebo	Queen Mary University of London	National Multiple Sclerosis Society;Novartis Pharmaceuticals;Barts & The London NHS Trust;University College, London;Royal Free Hospital NHS Foundation Trust;Southend University Hospital;Basildon and Thurrock University Hospitals NHS Foundation Trust;St George's Healthcare NHS Trust;Barnet and Chase Farm Hospitals NHS Trust	Not recruiting	18 Years	60 Years	All	30	Phase 2	United Kingdom
453	NCT02212886	October 2014	1 April 2019	Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS	A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis	Drug: GA Depot 80 mg;Drug: GA Depot 40 mg	Mapi Pharma Ltd.		Not recruiting	18 Years	70 Years	All	25	Phase 1/Phase 2	Israel
454	NCT02228213	October 2014	16 December 2017	Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis	A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Biological: MIS416;Drug: Saline	Innate Immunotherapeutics	INC Research	Not recruiting	18 Years	70 Years	All	93	Phase 2	Australia;New Zealand
455	NCT02234869	October 2014	19 February 2015	Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy	Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017)	Relapsing Multiple Sclerosis	Drug: Interferon Beta;Drug: BIIB017 (Peginterferon beta-1a)	Biogen Idec		Not recruiting	18 Years	65 Years	Both	0	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
456	NCT02269930	October 2014	19 February 2015	Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers	An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers	Multiple Sclerosis	Drug: peginterferon beta-1a;Drug: Rebif	Biogen Idec		Not recruiting	18 Years	45 Years	Both	30	Phase 1	United States
457	NCT02280096	October 2014	28 December 2015	Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis	Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.	Multiple Sclerosis	Drug: 4-aminopyridine;Drug: Placebo	Coordinación de Investigación en Salud, Mexico		Not recruiting	18 Years	60 Years	Both	24	Phase 2	Mexico
458	NCT02282826	October 2014	25 April 2016	A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: GZ402668;Drug: placebo;Drug: acyclovir	Genzyme, a Sanofi Company		Not recruiting	18 Years	65 Years	Both	48	Phase 1	Germany
459	NCT02286557	October 2014	19 February 2015	Testing the Effects of Methylphenidate on Multiple Sclerosis	Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial	Fatigue in Multiple Sclerosis	Drug: Methelphenidate;Drug: Placebo	Kessler Foundation		Not recruiting	18 Years	65 Years	Both	36	Phase 2
460	NCT02296346	October 2014	26 August 2019	Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis	A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)	Secondary Progressive Multiple Sclerosis	Drug: SoluMedrol;Device: Extracorporeal Photopheresis	University of Utah	Mallinckrodt	Not recruiting	18 Years	75 Years	All	13	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
461	EUCTR2011-005249-12-GB	29/09/2014	10 September 2018	Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis	A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension - TERIKIDS	Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Authorised			Female: yes Male: yes	165	Phase 3	United States;Serbia;Portugal;Estonia;Morocco;Greece;Spain;Ukraine;Lebanon;Ireland;Russian Federation;Israel;France;Macedonia, the former Yugoslav Republic of;Australia;Tunisia;Netherlands;China;Slovenia;Turkey;Lithuania;United Kingdom;Canada;Belgium;Poland;Bulgaria
462	NCT02232061	September 29, 2014	14 October 2019	Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod	Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod	Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Recruiting	N/A	N/A	All	40	Phase 4	Belgium;Germany;Italy
463	EUCTR2013-003600-40-GB	15/09/2014	3 April 2017	Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE)	A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE)	Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampridine Product Code: BIIB041 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: BIIB041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	590	Phase 3	United States;Serbia;Finland;Ukraine;Lithuania;Russian Federation;United Kingdom;Switzerland;Italy;Czech Republic;Poland;Bulgaria;Netherlands
464	EUCTR2014-003209-14-FR	01/09/2014	4 August 2015	ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS	ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS - TYSADIFF	MULTIPLE SCLEROSIS;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TYSABRI 300 mg solution à diluer pour perfusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7	Hôpitaux Universitaires de Strasbourg		Authorised			Female: yes Male: yes			France
465	NCT02045732	September 2014	19 October 2017	A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)	A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)	Multiple Sclerosis	Biological: PF-06342674 0.25 mg/kg;Biological: Placebo;Biological: PF-06342674 1.5 mg/kg;Biological: PF-06342674 6.0 mg/kg	Pfizer		Not recruiting	18 Years	55 Years	All	4	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
466	NCT02193217	September 2014	2 March 2015	A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303		Relapsing-remitting Multiple Sclerosis	Drug: MT-1303-Low;Drug: MT-1303-High;Drug: Fingolimod;Drug: Placebo	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	55 Years	Both	81	Phase 1	United Kingdom
467	NCT02273635	September 2014	19 February 2015	Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS	Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis	Primary Progressive Multiple Sclerosis;Multiple Sclerosis, Secondary Progressive	Drug: Andrographolides;Drug: placebo	Innobioscience SpA	Pontificia Universidad Catolica de Chile;University of Chile;Universidad Austral de Chile	Recruiting	18 Years	70 Years	Both	68	Phase 1/Phase 2	Chile
468	NCT02282878	September 2014	16 December 2017	The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis	The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: High/Low Sodium Diet	Yale University		Recruiting	18 Years	60 Years	All	25	N/A	United States
469	NCT02287948	September 2014	15 February 2016	Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects	Validation Study for Using Wii FIT Balance Board to Recording Balance Parameters in Healthy Subjects and Multiple Sclerosis Subjects	Postural Balance;Multiple Sclerosis	Device: Nintendo Wii Fit Balance Board	University Hospital of Ferrara		Not recruiting	18 Years	80 Years	Both	40	N/A	Italy
470	NCT02293967	September 2014	23 March 2015	Mass Balance Study of MT-1303	An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.	Relapsing-remitting Multiple Sclerosis	Drug: MT-1303	Mitsubishi Tanabe Pharma Corporation		Not recruiting	30 Years	65 Years	Male	8	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
471	NCT02777060	September 2014	30 May 2016	Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures	Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures	Diabetes;Cancer;Multiple Sclerosis;Arthritis;Parkinson's Disease;Cognitive Disorders;Brain Injury;Stroke	Procedure: Exergame;Procedure: Home based balance training	University of Arizona		Recruiting	18 Years	N/A	Both	200	N/A	United States
472	ChiCTR-ICR-15007177	2014-08-30	18 April 2017	A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis	A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis	Neuromyelitis Optica associated Optic Neuritis	1:Intravenous 100mg Rituximab, 1/week4 ;2:Oral azathioprine* (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (1000-1500mg/day);	The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital		Recruiting	18	70	Both	1:30;2:30;	New Treatment Measure Clinical Study	China
473	NCT02283853	August 28, 2014	16 September 2019	Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)	Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	Relapsing-Remitting Multiple Sclerosis	Drug: dimethyl fumarate;Drug: Interferon ß-1a	Biogen		Not recruiting	10 Years	17 Years	All	142	Phase 3	Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;Argentina;Czech Republic;Romania
474	EUCTR2011-005249-12-EE	13/08/2014	28 August 2014	Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis	A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension - TERIKIDS	Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Authorised			Female: yes Male: yes	165		United States;Estonia;Greece;Canada;Spain;Belgium;Lebanon;Turkey;Australia;Russian Federation;Israel;China
475	NCT02073279	August 5, 2014	17 June 2019	Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica (NMO);NMO Spectrum Disorder (NMOSD)	Drug: Satralizumab;Drug: Placebo	Hoffmann-La Roche	Chugai Pharmaceutical	Not recruiting	18 Years	74 Years	All	95	Phase 3	United States;Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Taiwan;Turkey;Ukraine;Bosnia and Herzegovina;Puerto Rico;Singapore
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
476	NCT02209467	August 2014	17 November 2015	Balance and Falls in Multiple Sclerosis	Balance and Falls in Multiple Sclerosis: Intervention and Perceptions From Patients and Next of Kins	Multiple Sclerosis	Other: Group balance training	Örebro County Council		Not recruiting	18 Years	N/A	Both	52	N/A	Sweden
477	NCT02218879	August 2014	12 September 2016	Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS	Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Tecfidera	Yale University		Not recruiting	18 Years	60 Years	Both	7	N/A	United States
478	EUCTR2014-000092-62-BE	30/07/2014	8 August 2016	Management of the infusion-associated reactions in RRMS patients treated with Lemtrada	Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada. - EMERALD	Relapsing-remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	56	Phase 4	France;Spain;Belgium;Netherlands;Switzerland
479	NCT02201108	July 16, 2014	7 October 2019	Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis	A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension	Multiple Sclerosis	Drug: Teriflunomide;Drug: Placebo	Genzyme, a Sanofi Company		Not recruiting	10 Years	18 Years	All	165	Phase 3	United States;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Israel;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;Australia;Macedonia, The Former Yugoslav Republic of;Poland
480	NCT02159573	July 2014	13 June 2016	Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)	A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)	Relapsing-Remitting Multiple Sclerosis	Biological: natalizumab;Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	530	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
481	NCT02201849	July 2014	19 February 2015	A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults	A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults	Multiple Sclerosis	Drug: Study Drug;Drug: Active Control;Drug: Placebo	Alkermes, Inc.		Not recruiting	18 Years	55 Years	Both	104	Phase 1	United States
482	NCT02217982	July 2014	16 December 2017	Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation	A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration	Relapsing Remitting Multiple Sclerosis	Drug: Simethicone;Drug: Loperamide;Other: Peanut Butter	Rocky Mountain MS Research Group, LLC	Biogen	Not recruiting	18 Years	N/A	All	5	Phase 4	United States
483	NCT02727907	July 2014	8 August 2016	Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis	International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: BCD-033 (interferon beta 1a);Drug: Rebif (interferon beta 1a);Drug: Placebo	Biocad		Not recruiting	18 Years	55 Years	Both	147	Phase 2/Phase 3	Russian Federation
484	EUCTR2013-003126-83-DE	23/06/2014	7 October 2014	Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.	A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-ß-1a 30 µg IM Weekly in Subjects with Relapsing Multiple Sclerosis - Efficacy and safety of ONO-4641 versus Interferon-ß-1a in patients with multiple sclerosis	Relapsing multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: Avonex CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Not Recruiting			Female: yes Male: yes	1176	Phase 3	United States;United Arab Emirates;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;France;Peru;Denmark;South Africa;Netherlands;Finland;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Georgia;Bulgaria;Germany;New Zealand;Sweden
485	NCT02121444	June 23, 2014	16 December 2017	BAY86-5046 (Betaseron), Non Interventional Studies	BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®	Multiple Sclerosis	Drug: Interferon beta-1b (Betaferon, BAY 86-5046);Device: BETACONNECT auto-injector.	Bayer		Not recruiting	18 Years	N/A	All	151	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
486	EUCTR2013-002324-16-CZ	13/06/2014	22 October 2018	Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis	A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: VAY736 Pharmaceutical Form: Powder for concentrate for solution for infusion Current Sponsor code: VAY736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	96	Phase 2	United States;Czech Republic;Poland;Ukraine;Russian Federation
487	EUCTR2013-002318-11-SE	05/06/2014	23 October 2017	Phase 3 Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMs).	Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension - CONNECT	Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: AVONEX Product Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: range Concentration number: 7.5-30	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	132	Phase 3	Serbia;United States;Spain;Turkey;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;Denmark;Bulgaria;Kuwait;Germany;Sweden
488	EUCTR2013-002324-16-PL	04/06/2014	12 November 2018	Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis	A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: VAY736 Pharmaceutical Form: Powder for concentrate for solution for infusion Current Sponsor code: VAY736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	96	Phase 2	United States;Czech Republic;Poland;Ukraine;Russian Federation
489	EUCTR2011-005249-12-ES	03/06/2014	28 February 2019	A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosis	A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis - TERIKIDS	Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	165	Phase 3	Portugal;United States;Estonia;Slovenia;Greece;Spain;Ireland;Lebanon;Lithuania;Turkey;Israel;Russian Federation;United Kingdom;France;Canada;Belgium;Poland;Australia;Bulgaria;Netherlands;China
490	NCT01883661	June 2014	19 February 2015	Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)	Role of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs) In Patient With Multiple Sclerosis .It is Self Funded (Patients' Own Funding) Clinical Trial	Multiple Sclerosis	Biological: BMMNC	Chaitanya Hospital, Pune		Recruiting	18 Years	65 Years	Both	15	Phase 1/Phase 2	India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
491	NCT01941004	June 2014	16 December 2017	Safety and Efficacy of Fingolimod in MS Patients in China	A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis (Relapsing Remitting)	Drug: fingolimod;Drug: Placebo (6mos) + open label fingolimod (6 mos)	Novartis Pharmaceuticals		Not recruiting	18 Years	50 Years	All	0	Phase 3
492	NCT02117050	June 2014	19 October 2017	RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate	RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)	Multiple Sclerosis	Drug: Rebif®	EMD Serono		Not recruiting	18 Years	65 Years	All	1	Phase 4	United States
493	NCT02133664	June 2014	16 December 2017	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognition	Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo	Oregon Health and Science University	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	All	54	Phase 1/Phase 2	United States
494	NCT02258217	June 2014	16 December 2017	Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)	Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)	Relapsing Remitting Multiple Sclerosis	Drug: Acthar	OhioHealth		Not recruiting	18 Years	N/A	All	30	N/A	United States
495	EUCTR2013-003752-21-GB	19/05/2014	7 January 2019	A late stage clinical trial to investigate the efficacy and safety of SA237 in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder	A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of SA237 in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)	Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: SA237-120 PFS with NSD Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120-	Chugai Pharmaceutical Co. Ltd		Authorised			Female: yes Male: yes	70	Phase 3	France;United States;Hungary;Taiwan;Poland;Spain;Germany;Japan;Italy;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
496	JPRN-UMIN000013453	2014/05/10	7 October 2019	A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody	A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody - RIN-1	Neuromyelitis optica	Rituximab intravenous infusion Placebo	Clinical Research Center, NHO Utano National Hospital	Zenyaku Kogyo Co., Ltd.	Not Recruiting	16years-old	80years-old	Male and Female	40	Phase 2,3	Japan
497	EUCTR2013-001486-17-DE	06/05/2014	25 April 2016	TOLERATE - A Study that evaluates the Gastrointestinal Tolerability of DMF in Multiple Sclerosis Patients	A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects with Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)	Relapsing-Remitting Multiple Sclerosis MedDRA version: 18.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes			Germany
498	EUCTR2013-001895-40-IE	02/05/2014	18 January 2016	A study to evaluate the effect of aspirin on flushing in patients with RRMS treated with Tecfidera	A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Tecfidera™ (dimethyl fumarate) delayed-release capsules (ASSURE) - ASSURE	Relapsing-Remitting Multiple Sclerosis MedDRA version: 16.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Micropirin Pharmaceutical Form: Capsule INN or Proposed INN: ACETYLSALICYLIC ACID CAS Number: 50-78-2 Other descriptive name: ASA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	240	Phase 4	Ireland;United Kingdom
499	JPRN-JapicCTI-142447	01/5/2014	16 July 2019	Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Intervention name : BAF312 INN of the intervention : Siponimod Dosage And administration of the intervention : BAF312 will be provided in a dose titration from 0.25 mg to a 2 mg dose. Control intervention name : Placebo Dosage And administration of the control intervention : Matching Placebo administered orally.	Novartis Pharma K.K.		Not Recruiting	18	60	BOTH	1530	Phase 3
500	NCT02046629	May 2014	19 February 2015	A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers	An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects	Multiple Sclerosis	Drug: Teriflunomide HMR1726;Drug: cholestyramine	Sanofi		Not recruiting	18 Years	45 Years	Both	12	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
501	NCT02064816	May 2014	16 December 2017	A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis	Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif®	Merck KGaA		Not recruiting	18 Years	60 Years	All	212	Phase 4	Germany
502	NCT02086188	May 2014	11 November 2019	Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis	Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR)	Multiple Sclerosis	Drug: Mirabegron;Drug: Placebo	Theodore R. Brown, MD MPH	Astellas Pharma Inc	Not recruiting	18 Years	N/A	All	28	Phase 4	United States
503	NCT02143167	May 2014	3 September 2018	Resistance Training and Amino Pyridine in Multiple Sclerosis	RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: SR-fampridine;Drug: Placebo	University of Southern Denmark	Region of Southern Denmark;Biogen	Not recruiting	18 Years	60 Years	All	40	Phase 4	Denmark
504	NCT02579681	April 30, 2014	16 December 2017	Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012	Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012	Multiple Sclerosis, Relapsing-Remitting	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	All	221	Phase 3	Italy
505	EUCTR2014-000296-12-FI	15/04/2014	28 April 2014	N/A	N/A	Multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Trade Name: Gilenya Product Name: Fingolimodi Pharmaceutical Form: Capsule, hard	Turku University Hospital		Authorised			Female: yes Male: yes			Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
506	EUCTR2012-000734-19-ES	10/04/2014	14 April 2014	Bone marrow cell treatment as treatment of multiple sclerosis	Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES	Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: XCEL-MC-ALPHA Product Code: XCEL-MC-ALPHA Pharmaceutical Form: Suspension for injection INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved Other descriptive name: Mesenchymal Stem Cells Concentration unit: U unit(s) Concentration type: range Concentration number: 800000-1200000 Pharmaceutical form of the placebo: Suspension for injection Route of administration of the placebo: Intravenous use	Banc de Sang i Teixits		Authorised			Female: yes Male: yes			Spain
507	EUCTR2013-002660-17-IT	09/04/2014	11 April 2016	Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis	Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis - ACROSS	multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolmod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Farma SpA		Not Recruiting			Female: yes Male: yes	281	Phase 2	France;Portugal;Canada;Finland;Spain;Poland;Denmark;Germany;United Kingdom;Switzerland;Italy
508	NCT01933802	April 2014	11 June 2018	Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis	Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: intrathecal administration of autologous MSC-NP	Tisch Multiple Sclerosis Research Center of New York		Not recruiting	18 Years	70 Years	All	20	Phase 1	United States
509	NCT01973517	April 2014	17 September 2018	High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases	7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases	Multiple Sclerosis	Drug: Feraheme;Drug: Gadolinium-based contrast	Stanford University		Not recruiting	18 Years	N/A	All	0	Phase 3	United States
510	NCT02865018	April 2014	22 August 2016	Neuromyelitis Optica (NMO) & Cetirizine	An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica	Neuromyelitis Optica	Drug: cetirizine	Icahn School of Medicine at Mount Sinai	Guthy Jackson Foundation	Not recruiting	18 Years	85 Years	Both	16	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
511	EUCTR2013-002419-87-GB	18/03/2014	28 February 2019	PROXIMUS (PRotective role of OXcabazepine In MUltiple Sclerosis)	Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial - PROXIMUS - PRotective role of OXcabazepine In MUltiple Sclerosis	Multiple sclerosis MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Trileptal Product Name: Oxcarbazepine Other descriptive name: Trileptal Concentration unit: mg milligram(s) Concentration number: 150- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Queen Mary University London		Not Recruiting			Female: yes Male: yes	30	Phase 2	United Kingdom
512	EUCTR2013-002351-15-EE	13/03/2014	7 October 2014	Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.	A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-ß-1a 30 µg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis - Efficacy and safety of ONO-4641 versus Interferon-ß-1a in patients with multiple sclerosis	Relapsing remitting multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: Avonex CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifmod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Not Recruiting			Female: yes Male: yes	1176	Phase 3	United States;United Arab Emirates;Portugal;Belarus;Serbia;Estonia;Morocco;Slovakia;Spain;Ukraine;Lebanon;Chile;Russian Federation;Colombia;Italy;France;Jordan;Denmark;Peru;Latvia;Tunisia;Bosnia and Herzegovina;Finland;Turkey;Lithuania;Austria;United Kingdom;Egypt;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Georgia;Bulgaria;Germany;Japan;Sweden
513	EUCTR2013-004616-21-DE	13/03/2014	14 March 2016	A study to assess immune function and typical disease characteristics in patients with multiple sclerosis, when switching from the medication Natalizumab to the medication Gilenya.	A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod) - ToFingo Successor	relapsing remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: BG00002 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Universitätsklinikum Münster		Not Recruiting			Female: yes Male: yes			Germany
514	NCT02087813	March 2014	23 April 2019	Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses	A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks	Neuromyelitis Optica	Drug: Alpha1-antitrypsin;Drug: methylprednisolone	Stanford University		Not recruiting	18 Years	75 Years	All	0	Phase 1	United States
515	NCT02137109	March 2014	26 October 2015	Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri	Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	N/A	18 Years	Both	400	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
516	NCT02208050	March 2014	10 September 2018	A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis	A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Fampridine;Drug: Placebo	University College Dublin		Not recruiting	18 Years	70 Years	All	66	Phase 4	Ireland
517	NCT02028884	February 20, 2014	9 September 2019	Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)	A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)	Neuromyelitis Optica (NMO);NMO Spectrum Disorder (NMOSD)	Drug: Satralizumab;Drug: Placebo;Drug: Baseline Treatment	Hoffmann-La Roche	Chugai Pharmaceutical	Not recruiting	12 Years	74 Years	All	83	Phase 3	United States;France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom
518	NCT02084121	February 2014	30 September 2019	Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)	Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)	Metachromatic Leukodystrophy	Biological: Enriched Hematopoetic Stem Cell Infusion	University of Louisville	Duke University	Not recruiting	3 Years	N/A	Male		Phase 4	United States
519	NCT02166346	February 2014	11 June 2018	Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)	Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)	Transverse Myelitis;Neuromyelitis Optica;Idiopathic Transverse Myelitis;Myelitis NOS	Drug: Dalfampridine;Drug: Placebo	Johns Hopkins University	Acorda Therapeutics	Not recruiting	18 Years	70 Years	All	24	Phase 2	United States
520	NCT02849782	February 2014	20 August 2018	Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.	Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances	Multiple Sclerosis	Drug: Fampridine	Centre Hospitalier Universitaire de Besancon		Recruiting	18 Years	80 Years	All	98	Phase 4	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
521	NCT03033355	February 2014	11 June 2018	Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder	A Prospective Study of Higher Neural Control Changes Following Intradetrusor Injection of BotulinumtoxinA in Patients With Multiple Sclerosis and Lower Urinary Tract Symptoms.	Multiple Sclerosis;Lower Urinary Tract Symptoms;Neurogenic Bladder;Detrusor, Overactive;Urge Incontinence	Drug: Intradetrusor injection of Botulinum Toxin-A	Rose Khavari, M.D.	The Methodist Hospital System	Recruiting	18 Years	N/A	Female	50	Phase 1	United States
522	EUCTR2012-005450-30-AT	08/01/2014	27 October 2014	Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - ABIRISK	Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44-	Medizinische Universität Innsbruck		Authorised			Female: yes Male: yes	100		Austria
523	JPRN-UMIN000012705	2014/01/07	2 April 2019	The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosis		Relapsing-remitting multiple sclerosis	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 2 years.	Department of Immunology, National Institute of Neuroscience, NCNP		Recruiting	20years-old	65years-old	Male and Female	10	Not applicable	Japan
524	NCT01892345	January 2014	1 April 2019	A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder	Drug: Eculizumab	Alexion Pharmaceuticals		Not recruiting	18 Years	N/A	All	143	Phase 3	United States;Argentina;Australia;Canada;Colombia;Croatia;Czechia;Denmark;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Malaysia;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;Austria;Czech Republic;Singapore
525	NCT02034188	January 2014	16 December 2017	Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: Umbilical cord mesenchymal stem cells	Translational Biosciences		Not recruiting	18 Years	55 Years	All	20	Phase 1/Phase 2	Panama
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
526	NCT02040298	January 2014	25 April 2016	Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis	A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Clemastine;Drug: Placebo	University of California, San Francisco		Not recruiting	18 Years	60 Years	Both	50	Phase 2	United States
527	EUCTR2013-004626-28-FI	20/12/2013	23 December 2013	Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?	Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?	Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Trade Name: REBIF Product Name: beetainterferoni -1a Pharmaceutical Form: Solution for injection CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 6- Trade Name: Gilenya Product Name: Fingolimodi Pharmaceutical Form: Capsule, hard CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- Trade Name: Avonex Pharmaceutical Form: Solution for injection Trade Name: Betaferon Pharmaceutical Form: Concentrate and solvent for solution for injection Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Lemtrada Pharmaceutical Form: Concentrate for solution for infusion CAS Number: 216503-57-0 Other descriptive name: ALEMTUZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12-	Turku University Hospital		Authorised			Female: yes Male: yes			Finland
528	NCT02038049	December 20, 2013	4 November 2019	A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis	A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis	Relapse Remitting Multiple Sclerosis	Drug: VAY736;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	8	Phase 2	United States;Czechia;Ukraine;Czech Republic;Germany;Poland;Russian Federation
529	EUCTR2013-002283-25-CZ	18/12/2013	10 July 2015	A study To Evaluate the Efficacy, Safety and Tolerability of Plovamer Acetate Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis	A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis - Efficacy, safety, and tolerability of plovamer acetate	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Merck KGaA		Not Recruiting			Female: yes Male: yes	550	Phase 2	Serbia;United States;Greece;Finland;Spain;Turkey;Colombia;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Poland;Croatia;South Africa;Bulgaria
530	EUCTR2013-002558-64-IT	18/12/2013	16 October 2017	improvement of cognitive performance after administration of fampridina in patients with multiple sclerosis	A randomised, placebo-controlled trial investigating the role of fampiridina in improving cognitive function of patients with multiple sclerosis.	MULTIPLE SCLEROSIS MedDRA version: 20.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: fampyra Product Name: FAMPYRA Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: CP1/2013 Concentration unit: mg milligram(s) Concentration type: equal Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	dipartimento di neurologia e psichiatria		Not Recruiting			Female: yes Male: yes	123	Phase 4	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
531	EUCTR2013-001151-12-DE	12/12/2013	22 October 2018	EXTENSION STUDY OF ECULIZUMAB IN RELAPSING NEUROMYELITIS OPTICA SUBJECTS	A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)	Neuromyelitis Optica MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SOLIRIS Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ECULIZUMAB CAS Number: 219685-50-4 Current Sponsor code: h5G1.1-mAb Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Alexion Pharmaceuticals, Inc.		Authorised			Female: yes Male: yes	132	Phase 3	United States;United Arab Emirates;Saudi Arabia;Taiwan;Hong Kong;Spain;Russian Federation;Chile;Colombia;Italy;France;Australia;Denmark;Peru;Korea, Republic of;Finland;Turkey;Austria;United Kingdom;Czech Republic;Canada;Argentina;Brazil;Belgium;Singapore;Croatia;Germany;Japan;Sweden
532	EUCTR2013-002916-28-LV	12/12/2013	28 February 2019	An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis	An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ATX-MS-1467 Product Code: MSC2358825A Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: MSC2304479A CAS Number: 1147979-29-0 Current Sponsor code: ATX-MS-01 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304480A CAS Number: 1147979-31-4 Current Sponsor code: ATX-MS-04 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304481A CAS Number: 1147979-32-5 Current Sponsor code: ATX-MS-06 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304482A CAS Number: 1147979-30-3 Current Sponsor code: ATX-MS-07 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200-	Merck KGaA		Authorised			Female: yes Male: yes	20	Phase 2	Russian Federation;Latvia
533	NCT02047734	December 3, 2013	15 July 2019	Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (Radiance Study)	A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients	Relapsing Multiple Sclerosis	Drug: Ozanimod 0.5 mg;Drug: Ozanimod 1 mg;Drug: Ozanimod placebo;Drug: Interferon ß-1a;Drug: IFN ß-1a placebo	Celgene		Not recruiting	18 Years	55 Years	All	1320	Phase 3	United States;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom
534	JPRN-jRCTs031180346	02/12/2013	7 October 2019	Treatment with an anti-interleukin-6 receptor antibody for multiple sclerosis	The efficacy and safety of an anti-interluekin-6 receptor antibody in multiple sclerosis	multiple sclerosis;D009103	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight.	Takashi Yamamura		Not Recruiting	>= 20age old	<= 65age old	Both	6	N/A	none
535	NCT02035514	December 2013	9 January 2017	Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS)	Biological: Bone marrow autologous mesenchymal stem cells transplantation	Germans Trias i Pujol Hospital	Ministerio de Sanidad, Servicios Sociales e Igualdad	Not recruiting	18 Years	50 Years	Both	9	Phase 1/Phase 2	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
536	NCT02146534	December 2013	18 March 2019	Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients	Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study.	Multiple Sclerosis	Drug: extended release fampridine;Drug: Placebo	Clinique Neuro-Outaouais	CogState Ltd.	Not recruiting	18 Years	N/A	All	44	Phase 4	Canada
537	NCT02047097	November 30, 2013	22 July 2019	Dimethyl Fumarate (DMF) Observational Study	A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)	Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Recruiting	18 Years	N/A	All	5600	Phase 4	United States;Argentina;Australia;Austria;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Slovakia;Spain;Switzerland;United Kingdom;Czech Republic
538	EUCTR2013-000529-30-GB	27/11/2013	23 December 2013	prolonged-release oral fampridine in Neuromyelitis Optica (NMO), Pilot feasibility Study	A pilot study to assess efficacy of prolonged-Release oral fampridine on ambulation and visual function in Neuromyelitis Optica - Assessment of fampridine-PR in NMO	Neuromyelitis optica (NMO);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: fampyra 10mg prolonged release tablets Pharmaceutical Form: Prolonged-release tablet	Walton Centre Foundation Trust		Authorised			Female: yes Male: yes	0		United Kingdom
539	EUCTR2013-002082-19-BE	25/11/2013	8 August 2016	A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared to Interferon ß-1a (Avonex, authorised drug) administered once weekly.	A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of Laquinimod (0.6 mg/day or 1.2 mg/day) compared to Interferon ß-1a administered Intra Muscular Once Weekly in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) - LIBRETTO	Relapsing remitting multiple sclerosis MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Laquinimod capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248281-84-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Avonex Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Current Sponsor code: INTERFERON BETA-1A Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Teva Pharmaceutical Industries, Ltd.		Not Recruiting			Female: yes Male: yes	600	Phase 3	Finland;Spain;Ireland;Switzerland;United Kingdom;Italy;France;Belgium;Denmark;Norway;Germany;Netherlands;Sweden
540	EUCTR2013-002283-25-HU	25/11/2013	16 March 2015	A study To Evaluate the Efficacy, Safety and Tolerability of Plovamer Acetate Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis	A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis - Efficacy, safety, and tolerability of plovamer acetate	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Merck KGaA		Not Recruiting			Female: yes Male: yes	550	Phase 2	Serbia;United States;Greece;Finland;Spain;Turkey;Colombia;United Kingdom;Italy;Hungary;Czech Republic;Mexico;Poland;Croatia;South Africa;Bulgaria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
541	EUCTR2013-001439-34-FI	18/11/2013	13 June 2016	Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients	A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients - TERI-PRO	Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aubagio Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14-	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	1000	Phase 4	United States;Greece;Canada;Finland;Belgium;Spain;Austria;Chile;Germany;United Kingdom;Switzerland;Sweden
542	NCT01939002	November 2013	19 October 2017	Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-ß) Therapies to Peginterferon Beta-1a (BIIB017)	An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017	Relapsing Multiple Sclerosis	Drug: BIIB017;Drug: naproxen	Biogen		Not recruiting	18 Years	65 Years	All	251	Phase 3	United States
543	NCT01968902	November 2013	16 December 2017	Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients	A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis	Muscle Spasticity;Multiple Sclerosis	Biological: incabotulinumtoxinA;Biological: Placebo	Multiple Sclerosis Center of Northeastern New York	Merz North America, Inc.	Not recruiting	18 Years	65 Years	All	27	Phase 4	United States
544	NCT01982942	November 2013	11 June 2018	Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis	A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Secondary Progressive	Drug: ibudilast;Drug: Placebo oral capsule	MediciNova	National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS);National Multiple Sclerosis Society	Not recruiting	21 Years	65 Years	All	255	Phase 2	United States
545	NCT02048358	November 2013	19 February 2015	Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients	Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201	Healthy Volunteers;Multiple Sclerosis	Drug: 2B3-201;Drug: Placebo;Drug: Methylprednisolone hemisuccinate	BBB-Therapeutics B.V.		Not recruiting	18 Years	65 Years	Both	47	Phase 1	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
546	NCT03133403	November 2013	11 June 2018	Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Tecfidera (BG12);Drug: Gilenya;Drug: Tysabri®;Drug: Avonex/Betaseron/Copaxone/Rebif;Procedure: Hematopoietic stem cell transplantation (HSCT)	Sheffield Teaching Hospitals NHS Foundation Trust		Recruiting	18 Years	55 Years	All	5	Phase 2/Phase 3	United Kingdom
547	NCT01930708	October 31, 2013	15 July 2019	A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes	A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	All	1114	Phase 4	Austria;Belgium;Canada;Czechia;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;Czech Republic
548	NCT01911767	October 30, 2013	1 April 2019	Biogen Multiple Sclerosis Pregnancy Exposure Registry	Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry	Multiple Sclerosis;Exposure During Pregnancy	Drug: Dimethyl fumarate;Drug: Peginterferon beta-1a	Biogen		Recruiting	N/A	N/A	Female	1125	Phase 2	United States;Australia;Germany;Ireland;Italy;Spain;United Kingdom;Canada
549	NCT01326715	October 17, 2013	14 October 2019	Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis	Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis	Multiple Sclerosis	Drug: Mangafodipir (Teslascan)	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	70 Years	All	15	Phase 1	United States
550	NCT01863888	October 2013	23 March 2015	Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis	Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: teriflunomide HMR1726;Drug: cholestyramine;Drug: charcoal	Sanofi		Not recruiting	18 Years	55 Years	Both	70	Phase 3	Belgium;Germany;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
551	NCT01868048	October 2013	22 August 2016	Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.	A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.	Spasticity;Multiple Sclerosis	Drug: Sativex;Drug: Placebo	GW Research Ltd		Not recruiting	18 Years	N/A	Both	0	Phase 3
552	NCT01911377	October 2013	12 October 2015	Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS	The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis	Neuropathic Pain;Allodynia	Drug: Botulinum Toxin Type A;Drug: Normal Saline for Injection	University of Manitoba	Allergan	Not recruiting	18 Years	70 Years	Both	12	Phase 2	Canada
553	NCT01950234	October 2013	11 November 2019	ACTH in Progressive Forms of MS	Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis	Drug: ACTH;Drug: Placebo	University of Minnesota	Mallinckrodt	Not recruiting	18 Years	N/A	All	100	Phase 2	United States
554	NCT01970410	October 2013	11 June 2018	Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide	Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective?	Multiple Sclerosis	Drug: teriflunomide	Multiple Sclerosis Center of Northeastern New York	Providence Multiple Sclerosis Center	Not recruiting	21 Years	60 Years	All	70	Phase 4	United States
555	NCT02220244	October 2013	16 December 2017	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule	MedDay Pharmaceuticals SA		Not recruiting	18 Years	75 Years	All	105	Phase 3	France;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
556	NCT02220933	October 2013	16 December 2017	Effect of MD1003 in Spinal Progressive Multiple Sclerosis	Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule;Drug: Placebo	MedDay Pharmaceuticals SA		Not recruiting	18 Years	75 Years	All	144	Phase 3	France
557	NCT02753088	October 2013	14 November 2016	Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis	International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC BIOCAD, Russia) and Copaxone®-Teva (Teva Pharmaceutical Industries Limited, Israel) in Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: BCD-063;Drug: Copaxone-Teva;Drug: Placebo	Biocad		Not recruiting	18 Years	55 Years	Both	158	Phase 3
558	EUCTR2012-005324-16-BE	27/08/2013	17 August 2015	Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis	Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis - TERI-DYNAMIC	multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14-	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	68		Belgium;Germany;Netherlands
559	EUCTR2013-001409-10-DK	08/08/2013	17 October 2016	Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS	FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS - FATIMS	Multiple Sclerosis MedDRA version: 14.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Odense University Hospital		Authorised			Female: yes Male: yes		Phase 4	Denmark
560	JPRN-UMIN000010094	2013/08/01	2 April 2019	A pilot study of Elaspol (Sivelestat Sodium) for neuromyelitis optica		neuromyelitis optica	4.8mg/kg Sivelestat Sodium will administered constantly for 5 days in combination with 3 days intravenous methyl-prednisolone administration to sero-positive neuromyelitis optica patients who relapsed within 72 hours before starting treatment.	Tohoku University Hospital		Not Recruiting	20years-old	55years-old	Male and Female	10	Phase 1,2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
561	NCT01890655	August 2013	18 April 2016	Extension Study of MT-1303	A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study	Relapsing-remitting Multiple Sclerosis	Drug: MT-1303-Low;Drug: MT-1303-Middle;Drug: MT-1303-High	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	60 Years	Both	367	Phase 2	Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom
562	NCT01903291	August 2013	8 August 2016	Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS	A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate	Relapsing Forms of Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	333	N/A	United States
563	NCT01906684	August 2013	19 February 2015	Comprehensive Analysis of Relapse in Multiple Sclerosis	Comprehensive Analysis of Relapse in Multiple Sclerosis	Multiple Sclerosis	Drug: Acthar Gel	Tanner Foundation for Multiple Sclerosis	Questcor Pharmaceuticals, Inc.;Auburn University MRI Research Center;iReportoire Inc	Not recruiting	19 Years	65 Years	Both	20	N/A	United States
564	NCT01917019	August 2013	16 December 2017	A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension	Multiple Sclerosis, Remittent Progressive;Multiple Sclerosis, Primary Progressive;Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Multiple Sclerosis	Drug: Placebo;Drug: BIIB041 (fampridine)	Biogen		Not recruiting	18 Years	70 Years	All	101	Phase 3	Japan
565	NCT02141022	August 2013	23 May 2016	Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya	A Pilot Study of Plasticity-Based and Adaptive Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya	Multiple Sclerosis;Cognitive Deficits;Gilenya Modifying Therapy for MS	Other: plasticity-based computerized cognitive remediation program;Drug: Gileyna	Stony Brook University	Novartis	Not recruiting	18 Years	70 Years	Both	20	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
566	NCT02290444	August 2013	10 December 2018	Effects of Acthar on Recovery From Cognitive Relapses in MS	Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis	Multiple Sclerosis	Drug: Adrenocorticotropic Hormone	State University of New York at Buffalo		Not recruiting	18 Years	65 Years	All	60	Phase 3	United States
567	NCT02225977	July 31, 2013	3 September 2018	Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.	Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.	Multiple Sclerosis	Drug: Gilenya	University of Southern California		Not recruiting	18 Years	65 Years	All	125	Phase 3	United States
568	EUCTR2012-004807-10-DE	17/07/2013	23 July 2018	Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis	Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis	MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting visual acuity < 0.7, duration of symptoms should be = 4 weeks MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Urbason® solubile forte 1000 mg Product Name: Methylprednisolone Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Methylprednisolone CAS Number: 83-43-2 Other descriptive name: METHYLPREDNISOLONE Concentration unit: g gram(s) Concentration type: equal Concentration number: 1-	University Medical Center Hamburg Eppendorf		Not Recruiting			Female: yes Male: yes	40	Phase 2	Germany
569	JPRN-UMIN000011111	2013/07/16	2 April 2019	Spinal blood flow and metabolism in neurological diseases		motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy	PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O	Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences		Recruiting	20years-old	Not applicable	Male and Female	70	Not applicable	Japan
570	NCT01817166	July 16, 2013	15 July 2019	Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome	Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.	Multiple Sclerosis	Drug: Vitamin D;Drug: Placebo;Other: Imaging;Biological: Lumbar puncture;Biological: Blood sampling;Biological: Urine samples	Centre Hospitalier Universitaire de Nimes		Recruiting	18 Years	56 Years	All	316	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
571	EUCTR2012-005086-12-AT	05/07/2013	11 April 2016	Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin	Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - PREDICT trial	relapsing multiple sclerosis MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Octagam 50 mg/ml Pharmaceutical Form: Solution for infusion INN or Proposed INN: Human normal immunoglobulin CAS Number: 308067-58-5 Current Sponsor code: Octagam 5% Other descriptive name: IMMUNOGLOBULIN G Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Copaxone 20 mg/ml Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Rebif 44 micrograms Product Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: INTERFERON BETA-1a CAS Number: 145258-61-3 Concentration unit: million IU million international units Concentration type: equal Concentration number: 12- Trade Name: Betaferon 250 microgram/ml Product Name: Betaferon 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1b CAS Number: 145155-23-3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia 250 microgram/ml Product Name: Extavia 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1a CAS Number: 145155-23-3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250-	Octapharma AG		Not Recruiting			Female: yes Male: yes	216	Phase 3b	Hungary;Poland;Austria;Russian Federation;Bulgaria;Germany
572	NCT01647880	July 2013	10 December 2018	MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)	Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis	Multiple Sclerosis	Drug: Verum arm receiving Gilenya®;Drug: Active Comparator receiving Extavia®	Charite University, Berlin, Germany	NeuroCure Clinical Research Center, Charite, Berlin	Not recruiting	18 Years	55 Years	All	15	Phase 2/Phase 3	Germany
573	NCT01710228	July 2013	9 January 2017	Alternative Treatment Paradigm for Natalizumab Trial	Alternative Treatment Paradigm for Natalizumab Trial	Multiple Sclerosis (MS)	Drug: methylprednisolone	University of Texas Southwestern Medical Center	Teva Pharmaceutical Industries;The University of Texas Health Science Center, Houston;University of Alabama at Birmingham;Charite University, Berlin, Germany	Not recruiting	18 Years	60 Years	Both	0	Phase 2	United States
574	NCT01896700	July 2013	11 June 2018	Methylphenidate to Improve Balance and Walking in MS	Methylphenidate to Improve Balance and Walking in MS	Multiple Sclerosis	Drug: Methylphenidate;Drug: Placebo	Oregon Health and Science University	Portland VA Medical Center	Not recruiting	20 Years	65 Years	All	24	Phase 2/Phase 3	United States
575	NCT01900093	July 2013	16 December 2017	Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses	An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone	Multiple Sclerosis	Drug: Acthar Gel	Aaron Miller	Mallinckrodt	Recruiting	18 Years	65 Years	All	10	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
576	NCT02048072	July 2013	19 October 2017	Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS	Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubförmig Verlaufender Multipler Sklerose	Multiple Sclerosis;Autonomic Nervous System Dysfunction	Drug: Gilenya	Jochen Vehoff		Not recruiting	18 Years	60 Years	All	33	Phase 4	Switzerland
577	EUCTR2011-006262-40-CZ	18/06/2013	4 July 2016	A study to assess the safety and efficacy of BIIB033 in patients with relapsing forms of multiple sclerosis when used concurrently with Avonex®	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex®	Relapsing forms of mul